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Summary
Individuals affected by mitochondrial diseases such as Keams-Sayre syndrome (KSS) 
frequently possess a heteroplasmic population of mitochondrial DNA molecules consisting of 
multiple copies of both a wild-type mitochondrial genome and a mitochondrial genome which 
has undergone a major rearrangement. One hypothesis to account for the pathogenic effects 
of rearranged mtDNA molecules is that in affected individuals abnormal proteins, encoded by 
chimeric mitochondrial genes created by the rearrangement of mitochondrial DNA, 
contribute to mitochondrial dysfunction. In order to investigate the relationship between the 
expression of a chimeric peptide in mammalian mitochondria and mitochondrial dysfunction, 
three synthetic genes were constructed. The first, designated PI ("Patient I construct"), was a 
chimeric version of mouse cytochrome c oxidase I (COXI) based on a rearranged COXI gene 
found in the mutant mtDNA of a KSS patient (Poulton et al., 1989). The second, PIZ, was an 
epitope-tagged version of PI, and the third was a full length, universal-code version of mouse 
COXI.
As no transfection system for mammalian mitochondria has been developed, it was necessary 
to construct genes which could be transcribed in the nucleus and translated in the cytosol, 
with subsequent import to mitochondria of the encoded protein. The alteration of the coding 
sequence of COXI from the mammalian mitochondrial genetic code to the universal code 
required 43 programmed point mutations using site-directed mutagenesis. In order that the 
proteins encoded by the synthetic genes could be targeted to mitochondria, a sequence 
encoding the cytochrome c oxidase IV mitochondrial transit peptide was subcloned 5' to the 
code-corrected genes. The epitope-tagged gene PIZ incorporated an epitope recognised by a 
mouse monoclonal antibody against a herpes simplex viral protein, to facilitate expression 
analysis
Expression of PI, PIZ and the universal-code version of mouse COXI all appeared to be 
highly toxic to E. coli, based both on difficulties experienced in subcloning, and on 
expression analysis of the
constructs. Several hypotheses to account for this are discussed, including the possible 
interference with assembly/activity of the bacterial cytochrome c oxidase, and potential 
effects of the amphipathic transit peptide on membrane integrity.
Mouse cell-lines which had incorporated both the PI and PIZ constructs were generated. 
However, the lack of an effective antibody with which to detect PI prohibited characterisation 
of the Pi-transfected cell-lines at the protein level. Northern and Western analysis suggested 
that PIZ was expressed at both the RNA and protein levels in several PlZ-transfected 3T3 
clones. Western analysis also suggested that the PIZ protein may have been correctly 
processed proteolytically, which would indicate that the protein may be imported into the 
mitochondria.
In order to test whether the chimeric peptide conferred a respiratory phenotype in the 3T3 cell 
line, assays of growth in media containing one of two alternative carbon sources (glucose or 
galactose) as the catabolic substrate were performed. Statistical analysis of the cell growth 
assays suggests that PIZ expression was inhibiting respiration. Staining with mitochondrial- 
specific dyes also suggested that respiration was inhibited in the PlZ-transfected cell-line so 
tested (clone PIZ8.3).
Clone PIZ8.3 appeared to have incorporated multiple copies of the PIZ transgene. Under 
growth conditions which increase the requirement for respiration (galactose as the carbon 
source), clone PIZ8.3 was apparently deleting some copies of the transgene. This would 
support the conclusion that expression of the transgene is detrimental to respiration and cell 
survival or growth.
The synthetic genes and cell-lines which have been created in this study can contribute to 
further investigation of the relationship between a chimeric mitochondrial peptide and 
mitochondrial dysfunction by enabling biochemical analysis of the observed respiration 
deficiency. They may also facilitate analysis of the pathogenicity in an organism through the 
creation of transgenic mice. The results obtained in this study support the view that the 
expression of chimeric genes encoded across rearrangement break-points in mitochondrial 
DNA has a deleterious effect on mitochondrial function, and hence could play a significant 
role in mitochondrial disease pathogenesis.
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Chapter 1 
Introduction
1.1 Mitochondria - structure and function
A common analogy is that mitochondria are the powerhouse of the eukaryotic cell.
By the process of oxidative phosphorylation they produce the bulk of the cell's ATP, 
the form in which energy is stored. Mitochondria also perform other biochemical 
functions vital to the cell. The citric acid cycle is the pathway by which all fuel 
molecules, such as fatty acids, amino acids, and carbohydrates, are oxidised to C 02. 
Deficiencies in mitochondrial function have been linked to a growing number of 
human diseases. In order to investigate a possible mechanism of pathogenesis for one 
of these diseases, it is necessary to review what is presently known of both normal 
and abnormal mitochondrial function.
Structurally, the mitochondrion is a double membrane-bound compartment in which 
the membranes define two internal spaces, the intermembrane space and the matrix 
(reviewed in Alberts, 1983). The mitochondrial outer membrane is permeable to most 
small molecules and ions, whereas the inner membrane is virtually impermeable to all 
molecules, except those for which specific transport systems exist. The inner 
membrane is convoluted, forming structures known as cristae, and contains 
proteinaceous carriers to transport specific molecules, e.g., ADP and long chain fatty 
acids, into the mitochondrial matrix. Mitochondria are the only organelles in the 
mammalian cell apart from the nucleus to contain DNA, and it is in the matrix 
compartment that the mitochondrial DNA (mtDNA) molecules are located. In yeast, 
the mtDNA is attached to the inner membrane (Nunnari et al., 1997). It is within the 
inner membrane that the enzyme complexes of the respiratory chain are situated and 
oxidative phosphorylation occurs (fig. 1.1). Mitochondria can differ both structurally 
and physiologically depending on the cell type and tissue they are situated in.
Aerobic respiration is the primary function of mitochondria (fig. 1.1). Pyruvate 
(formed during the metabolisation of sugars) and fatty acids are imported into the
Outer
membrane
NADH
+ H + FADH
Intermembrane 
space
Inner
membrane
Matrix
Figure 1.1 Summary of the reactions involved in aerobic metabolism
A schematic diagram of the mitochondrial double membrane boundary is shown. The 
components of the electron transport chain are situated in the inner membrane. The enzyme 
complexes of the electron transport chain are shown as :
I NADH dehydrogenase (Complex I)
II succinate Q reductase (Complex II)
III cytochrome c reductase (Complex III)
IV cytochrome c oxidase (Complex IV)
F0 and F| are components of the ATP synthase complex (Complex V)
CoQ coenzyme Q 
cyt c cytochrome c
 ►  Electron transfer between the components of the respiratory chain
Proton transfer across the inner mitochondrial membrane 
Metabolic reactions
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mitochondrial matrix where they are converted to acetyl coenzyme A, the substrate 
for the citric acid (TCA) cycle. NADH and FADH2 (reduced cofactors, products of 
the TCA cycle) are re-oxidised by the transfer of electrons via a series of electron 
carriers in the inner membrane enzyme complexes to the final acceptor, molecular 
oxygen. The movement of electrons along this electron transport chain is 
accompanied by the translocation of H+ ions from the matrix to the inter-membrane 
space, which generates an electrochemical proton gradient. The flow of these ions 
through the ATP synthase complex back to the matrix causes the release of ATP 
generated by the phosphorylation of ADP. Thus the processes of oxidation and 
phosphorylation are coupled by the proton gradient formed across the inner 
membrane (reviewed in Stryer, 1988).
Historically there have been 3 models proposed for the configuration of mitochondria 
within the mammalian cell:- (1) the conventional model is that mitochondria are 
present in multiple discrete granular units, classically described as rod-shaped 
structures, about 0.5 |im in diameter. (2) A second model is that one giant 
mitochondrion, existing in the form of a network, is distributed throughout the cell. 
(3) An intermediate model consists of a parental intracellular network which is fluid 
in that smaller units can become separated and, conversely, assimilated back into the 
parental network. A growing body of evidence supports the third model. In a study 
using fluorescence labeling to analyse the shape and distribution of organelles in 
relation to the cytoskeleton in fibroblasts, mitochondria appeared to form an 
interconnected network of elongated tubules, similar to and perhaps associated with 
the endoplasmic reticulum. Mitochondria were additionally found to be present in 
vesicular form (Soltys and Gupta, 1992). It was unclear from this study whether the 
two forms have the potential for interconversion, whether the two forms are in any 
way functionally different or, indeed, if the observation of the vesicular form is an 
artifact. However, experiments utilising mitochondria with different mitochondrial 
DNA (mtDNA) genotypes have found evidence for genetic complementation within
the mitochondrial compartment (Takai et al., 1997). Cybrids were constructed by 
introducing mitochondria from enucleated HeLa cells into recipient cells; both 
mtDNA molecular forms carried identifiable genetic markers. For the observed 
genetic complementation to have occurred, the 'foreign' mitochondria must have 
interacted with the endogenous mitochondria, enabling the matrix compartments of 
the respective mitochondria to have been in contact. Thus, assuming mitochondrial 
fusion was not caused by the technique utilised for cybrid formation, a mechanism 
may be inferred to exist for fusion of mitochondria with each other. This supports a 
model of a fluid network of mitochondria which can 'bud off into smaller units, or 
reaggregate with the parental network. It is also possible that different cell types may 
have different mitochondrial configurations.
1.2 Mitochondrial genome - coding information and organisation
One distinguishing feature of mitochondria is that they contain DNA. Plastids, such as 
chloroplasts found in higher plants, are the only other organelles to contain genetic 
information, apart from the nucleus. The mitochondrial genomes of most organisms 
studied to date are circular, double-stranded DNA molecules. In humans, the two 
strands are conventionally referred to as the heavy- and light-strand (H- and L-strand) 
because of the disparity in guanine content, enabling separation of the two mtDNA 
strands on caesium chloride gradients. The genetic information contained encodes 
components of the mitochondrial translational machinery and subunits of the electron 
transport complexes and ATP synthase, although the exact complement varies 
between organisms. The mtDNAs of all organisms studied to date encode a minimum 
of 2 rRNAs (large subunit and small subunit which are the equivalents of the E. coli 
16S and 23 S rRNAs), cytochrome b and cytochrome c oxidase subunit I (COXI). The 
complement of transfer RNA (tRNA) genes varies considerably, from kinetoplastids, 
in which the mitochondria appear to import all tRNAs from the cytosol, to those of 
plants, which import a few nuclear-encoded tRNAs, to vertebrate mtDNA, which
encodes 22 tRNAs - sufficient to decode the mitochondrially encoded protein genes. 
(Review Gray, 1992). Plant mitochondrial DNA also encodes a 5S rRNA. Both plant 
and many protistan mtDNAs contain genes for ribosomal proteins. Some fungal and 
plant mitochondrial genomes contain coding sequences for maturases, which are 
required for post-transcriptional processing of precursor RNAs. RNA editing of 
mitochondrial transcripts is required for appropriate gene expression in kinetoplastids 
and in plants
The role of the mitochondrial genome is essentially consistent in all these organisms, 
that is to specify a limited number of constituents of the oxidative phosphorylation 
system and of an apparatus which enables the synthesis of polypeptide subunits from 
the mitochondrially encoded mRNAs. Given that all known respiration-competent 
mitochondria contain DNA, it is notable that at least in most organisms, mtDNA does 
not encode either the replicative or transcriptional machinery. Therefore, either 
mtDNA has always been dependent on nuclear-encoded machinery, or at some point 
in time the mitochondrial genome was independent of the nuclear genome, encoding 
all the necessary components for biogenesis, but has since lost this information to the 
nucleus.
1.2.1 The endosymbiont hypothesis
Mitochondria are believed to be relics of an endosymbiotic relationship between a 
primitive eukaryote and an engulfed prokaryote (Gray, 1992). This theory was based 
initially on the similarity between organellar and eubacterial translation systems, but 
has been more recently supported by comparative sequence analysis of prokaryotic, 
nuclear and organellar genomes. These phylogenetic analyses have primarily used 
ribosomal RNA sequences and respiratory chain coding sequences. The modem 
genome bearing coding sequences most similar to mtDNA belongs to the a -  
Proteobacteria, e.g. Agrobacterium (Yang et al., 1985; Raitio et al., 1987). Another
study has utilised the protein sequences of the mitochondrial heat shock proteins (Hsp 
60s), which suggests that the chaperonins of the Ehrlichia/Rickettsia cluster of the a -  
Proteobacteria show the closest relationship to the mitochondrial chaperones of 
eukaryotes from all kingdoms (Viale and Arakaki, 1994). However, it has been 
proposed by some authors that multiple primary endosymbiotic events may have 
occurred, leading to the progenitors of the fungal, plant and metazoan kingdoms 
(Kochel and Kuntzel, 1982; Gray et al., 1984). One analysis based on the relative 
abundance of di-, tri-, and tetranucleotides in mitochondrial genomes suggests that the 
animal mitochondrial genome may be descended from a Sulfolobus- or Mycoplasma- 
like endosymbiont, rather than an a-Proteobacteria (Karlin and Campbell, 1994).
If the endosymbiont hypothesis is correct, then the original genome of the engulfed 
prokaryote should have encoded all components necessary for biogenesis. Therefore, 
it has been proposed that many genes (e.g., those encoding the majority of the 
oxidative phosphorylation system) have been transferred to the nuclear genome from 
the organellar genome. However, all eukaryotes studied to date possessing 
respiration-competent mitochondria contain a mitochondrial genome, however 
minimal. Why has a mitochondrial genome persisted in the eukaryotic cell? One 
theory is that some proteins encoded by mtDNA must be produced within the 
mitochondrion because they would be toxic when cytosolically expressed, or their 
importation into the organelle is for some reason not possible. As a general theory this 
can only apply to two proteins, cytochrome b and cytochrome c oxidase subunit I, 
because the genes encoding them have been found in the mtDNAs of all eukaryotes to 
date. Alternatively it has been suggested that at a given point in cellular evolution the 
transfer of genetic information from organelles to the nucleus ceased, perhaps due to 
increasing divergence in the gene expression systems used in the two compartments. 
However, within relatively recent evolutionary time, i.e., during angiosperm 
evolution, the gene encoding the cytochrome c oxidase II subunit has been transferred 
to the nuclear genome in legumes, probably via an RNA-mediated mechanism
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(Nugent and Palmer, 1991). In both cowpea and soybean the functional copy of the 
gene for coxll is located in the nuclear genome (Covello and Gray, 1992). Another 
possible explanation for the retention of a mitochondrial genome is that by some 
mechanism it confers greater sensitivity to respond to the energy requirements of the 
cell.
1.2.2 Organisation of the mammalian mitochondrial genome
The mammalian mitochondrial genome encodes 2 ribosomal RNAs, 22 transfer RNAs 
(sufficient for mitochondrial translation), and 13 protein subunits of the electron 
transport complexes and ATP synthase (fig. 1.2). The proteins encoded are subunits 
1-6 (including 4L) of NADH dehydrogenase (complex I), cytochrome b (complex 
III), subunits I-III of cytochrome c oxidase (complex IV) and subunits 6 and 8 of ATP 
synthase. The coding information is tightly packed in the ~16 kb genome, with very 
little intergenic sequence. Many protein-coding genes end with a 'T ' or 'TA' after the 
final sense codon, and the actual stop codon ('TAA') is generated by polyadenylation 
of the messenger RNA.
Only two non-coding regions are contained within the mammalian mitochondrial 
genome, and only one is of significant length. The major non-coding region is called 
the control region or D-loop region, for displacement loop. It spans 879 bp in the 
mouse mitochondrial genome, and 1122 bp in the human mitochondrial genome 
(Bibb et al., 1981; Anderson et al., 1981). This region contains the transcriptional 
promoters for both the H- and L-strands (mitochondrial transcription is polycistronic, 
producing primary transcripts the length of the entire genome) and the replication 
origin for leading-strand synthesis (replication initiates in a unidirectional fashion). 
The D-loop is so called due to the unusual 3-stranded structure characteristic of the 
region; the H-strand is displaced by a nascent segment of H-strand (also known as 7S 
DNA, extending 520-700 nt in mouse, 570-655 nt in human) which is repeatedly
Figure 1.2 Structure of the mammalian mitochondrial genome
The origins of heavy strand and light strand replication are noted as Oh and Ol , respectively. 
The D-loop is indicated by the shaded box. The large and small ribosomal subunits are 
designated 16S rRNA and 12S rRNA, respectively. Genes for the tRNAs are designated by the 
standard one-letter symbol. Protein coding genes are designated as follows: ND1, ND2, ND3, 
ND4, ND4L, ND5, ND6 are subunits of NADH dehydrogenase; cyt b is cytochrome b\ COXI, 
COXII, COXIII are subunits I, II and III of cytochrome c oxidase; A6 and A8 are subunits 6 
and 8 of ATP synthase. The direction of transcription for both tRNA and protein coding genes 
is indicated by the accompanying arrows.
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synthesised and degraded (Clayton, 1982). The shorter non-coding region (32 nt in 
mouse, 31 nt in human) contains the origin of lagging-strand (L-strand) replication 
and is surrounded by a cluster of tRNA genes (Bibb et al., 1981; Anderson et al., 
1981).
1.2.3 Organisation of the plant mitochondrial genome
Plants are reported to contain a large range of linear and circular mtDNA molecules 
that may be hundreds of kilobases in size. Some plant species also contain 
mitochondrial plasmids - small linear or circular autonomously replicating molecules. 
A distinctive feature of plant mtDNA is the presence of repetitive sequences, 
frequently ranging from 1-10 kb in size, that facilitate recombination events. These 
recombination events generate rearranged mitochondrial genomes as well as 
subgenomic sized molecules. The "master circle" is the proposed mitochondrial 
genome which is the smallest size of molecule that can accommodate all the mtDNA 
mapped by restriction analysis for a given species. It is used as a conceptual 
reference point, although it may not in fact exist in vivo. Data from electron 
microscopy and pulse-field gels are not conclusive on this point. Not all repetitive 
sequence elements appear able to function as recombination sites, but no consensus 
sequence has been identified which could act as a substrate for a site-specific 
recombination system. Homologous recombination is the probable mechanism, 
although no in vitro assay has yet demonstrated this process in action (Hanson and 
Folkerts, 1992).
Although the plant mitochondrial genome is large (10 - 100-fold larger than the 
animal mitochondrial genome), it encodes essentially the same complement of 
respiratory chain genes as the mammalian mitochondrial genome (discussed in 
section 1.2.2) which is only ~16 kb. The plant mitochondrial genome encodes a few
additional components of the translational apparatus, including multiple ribosomal
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proteins. However, it is estimated that plant mitochondrial genomes contain -100 
ORFs, and may therefore encode a variety of other gene products (Oda et al., 1992). 
The entire 367 kb mitochondrial genome of Arabidopsis thaliana has been sequenced 
(Unseld et al., 1997). 57 genes have been identified, and another 85 potential ORFs 
of 100 codons or more are present. Whereas the variety in gene content between 
organisms studied to date is low, the amount of non-coding sequence in mtDNA 
varies substantially. In plants it is estimated that less than 10% of mtDNA is coding 
sequence, whereas in vertebrates coding sequence accounts for more than 90% of the 
genome; the distribution of coding sequence also differs, in that in plant 
mitochondrial genomes the genes are scattered, interspersed with non-coding 
sequences, whereas in animals the genes are contiguous. In contrast to animals, 
plants show great variability in the gene order between closely related species and 
within a species. This is the main source of diversity between plant mitochondrial 
genomes, as the mutation rate of plant mtDNA is estimated to be 0.2 
substitution/site/billion years, roughly 100-fold less than animal mtDNA, and 10-fold 
less than nuclear DNA (Hanson and Folkerts, 1992; Gray, 1992; Albert et al., 1996).
1.3 Mitochondrial biogenesis
As discussed in section 1.1, a growing body of evidence supports the view of the 
mitochondrial compartment within the mammalian cell as a dynamic and continuous 
network. This is compatible with what is known of the biogenesis of mitochondria, 
i.e., that organelles arise through growth and division rather than by de novo 
formation within daughter cells. The amount and composition of mitochondria is 
dependent on the specific needs of the given cell-type, e.g., an increased energy 
requirement as a result of repeated muscular contraction results in mitochondrial 
proliferation (Hood et al., 1994). In order for the organelle to be responsive to 
cellular demands, it is likely that some mechanism exists for the nuclear genome to
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influence mitochondrial activity. Conversely, it is possible that some mechanism 
exists for the mitochondrial genome to communicate with the nuclear genome.
1.3.1 Replication of mammalian mtDNA
Within the dynamic network of mitochondria reside multiple mtDNA molecules, of 
the order of 103 per cell (Clayton, 1982; Robin and Wong, 1988)). During the course 
of the cell cycle, mitochondrial DNA undergoes replication such that mtDNA copy 
number remains constant through generations of cell growth and division. However, 
any one molecule may be replicated multiple times or not at all within a given cycle 
(Flory and Vinograd, 1973). It has been reported that the replication event is not 
regulated temporally with respect to the phase within the cell cycle (Bogenhagen and 
Clayton, 1977), but the approach adopted may lack sensitivity given that the cultures 
were asynchronous. Other data suggests that the replication of mitochondrial and 
nuclear DNA may be coordinated (Van den Bogert et al., 1993), but it is possible that 
the coordination observed in this case is an artifact caused by synchronisation of the 
cell culture. There may be a spatial determinant which affects whether a given 
molecule replicates within a cell cycle; in cultured rat neural cells it was shown that 
replication of mtDNA is first observed in molecules near to the nucleus (Davis and 
Clayton, 1996). It has been proposed that newly replicated mtDNA radiates 
outwards throughout the organelle network, and that this is achieved by movement of 
replicated molecules rather than transport/diffusion of a signal/factor required for the 
more peripheral molecules to replicate. The authors acknowledge that in other cell 
systems no such spatial determinism has been observed, perhaps due to the smaller 
size of the cell. It is therefore possible that the observation represents a special 
property of neural cells resulting from their shape/topology, rather than a general 
feature of mitochondrial replication.
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Replication of mtDNA occurs within the mitochondrial matrix. It is dependent on the 
importation of protein, and possibly RNA from the cytosol, since all characterised 
components of the replication machinery are nuclear-encoded (reviewed by Clayton 
1982, 1991). The control region for mitochondrial DNA synthesis is located within 
the non-coding region of the genome termed the D-loop (displacement loop), a 3- 
stranded structure in which a short segment of daughter H-strand DNA is hybridised 
to the L-strand displacing the parental H-strand. Replication by the mitochondrial 
DNA polymerase (DNA polymerase y) is initiated at the heavy-strand origin (Oh) 
utilising a pre-existing RNA primer, which is generated by the transcription 
machinery. The existence of several discrete nascent L-strand transcripts terminating 
within the D-loop region has been demonstrated (Chang and Clayton, 1985; Chang et 
al., 1985). Initiation of synthesis of the RNA primer for heavy strand synthesis and 
transcription of the L-strand of mtDNA both occur at the LSP sequence (L-strand 
promoter) and there are no known distinguishing features between the two events 
(Chang and Clayton, 1985; Chang et al., 1985). Transcription proceeds through a 
region of three short conserved sequence elements called conserved sequence blocks 
(CSB) III, II, and I. During in vitro transcription by human mtRNA polymerase, 
persistent RNA-DNA hybrid structures are generated in the CSB region, referred to as 
R-loops (Xu and Clayton, 1996). It is within or downstream of CSB I that the 
transition from RNA synthesis to DNA synthesis occurs. It has been proposed that an 
endonuclease recognises the RNA-DNA hybrid molecule in this region, and cleaves 
the nascent transcript, freeing the 3' OH group for priming DNA synthesis (Chang and 
Clayton, 1987).
The processing of the putative RNA primer is the subject of controversy. It has been 
suggested that RNase MRP (characterised in several species by Clayton and co­
workers) is the endonuclease responsible for primer formation; however, the majority 
of RNase MRP is isolated from the nuclear fraction of the cell (Topper and Clayton,
1990) and has been localised to the nucleolus (Yuan et al., 1989). Using in situ
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hybridisation a mitochondrial localisation for a minor fraction of RNase MRP has 
been shown in mouse (Li et al., 1994). Utilising model R-loops, mouse RNase MRP 
has been shown to cleave the RNA-DNA hybrid molecule appropriately for the 
generation of replication primers including the site appropriate to the major species of 
H-strand DNA that has been isolated, which has a 5' end located within or 
downstream of CSB I (Lee and Clayton, 1997). The low abundance of MRP RNase 
in the mitochondrial compartment of cells such as HeLa (Kiss and Filipowicz, 1992) 
can be accounted for by imputing to the endonuclease a regulatory role in the rate of 
mtDNA replication (Topper et al., 1992).
It is possible that there is no universal mechanism for the initiation of mitochondrial 
DNA replication. Another endonucleolytic enzyme has been localised to both 
mitochondrial and non-mitochondrial compartments within the cell, endonuclease G. 
This enzyme, isolated from calf thymus, is capable of generating RNA primers 
suitable for the initiation of mtDNA replication. An RNA-DNA heteroduplex which 
contained the mouse mtDNA control region was recognised as a substrate (Cote and 
Ruiz-Carrillo, 1993). However, none of the cleavage sites generated by this enzyme 
corresponds to the exact terminus of the major, nascent H-strand species (Chang and 
Clayton, 1985; Chang et al., 1985). The detection of a possible transcription pause 
site in CSB I (using an in organello system with rat liver mitochondria) suggests that 
endonuclease activity may not be required for primer formation at this site (Cantatore 
et al., 1995). In vitro transcription experiments demonstrated the formation of 
persistent RNA-DNA hybrids. The RNA species had 3' ends which mapped within or 
downstream of CSB I, supporting the hypothesis for a transcription pause site here 
(Xu and Clayton, 1996). Thus, the actual role of MRP RNase could conceivably be 
for primer removal.
DNA synthesis proceeds unidirectionally from Oh by strand displacement. It is
unclear whether leading-strand replication occurs via de novo DNA synthesis from
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the RNA primer, or by extension of the pre-existing D-strand in the D-loop. Once 
DNA synthesis has reached approximately two-thirds of the way around the genome, 
the O l  (light-strand origin) is exposed on the displaced strand. Although the 
sequences for the light-strand origins are highly diverged between species, a potential 
stem-loop secondary structure is conserved (Martens and Clayton, 1979, Tapper and 
Clayton, 1981). Here a mtDNA-specific primase initiates priming and DNA synthesis 
of the lagging strand (Wong and Clayton, 1985a, b). In human and mouse no 
alternative priming site for lagging strand synthesis has been detected. It is believed 
that the O l  plays no regulatory role, i.e., if replication is initiated at O h , second strand 
synthesis will begin automatically once the O l  is exposed. Segregation of the two 
daughter molecules precedes the completion of L-strand replication.
Replication of mtDNA is controlled by the nuclear genome. There are several 
potential points of regulation in this model of replication. Both the hypothetical 5' and 
3' processing events of the primer for H-strand synthesis are obvious candidates. 
Another is the point at which DNA synthesis extends beyond the D-loop; some 
mechanism must regulate whether DNA synthesis terminates to form the D-strand, 
proceeds beyond that point to replicate a full strand of the genome, or indeed uses the 
D-strand as a substrate for elongation. A bovine protein has been isolated which 
binds to the replication pause site on both bovine and human template DNA in a 
sequence-specific manner (Suzuki et al., 1996). The provision of one or more 
components of the system (e.g., the DNA polymerase) by the nuclear genome may be 
regulated. As an example, functional binding sites for nuclear respiratory factor-1 
(NRF-1), a transcription activator, have been demonstrated in the regulatory region 
upstream of the genes encoding both human and mouse RNase MRP RNA. NRF-1 is 
a candidate for playing a coordinating role in mitochondrial and nuclear respiratory 
gene expression (Evans and Scarpulla, 1990, Virbasius et al., 1993). Finally, 
mitochondrial transcription factor A (mtTFA) may play a role in RNA primer
15
formation due to its involvement in promoter selection by the transcriptional 
apparatus (see section 1.3.2).
1.3.2 Transcription and processing of mitochondrial RNA
As discussed in section 1.3.1, the D-loop region is the control region for 
mitochondrial replication and transcription. The promoters for both L-strand and H- 
strand transcription (LSP and HSP, respectively) are located within this region. Both 
promoters contain binding sites for the transcription factor mtTFA, which has been 
shown to activate transcription in vitro (Fisher et al., 1987) and in vivo (Montoya et 
al., 1997). mtTFA has the capacity to unwind and bend DNA, which may be 
necessary for precise transcriptional initiation to take place (Fisher et al., 1992). The 
binding affinity of mtTFA for the LSP is greater than for the HSP, which corresponds 
to the LSP being more active in vivo and in vitro. However, the exact role of mtTFA 
has yet to be determined. Human mtTFA (h-mtTFA) binds to the D-loop region of 
mtDNA at regularly phased intervals of -40-50 bp apart in a non-sequence specific 
manner, both in vitro and in organello. These intervals coincide with the spacing of 
transcriptional and replicative start sites (Ghivizzani et al., 1994). h-mtTFA contains 
two high-mobility-group-like domains (Parisi and Clayton, 1991). Thus, one of the 
main functions of h-mtTFA appears to be the packaging of the mtDNA in the control 
region.
Transcription in mitochondria is polycistronic, thus, the L-strand is transcribed as a 
single transcriptional unit, beginning upstream of the replication origin for the H- 
strand. This transcript has a low informational content, in that it contains only 8 
tRNAs and the mRNA for ND6. If the model of replication priming by a processed 
L-strand transcript is correct, then a full-length, polycistronic, mitochondrial 
transcript could also provide the H-strand replication primer. Alternatively, an
independent initiation event could provide RNA primers for replication. The
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existence of several species of nascent L-strand RNAs terminating within the D-loop 
region has been shown (Chang and Clayton, 1985; Chang et al., 1985).
There are two major species of H-strand transcripts; one spans the rDNA region only, 
and the other the entire genome. The rRNA genes and adjacent tRNA genes are 
transcribed more frequently than the other H-strand genes; estimates range from ~10 
times more frequently (in primary rat hepatocytes, Cantatore et al., 1987) up to ~50 
times more frequently (in HeLa cells, Gelfand and Attardi, 1981). The 3' ends of the 
16S rRNA exhibits heterogeneity, suggesting it is the product of a transcriptional 
termination mechanism rather than a precise processing event (Dubin et al., 1982). 
Using an in vitro system derived from human mitochondria, a bidirectional 
termination sequence was identified at the 16S rRNA-tRNALeu(UUR) gene boundary 
(Christianson and Clayton, 1986; Christianson and Clayton, 1988). A DNA-binding 
protein, mTERF, which binds to this region with high affinity and promotes 
transcriptional termination has been identified (Kruse et al., 1989; Micol et al., 1997).
The literature is contradictory about the site of transcriptional initiation for the 
polycistronic H-strand transcript. Research originating from Attardi's group indicates 
that there are two initiation points for H-strand transcripts; one is proximal to the 5' 
terminus of the 12S rRNA gene, responsible for the transcript which contains the 
mRNAs for the protein-coding genes, the other is located 20-40 bp upstream of the 
tRNAPhe gene, and is responsible for the synthesis of the rRNAs only (Montoya et al., 
1982; Montoya et al., 1983; Micol et al., 1997). Interpretation of the data by 
Clayton's group suggests that the template-directed transcriptional termination 
(mediated by mTERF) at the 16S rRNA-tRNA^OJUR) gene boundary is necessary and 
sufficient to explain the increased levels of rRNA transcription in comparison to the 
transcription of the protein-coding genes (Christianson and Clayton, 1986; Clayton,
1991). However, it was reported that mtTFA/H-strand promoter complexes did not
give clear footprints in vitro, and involvement of another factor/s in transcriptional
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initiation was postulated (Fisher et al., 1987). Thus, the sensitivity of rRNA synthesis 
(but not mRNA synthesis) to ATP levels at the point of initiation could indicate the 
involvement of additional factors in transcriptional initiation , and supports the theory 
of an independent H-strand promoter for rRNA synthesis (Micol et al., 1997).
The processing of the polycistronic mitochondrial transcripts requires the activity of 
at least one endonuclease to cleave precisely at the junctions between mRNAs, tRNAs 
and rRNAs. The tRNA punctuation model of mitochondrial RNA processing 
proposes that the secondary structure of the tRNA sequences, which are interspersed 
amongst the mRNA and rRNA sequences, may represent the primary recognition 
signal for processing (Ojala et al., 1981). It is noteworthy that a point mutation, 
identified in a case of human disease, which localises to the aminoacyl stem of a 
mitochondrial tRNA gene, has been associated with RNA processing defects (Bindoff 
et al., 1993). Northern blot analysis of RNA prepared from skeletal muscle and 
cultured skin fibroblasts indicate that RNA processing occurs in a tissue-specific 
manner. At junctions which lack a tRNA, it has been proposed that a stem-loop 
structure resembling a portion of a tRNA could function as the recognition signal 
(Ojala et al., 1981). A mitochondrial ribonuclease P has been identified and 
characterised as the mitochondrial processing endonuclease responsible for the 
cleavage on the 5' side of the tRNA sequences (Rossmanith et al., 1995). Cleavage of 
the 5' end of the tRNA precedes cleavage of the 3' end by a separate endonuclease.
All mitochondrial tRNAs require the post-transcriptional addition of the 3' terminal 
CCA, as it is not encoded by the mitochondrial genome. As mammalian 
mitochondrial DNA does not contain any introns, no splicing machinery is required. 
mRNAs and the rRNAs are polyadenylated, and it has been suggested that 
polyadenylation may be associated with the processing step which releases the 3' end 
of these RNA products from the polycistronic transcript (Ojala et al., 1981).
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It has been reported that transcription of mtDNA in both HeLa cells (Gelfand and 
Attardi, 1981) and in rat liver cells (Cantatore et al., 1987) is in excess of cellular 
requirements, and is not rate-limiting for mitochondrial protein synthesis.
1.3.3 Mitochondrial translation
Processing of the polycistronic RNA transcripts produces 11 mature transcripts, 9 of 
which are monocistronic mRNAs, and 2 of which are bicistronic mRNAs encoding 
overlapping reading frames. The mRNAs are uncapped and contain essentially no 5' 
untranslated sequence that could, for example, promote ribosome binding. This 
distinguishes mitochondrial mRNA from both cytosolic and bacterial ribosomal 
recognition systems. Analysis of secondary structure and RNAse protection 
experiments suggest that secondary structure in the 5' terminal region of 
mitochondrial mRNAs is integral to recognition by mitochondrial ribosomes, and 
mitochondrial initiation factors may be required for proper recognition and melting to 
allow translational initiation (O'Brien et al., 1990).
Translation of the mitochondrial mRNAs by mitochondrial ribosomes yields 13 
subunits of the mitochondrial respiratory chain. All protein components of the protein 
synthetic apparatus are nuclear-encoded; this includes ~85 different ribosomal 
proteins (nearly twice as many as in bacterial ribosomes) (O'Brien et al., 1990). In 
yeast, many mRNA-specific translation factors have been identified (Dunstan et al., 
1997; Steele et al., 1996) and such factors may also be involved in mammalian 
mitochondrial translation. In yeast, the putative RNA stem-loop structure found in 
the 5'-untranslated leader of the COXIII mRNA, which interacts with a COXII- 
specific translational activator (Dunstan et al., 1997), may be functionally 
homologous to the putative stem structure identified at the 5' terminus of the bovine 
COXII mRNA (O'Brien et al., 1990). Also in yeast are nuclear-encoded protein
factors required for the post-translational assembly of specific mitochondrial subunits,
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e.g., the SC01 protein which is required for the correct assembly of COXI and COXII 
(Krummeck and Rodel, 1990).
Both of the ribosomal RNAs and all 22 transfer RNAs are mitochondrially encoded.
In mammals only 22 tRNAs are required to decode the mitochondrial mRNAs 
because the genetic code differs slightly from the universal genetic code (Table 1.1), 
and because of expanded wobble that permits a single tRNA to decode all four 
codons, specifying some amino acids. Although most mitochondrial tRNAs can form 
the conventional cloverleaf structure, many deviations are observed as regards 
secondary structure (e.g., stem length) and sequence (nucleotides which are invariant 
in non-mitochondrial tRNAs and are involved in the tertiary structure) (Sprinzl et al.,
1985). It has been proposed that N-formyl-methionine is the amino terminal amino 
acid in mtDNA-encoded proteins, (this has been confirmed for COXI, Hensel and 
Buse, 1990) suggesting initiation of mitochondrial protein synthesis may require N- 
formyl-methionyl-tRNA (Chomyn et al., 1981).
TGA ATA AGA AGG
Universal stop lie Arg Arg
Mammalian mt Trp Met stop/NF stop/NF
Table 1.1 Mammalian mitochondrial genetic code
The table lists the differences between the universal genetic code and the mammalian 
mitochondrial genetic code. The four codons which specify different amino acids, or 
translational stops, within the two systems head the columns. NF indicates the codon 
is not found in the mitochondrial genomes of some mammalian species.
Given that some components of the respiratory chain are encoded by the nuclear and 
some by the mitochondrial genome, and that the assembled complexes require the 
protein subunits in equimolar amounts, it is puzzling as to why the mRNAs for the
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mitochondrial subunits are transcribed at a much higher level than those for the 
nuclear-encoded subunits. It has been suggested that only a small proportion of 
mitochondrial mRNA is destined to be translated. Alternatively, it has been 
suggested that mitochondrial translation may be inefficient (in comparison to that in 
the cytosol) and that the relatively high levels of mitochondrial transcripts are 
necessary to ensure equimolar amounts of the subunits for the respiratory chain 
complexes (Ostronoff et al., 1996; Cantatore et al., 1987; Van den Bogert et al.,
1993).
One hypothesis to account for developmental and/or physiological regulation of 
mitochondrial gene expression is that it is simply a gene dosage effect (Williams,
1986). However, this does not appear to apply to all physiological conditions (Van 
den Bogert et al., 1993). As an example, altering the thyroid state in rats did not 
change the copy number of mtDNA in various tissues despite substantial changes in 
the content of mitochondrial mRNAs (Wiesner et al., 1992). These authors found that 
mitochondrial gene expression in this situation is controlled directly at the 
transcriptional level. During cellular differentiation, mitochondrial gene expression 
may also be regulated at the level of translation, in contrast to the regulation of 
mitochondrial transcription which appears to occur during organelle proliferation 
(Ostronoff et al., 1996).
1.3.4 Protein import
As only 13 mitochondrial proteins are actually synthesised within the mitochondria, 
hundreds of nuclear-encoded mitochondrial proteins need to be synthesised within the 
cytosol, then imported into mitochondria. The protein import machinery within yeast 
has been extensively characterised, and, as far as is known, the general mechanism is 
broadly applicable to mammalian mitochondria as well (reviewed by Neupert, 1997;
Kubrich et al., 1995). Although some proteins are imported by mechanisms requiring
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specific carrier proteins, there is a general import mechanism for the majority of 
imported proteins. Once the nuclear encoded mitochondrial proteins have been 
imported, intra-mitochondrial sorting and processing occurs.
Nuclear-encoded mitochondrial precursor proteins generally have amino-terminal 
extensions which serve as mitochondrial targetting sequences, although there are 
exceptions to the rule (Mitoma and Ito, 1992). These presequences are positively 
charged and are capable of forming amphipathic oc-helices (the positively charged and 
hydrophobic residues facing opposite sides of the helix) (von Heijne, 1986). These 
presequences have been shown to be necessary and sufficient for mitochondrial 
import using the cytosolic protein dihydrofolate reductase as a reporter (Horwich et 
al., 1985; Hurt et a l , 1985). Although there is no consensus sequence, a three-amino 
acid motif within the transit peptides has been identified as common to a set of 50 
surveyed leader sequences (Hendrick et a l , 1989).
In order to be targeted correctly, the cytosolically synthesised mitochondrial precursor 
must adopt a conformation such that the targeting peptide is presented on the surface 
of the molecule. Cytoplasmic chaperone proteins associate with the precursor 
proteins in order to maintain a loosely folded, import-competent conformation 
(Murakami et al., 1988; Murakami and Mori, 1990; Caplan et al., 1992; Hachiya et 
al., 1993). Receptor proteins in the mitochondrial outer membrane interact with the 
precursor protein which is then delivered to a protein import channel across the outer 
membrane (Lill and Neupert, 1996). Translocation across the inner membrane 
initially requires membrane potential (which drives the presequence across) (Martin et 
al., 1991). One subcomplex of the inner membrane complex forms a protein- 
conducting channel; the other subcomplex involves mitochondrial chaperones on the 
matrix side, which promote translocation across the membranes (Berthold et al.,
1995; Blom et al., 1993; Gambill et al., 1993). mhsp70 can mediate both transport
across the inner membrane and protein folding in the matrix, dependent on which
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complex it is within (Horst et al., 1997). Cleavage of the transit peptide occurs during 
or after translocation (Hawlitschek et al., 1988; Yang et al., 1988). Refolding of 
proteins in the matrix is mediated by a variety of molecular chaperones (Rospert et 
al., 1996; Matouschek et al., 1995; Rassow et al., 1995). Precursors of subunits of 
the electron transfer system, which are assembled into the respiratory complexes in 
the inner membrane, may either be targeted to the matrix for processing and sorting, 
or targeted directly to the inner membrane, by a hydrophobic stop-transfer signal 
(Hurt et al., 1984; Miller and Cumsky, 1991).
1.3.5 Transmission of mammalian mitochondrial DNA
1.3.5.1 Germ-line transmission
It is conventional to describe the inheritance of mtDNA as strictly maternal in 
mammals. However, the failure to detect transmission of paternal mtDNA could be 
due to the limitations of technique. It has been estimated that there are 105 
mitochondrial DNA molecules in the egg, both of mouse and of human, whereas an 
individual sperm contains only about 102 mtDNA molecules (Piko and Matsumoto, 
1986; Chen et al., 1995). Utilising PCR, a very low level of paternal transmission has 
been demonstrated in interspecific, but not intraspecific, crosses in mice (Gyllensten 
et al., 1991; Kaneda et al., 1995). Gyllensten et al., (1991) propose dispersion of the 
paternally-inherited mtDNA throughout the tissues of hybrid mice and persistent 
transmission to successive generations. However, data presented by Shitara et al., 
(1998) shows that paternally-derived mtDNA is rarely present in ovarian tissue (6/91 
FI hybrid females), and the paternally-derived mtDNA was not present in 78 
unfertilised eggs obtained from FI hybrid females which were positive in the ovarian 
tissue (Shitara et al., 1998). In intraspecific crosses Kaneda et al., (1995) have shown 
that paternal mtDNA is detected at the early pronucleus stage, but is then eliminated. 
They then crossed a congenic strain (B6.mt^r), which has a Mus musculus (B6)
nuclear background but Mus spretus mtDNA, with B6 females, and demonstrated
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elimination of the paternal mtDNA as in normal intraspecific crosses. They therefore 
propose a species-specific mechanism for the elimination of paternal mtDNA by the 
oocyte which recognises one or more nuclear-encoded factor(s) (Kaneda et al., 1995). 
If this is the case, one wonders how the mechanism evolved, for intuitively a sperm 
which had demonstrated its respiratory fitness by successfully reaching an egg should 
contain functional mitochondria which would contribute to the fitness of the 
offspring. It has been suggested that maintaining homoplasmy of mtDNA (which 
would necessitate uniparental transmission) may better enable it to interact effectively 
with the nuclear genome (Poulton, 1995).
Whereas a great deal of speculation has focussed on a maternal inactivation 
mechanism of the paternally-derived mtDNA, recent data suggests that the male 
germline may inactivate its own mtDNA. Mitochondrial transcription factor A 
(mtTFA) is a transcriptional activator of mammalian mtDNA, and thus plays a 
contributory role in mtDNA replication (chap. 1.3.1). In both mouse and human it has 
been shown that there are testis-specific mtTFA transcripts. In mouse the testis- 
specific protein isoform is imported to the nucleus rather than to the mitochondria of 
spermatocytes and spermatids (Larsson et al., 1996). In humans, however, no such 
nuclear isoform is predicted from the sequence of the testis-specific transcripts. In 
differentiated human male germ cells a high level of testis-specific mtTFA transcripts 
correlates with a down-regulation of mtTFA protein levels and a parallel decrease in 
the amount of mtDNA (Larsson et al., 1997).
In the female germline it has been proposed that mtDNA transmission to the 
subsequent generation proceeds through a genetic bottleneck, also referred to as the 
ploidy paradox. The mechanism of this bottleneck seems to be mitotic segregation 
during germ-cell development (see following section). The number of independently 
segregating units in oocyte mitochondria has been inferred to be approximately 200,
based on experiments with heteroplasmic mice (Jennuth et al., 1996). This genetic
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founder effect would result in rapid fixation of a mutant genotype if the mutant were 
amongst the molecules replicated in a 'successful' oocyte. Rearranged mtDNA 
molecules have been detected in oocytes (Chen et al., 1995). However, the authors 
suggest that the low levels detected (maximally 0.1%) support the idea of a genetic 
bottleneck which filters out deleterious molecules. In cows heteroplasmic for a 
neutral point mutation the mtDNA genotypes of the progeny could segregate for 
either of the maternal mtDNA variants, and could become homoplasmic within three 
generations (Ashley et al., 1989). An interesting implication of maternal inheritance 
is that, if a mutation in mtDNA had a neutral effect on the phenotype in females, but a 
deleterious effect in males, selection pressure could not act directly to stop the 
mutation spreading in a population (Avise, 1991)
1.3.5.2 Mitotic segregation
Mitochondria, and the DNA molecules they contain, appear to be randomly 
partitioned between daughter cells (Papa et al., 1996). In mammals, normally all the 
mitochondrial genomes found within a given organism will be identical, a situation 
known as homoplasmic. If a cell harbours a mixed population of genetically different 
mitochondrial genomes, it is called heteroplasmic. In humans, this situation has been 
reported only in cases of disease-associated mutations. Over multiple generations of 
random partitioning during cellular division of heteroplasmic cells, the complement of 
mitochondrial DNA can shift, as a result of random partitioning, accompanied in 
some cases by selection, towards a higher proportion of mutant or wild-type mtDNA. 
This process is referred to as mitotic segregation.
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1.4 Rearrangements in mitochondrial DNA
1.4.1 Rearrangements in fungal mtDNA
The mitochondrial genomes of fungi, as of plants, exhibit great diversity. Closely 
related species can have mitochondrial genomes which vary in size by a factor of 
three, and even different strains of the same species can exhibit size variation due to 
the presence or absence of introns, and the number of repeat units found in the 
intergenic regions (Clark-Walker, 1992; Tzagoloff and Myers, 1986). Also in 
contrast to animal mitochondrial genomes is the variation in gene order which can be 
observed between similar species. As with plants, both linear and circular 
mitochondrial plasmids are commonly observed in natural isolates of fungi 
(Meinhardt et al, 1990; Yang and Griffiths, 1993). The majority of these plasmids do 
not appear to be associated with an identified phenotype of the host organism. 
Likewise, although there is evidence for the mobility of intronic elements, most do 
not appear to confer a particular phenotype on the fungal "host".
However, there are several examples whereby mitochondrial introns or plasmids do 
confer a phenotype on their particular fungal host. One example is found in 
Podospora anserina. This ascomycete has been used as a research model for 
senescence. During aging, an intron located in the COXI gene becomes liberated, 
either through precise excision or via reverse transcription of an RNA intermediate, to 
form a circular plasmid (Osiewacz and Esser; 1984; Kuck et al., 1985; Cummings et 
al., 1985; Belcour and Viemy, 1986). The amplification of this plasmid is associated 
with senescence (Stahl et al., 1978; Cummings et al., 1979). In longevity mutants this 
plasmid DNA (plDNA or asenDNA) is either absent, or amplification is delayed, 
suggesting that amplification of plDNA is integral to senescence (Viemy et al., 1982; 
Koll et al., 1985; Schulte et al., 1988; Hermanns et al., 1994). It is possible to
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transform juvenile protoplasts of P. anserina with plDNA and thereby induce 
premature senescence (Tudzynski et al., 1980).
Loss of mitochondrial function during aging of P. anserina cultures has been 
demonstrated (Tudzynski and Esser, 1979). The cessation of vegetative growth has 
also been correlated with multiple recombination and deletion events of the 
mitochondrial DNA (Belcour et al.} 1981; Kuck et al., 1981). It should be noted that 
two longevity mutants have been isolated which are associated with multiple 
recombination events in the mutant mitochondrial genome (Schulte et al, 1988). 
However, the rearranged mitochondrial genomes are stably inherited. In these 
mutants the senescence-associated intron has been deleted as well as a portion of the 
COXI gene. Although the cells have no functional COXI, Podospora possesses an 
alternative enzyme pathway which allows these mutants to survive. It has been 
hypothesised that senescence is due to the loss of mitochondrial function associated 
with inactivation of mitochondrial genes by integration of plDNA (Osiewacz and 
Esser, 1984; Kuck et al, 1985). Alternatively, a plDNA-encoded polypeptide may 
act as, or may induce, a recombinase, causing multiple rearrangements in the 
mitochondrial DNA of senescent mycelia (Schulte et al, 1988).
In Neurospora as well there are examples of a senescent phenotype associated with 
the integration of circular (e.g., Mauriceville and Varkud) or linear (kalilo and 
maranhar) plasmids (Akins et al, 1986; Bertrand et al, 1985; Court et al, 1991). As 
with the Podospora plDNA, these integration events are associated with 
rearrangements of the mitochondrial genome, and may produce the senescent 
phenotype via resultant mitochondrial dysfunction. The integration of kalilo or 
maranhar DNA causes the proliferation of defective mitochondrial DNA molecules 
resulting in the displacement of wild-type DNA. This leads to a decline in 
mitochondrial functions, senescence and eventual death (Bertrand et al, 1985).
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However, subgenomic molecules have also been found in small amounts in a wild- 
type strain of Neurospora (Gross et al, 1984).
In S. cerevisiae, cells harbouring deleted mitochondrial DNA (referred to as p "petites) 
arise spontaneously at a frequency of about 1% (Piskur, 1994). They can also be 
induced with ethidium bromide treatment and other chemicals, or can result from 
defective mitochondrial protein synthesis (Stribinski et al, 1996). The molecules 
consist of a deleted portion of the mitochondrial genome, frequently maintained in the 
form of a large repetitive DNA molecule. The repeating unit may originate from any 
region of the mtDNA molecule, and may be organised in tandem array or in 
palindromic repetitions. Cells of p" petite mutants contain the same total amount of 
mtDNA as wild-type strains (Sanders et al, 1973; Faye et al, 1973). The most 
common class of spontaneous p" petite are termed suppressive petites because when 
crossed with wild-type strains they primarily produce petite progeny.
The ploidy paradox (discussed in section 1.3.5) also aplies to yeast; in yeast 50 
mtDNA molecules is the average number per cell, 100 molecules in a diploid zygote. 
Although ~40 molecules enter the first bud, the genetically segregating units are 
estimated to be only 3-4 in number (Dujon et al, 1974; Birky et al, 1978). It has 
been postulated that one possible mechanism to achieve this would be sequestration 
of the replication machinery, i.e., if a molecule has already replicated it has an 
enhanced probability of replicating again due to access to the replication machinery 
(Gingold, 1981; Birky, 1983). Thus, a form of competition amongst mtDNA 
molecules may exist in which cis elements are important in determining transmission 
to progeny; in yeast p" petites the intergenic regions seem to be important (Piskur, 
1988; Blanc andDujon, 1980). In yeast, another pertinent factor is the site of budding; 
although mitochondrial proteins disperse and mix soon after parental mitochondria 
fuse, the mtDNA appears to be attached to the mitochondrial membrane (Azpiros and 
Butow, 1993;Nunnari et al., 1997).
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Recombination of yeast mtDNA in respiration-competent cells can involve both 
homologous and site-specific recombination (Rayko et al, 1993). The homologous 
recombination machinery is thought to be involved in petite formation (Boulet et al, 
1990). Recombination hotspots in Neurospora, Podospora, and S. cerevisiae occur in 
regions where single-strand breaks are deemed likely to occur or be stabilised, such as 
in hairpin loops and regions with extended repeats (Ripley, 1982). Repetitive 
sequences, both G/C clusters (Skelly and Clark-Walker, 1990) and A/T-rich repeats 
(De Zamaroczy et al, 1983), are implicated in the recombination events that lead to 
p" petite formation. As few as 6 bp of homology have been shown to be sufficient for 
the formation of p 'petites (Sor and Fukuhara, 1983). The involvement of a 
mismatch-repair mechanism in the intramolecular recombination process has been 
implicated in Neurospora (Gross et al, 1989). A recombination/repair endo- 
exonuclease NUC2 is involved in the production of petites, both spontaneously and in 
the presence of ethidium bromide (Chow and Kunz, 1991). A cruciform-cutting 
endonuclease, CCE1, thought specifically to resolve Holliday junctions in 
mitochondria, has been localised to the yeast mitochondrial inner membrane (Ezekiel 
and Zassenhaus, 1993). The gene encoding the protein (also known as MGT1) had 
previously been shown to be required for biased transmission of p" petite mtDNA in 
crosses between respiration competent and hypersuppressive petite cells ( Zweifel and 
Fangman, 1991). However, the mgtl/ccel mutation elevates the frequency of petite 
molecules in respiration-competent strains, and homologous recombination is still 
observed (Piskur, 1997).
In summary, rearrangements of mtDNA correlate with mitochondrial dysfunction in 
Podospora, Neurospora, and S. cerevisiae. The mechanism by which mtDNA 
rearrangements arise in these organisms may involve mitochondrial DNA repair 
machinery, and repetitive DNA sequences.
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1.4.2 Rearrangements in plant mtDNA
As discussed in section 1.2.3, rearrangements of the mitochondrial genome are not 
necessarily associated with a mutant phenotype in plants. However, rare 
recombination events do occur at sites other than in the large, recombinational repeat 
sequences, which lead to the creation of chimeric genes. These events often involve 
short homologous repeats. Two classes of maternally inherited disorder are linked to 
rearrangements of mtDNA in plants; the first is cytoplasmic male sterility (CMS), the 
second is abnormal growth associated with striped leaves (non-chromosomal stripe, 
NCS).
1.4.2.1 Cytoplasmic male sterility
CMS mutants are frequently healthy and vigorous apart from a deficiency in pollen 
development, although the morphology of the inflorescence may be more widely 
affected in some species (for reviews see Pring and Lonsdale, 1989; Hanson and 
Folkerts, 1992). In many systems, the CMS phenotype involves aberrations in 
parental anther tissues just prior to male meiosis, particularly tapetal tissue. The 
tapetal layer both synthesises and stores large amounts of nutrients (e.g., nucleic 
acids, proteins and lipids) which are used by the pollen mother cells and the 
developing pollen grains (Conley and Hanson, 1995). Male sterility can be caused by 
nuclear mutations, through nuclear/mitochondrial incompatibility, or by 
rearrangements of the mitochondrial genome. In the case of mitochondrial 
rearrangements, the genotype is usually homoplasmic and tends to be stable over 
many generations. The rearrangements create novel ORFs which segregate with the 
CMS phenotype in a number of systems, including Petunia, maize, Brassica, radish, 
sunflower and rice (reviewed by Conley and Hanson 1995). The first two 
mitochondrial loci shown to correlate with the CMS trait were found in the CMS-T
strain of maize (Dewey et al., 1986) and the S-pcf strain of Petunia (Young and
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Hanson, 1987). In both cases, multiple recombination events have led to a stably 
inherited, novel, chimeric gene which is expressed, producing a chimeric polypeptide 
and resulting in a tissue-specific phenotype.
In Petunia, CMS is associated with the presence of the novel, chimeric gene p c f  
(Boeshore et al, 1985; Young and Hanson, 1987). The gene is composed of a copy 
of the first portion of the ATP synthase subunit 9 gene (5' flanking region and 35 
codons), noncontiguous portions of exons 1 and 2 of coxll (158 codons), and an 
unidentified reading frame, urf-s (157 codons) (Young and Hanson, 1987). Although 
no sequences homologous to urf-s were found in the database, it has been reported 
that an urf-s probe hybridised to total DNA prepared from fertile petunia lines, and 
the progenitor sequence may therefore be present in 1 of the 3 plant genomes 
(Nivison et al, 1994). Northern analysis has demonstrated that in CMS Petunia the 
p c f  gene is transcribed. Three 5' termini have been mapped for the p c f  transcripts, and 
normal atp9 and coxll transcripts are also present. The major species of p c f  transcript 
(which is the shortest transcript) is present at a 5-fold higher level in anthers 
compared to leaves, whereas the atp9 transcripts are roughly equivalent between 
tissues. The absolute level of the p c f  transcript is also high in ovaries, but the authors 
discount the significance of this due to the increase in absolute levels of all 
mitochondrial RNA species in ovarian tissue. The p c f  transcript is not present in 
fertile lines (Young and Hanson, 1987). In fertile revertant lines restored by the 
nuclear gene R f  RNA levels of the shortest of the 3 mapped p c f  RNA  species are 
reduced (Pruitt and Hanson, 1991). The p c f  gene is cotranscribed with the 
downstream genes nad3 and rpsl2 (Rasmussen and Hanson, 1989). The atp9-coxII 
portion of the p c f  transcript, as well as the downstream nad3 and rps!2, are edited 
normally (Lu and Hanson, 1992; Nivison et al, 1994).
The predicted molecular mass of the pc/-encoded polypeptide is 43 kDa. The 
apparent molecular weight of this protein on denaturing gels is 55 kDa. However, the
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full-length protein was only detected by immunoprecipitation of protein from purified 
mitochondria, as it is a precursor protein which is rapidly processed (Nivison et al, 
1994). The mature protein, referred to as PCF, which had previously been shown to 
be specific to CMS lines, has an apparent molecular weight of 25 kDa (Nivison and 
Hanson, 1989) and an actual molecular mass of 19.5 kDa. Amino-terminal 
sequencing of PCF demonstrated it was encoded entirely by the urfS portion of the 
chimeric gene (Nivison et al, 1994). The other putative processing product(s) of the 
precursor protein are not detectable by anti-ATP9 or -COXII antiserum, although the 
anti-COXII antiserum could detect the full-length precursor protein (Nivison et al,
1994). PCF has been detected in both soluble and membrane fractions, and is 
therefore thought to be peripherally associated with the inner membrane rather than 
an integral membrane protein (Nivison and Hanson, 1989; Nivison et al, 1994). The 
abundance of PCF is reduced in fertility restored Petunia lines (Nivison and Hanson, 
1989). The protein is highly expressed in sporogenous tissue and the tapetal layer of 
the premeiotic and meiotic anthers in sterile plants, as well as in vascular tissue, an 
expression pattern similar to ATP synthase (Conley and Hanson, 1994).
Mitochondrially targeted PCF has been expressed in transgenic plants using both a 
constitutive promoter and a tapetal-specific promoter, but the plants were male fertile 
(Wintz et al, 1995). As both promoters exhibit low activity in sporogenous tissue in 
early meiosis, the constructs may have failed to mimic an essential factor in the 
production of the CMS phenotype. Additionally, the expression pattern differed from 
that observed in CMS plants as all transgenic PCF protein was present in the soluble 
fraction. The constructs contained only the urf-S region which encodes the 25 kDa 
protein; thus, the amino-terminal portion of the chimeric protein may include 
membrane-targetting information integral to the phenotype (Wintz et al, 1995).
In the CMS petunia strain a reduction in electron transport through the cyanide-
resistant alternative oxidase pathway has been documented by oxygen electrode
32
analysis of respiration in suspension cells and suspension cell mitochondria (Connett 
and Hanson, 1990). The alternative oxidase pathway allows biosynthetic activity to 
continue in the presence of high levels of ATP, which may be important to tissues 
such as the tapetal layer and sporogenous tissue. The presence of the nuclear gene R f  
restores fertility, reduces the abundance of the pcf-Qncoded peptide, and restores the 
activity of this pathway. Connett and Hanson (1990) propose that the activity of this 
pathway may be critical to pollen development and that PCF protein may directly 
disrupt its regulation.
Three strains of maize have been identified which carry the CMS trait. In the CMS-T 
strain, the associated chimeric mitochondrial gene is ur/13, which is derived from the 
5' flanking region of atp6, the 3' flanking region of the 26S rRNA gene (88 amino 
acids), 9 amino acids derived from an unknown sequence, and part of the 26S rRNA 
coding region (18 amino acids). Ur/13 encodes a 13 kDa integral membrane protein 
which has been detected in all tissues of CMS-T maize plants tested (etiolated 
seedlings, immature cobs, green leaves, roots). The presence of the nuclear restorer 
gene Rfl results in a decrease in abundance of the 13 kDa protein, and an alteration in 
the pattern of observed transcripts to that of fertile revertants(Dewey et al., 1987). 
However, the presence of a second nuclear gene R/2 is required to restore fertility. 
Alternatively, fertility can be restored by further rearrangement of the mitochondrial 
genome as in the maize CMS-T revertant line analysed by Fauron et al, (1990) in 
which a 165 kb duplication event was associated with a 423 bp deletion comprising 
the ur/13 locus (Fauron et al, 1990). In the CMS-T strain of maize, sensitivity to a 
fungal toxin (called both BmT-toxin and HmT toxin in the literature, dependent on 
the nomenclature used for the fungal pathogen) is associated with the male sterile 
phenotype. In the presence of the insecticide methomyl or the fungal toxin, CMS-T 
mitochondria exhibit uncoupling of oxidative phosphorylation and leakage of 
molecules such as NAD+. Expression of the 13 kDa protein in E. coli in the presence
of the fungal toxin or methomyl inhibits respiration (Dewey et al., 1988). The
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universal code equivalent of urfl3 has also been expressed in S. cerevisiae. When 
targetted to the mitochondria by a transit peptide and expressed in the presence of 
toxin/insecticide it mimics the effects seen in maize (Glab et al, 1990). It has been 
suggested that the 13 kDa protein encoded by urfl3 forms a channel in the 
mitochondrial membrane in the presence of the insecticide methomyl or the fungal 
toxin, thus permeabilising the membrane. Thus, the phenotype, protein expression, 
and an environmental factor have been shown to be associated in three systems.
Several theories have been proposed as to the molecular mechanism which causes the 
CMS phenotype. At the RNA level it has been suggested that interference with the 
transcription or processing of cotranscribed genes could play a role, as in Polima 
CMS Brassica (Singh and Brown, 1991). However, this does not appear to be the 
case in Petunia or maize CMS-T. The extreme demands placed on tapetal and 
sporogenous tissue may make them more vulnerable to disturbance of mitochondrial 
function, assuming a 'general' detrimental effect of the chimeric peptide. The reliance 
on the alternative oxidase pathway may be tissue-specific, and integral to 
pathogenesis (Connett and Hanson, 1990). An increased abundance of the 
detrimental protein in reproductive tissue as compared to other tissues may be 
significant (e.g., Petunia). It is possible that a tissue-specific gene product is involved 
(anther-specific and pollen-specific isoforms of proteins have been identified, Houlne 
and Boutry, 1994; DePaepe et al, 1993). In maize anthers some natural compound 
may act in a manner analagous to the fungal toxin or methomyl, thereby causing 
respiratory deficiency in a tissue-specific manner. It is conceivable that the second 
requisite restorer allele Rf2 may alter the expression of this hypothetical anther- 
specific factor.
34
1.4.2.2 Nonchromosomal stripe mutants
The other class of maternally inherited disorder which has been identified in plants is 
the non-chromosomal stripe (NCS) phenotype in maize. NCS plants exhibit stunted 
growth, aborted kernels, and a characteristic striping of the leaf. The striping can vary 
in colour from yellow to pale green/white, or the stripes can be necrotic. The 
mitochondrial genotype of these plants is heteroplasmic and the severity of the defect 
appears to be related to the relative amount of mutant mtDNA present. Maternal 
inheritance of the defect is demonstrated by reciprocal crosses with normal plants.
An individual cross between an NCS plant and a plant lacking the NCS mtDNA will 
generate a range of phenotypes in the progeny, including normal derivatives which 
have no striped leaves. Normal derivative plants do not transmit the phenotype and 
have been shown to be homoplasmic for wild-type mtDNA. The mutant mtDNA is 
generated by the deletion of a segment of DNA bordered by short repeat sequences of 
less than 100 bp. The deletion events in the NCS lines studied have generated 
chimeric genes. All the NCS lines referred to here are derived from line WF9, which 
also produced CMS-T; this suggests there may be a factor in the nuclear background 
which predisposes this line to mtDNA rearrangement (Newton and Coe, 1986). The 
NCS3 deletion involves the 5' region of the ribosomal protein gene rps3, and exhibits 
necrotic sectors in leaves. The NCS5 and 6 deletions involve the 5' end of coxll and 
exhibit yellow leaf sectors. The NCS2 deletion involves the 3' end of nad4 and 
exhibits broad, pale green stripes. (Hunt and Newton, 1991; Lauer et al, 1990; 
Newton et al., 1990; Marienfeld and Newton, 1994).
The sectored phenotype is due to somatic segregation of the mutant and wild-type
mtDNA molecules; in NCS6 mutants only the mutant mtDNA is detectable by
Southern blotting of DNA isolated from within the yellow stripes characteristic of the
line, while green sectors of leaf harbour equivalent amounts of the two molecules.
However, aborting kernels from this line are not homoplasmic mutant, which suggests
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that a threshold exists - either for the number of copies of wild-type mtDNA 
molecules required to encode the coxll message, or for the number of mutant 
molecules encoding the abnormal transcript that can be tolerated. In culture, 
heteroplasmic callus tissue can be maintained, but if respiratory stress is induced (e.g., 
by infrequently changing the media) there is a strong selection for the wild-type 
genome (Gu et al., 1993; Newton, 1994)
The aspect of the phenotype seen as striping of the leaves indicates a pleiotropic 
effect of the mtDNA lesion. In NCS6 both the structure and function of chloroplasts 
are altered in the yellow leaf sectors. These sectors contain about 30% of the normal 
levels of chlorophyll, and fluorescence data suggest a limitation, though not a block, 
in photosynthetic electron transport after PSII. Electron microscopy shows the 
chloroplasts to be small with a poorly developed thylakoid membrane system and no 
accumulation of starch granules. CO2 fixation data shows no detectable labelling of 
yellow leaf sectors with 14C. Since the fluorescence and protein data would indicate a 
reduced level of photosynthesis, the implication is that mitochondria have a role in the 
development of chloroplasts and carbon metabolism. Chloroplast biogenesis and 
function may be affected by intracellular ATP levels based on previous studies using 
oligomycin as an inhibitor of mitochondrial ATPase (Kromer and Heldt, 1991; Gu et 
al., 1993).
The cases of CMS presented here demonstrate how a mitochondrial mutant can have a
tissue-specific phenotype, either through interaction with a tissue-specific factor or
possibly where available levels of cellular energy are critical to the development or
performance of a given tissue. The NCS mutants show us that where heteroplasmy
exists, different tissues may have varied threshholds for exhibiting a mutant
phenotype. They also demonstrate how gross the pleiotropic effects of a
mitochondrial defect can be. The question of why variation in the specific site of the
mitochondrial lesion produces subtle variation of the phenotype needs to be
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addressed. The mechanism which generates the illegitimate rearrangements in plants 
frequently involves short repeat sequences (6-100 bp) at the deletion junctions. Hunt 
and Newton (1991) suggest that intramolecular recombination between the short 
reiterated sequences is a more likely mechanism than replication slippage, due to 
examples such as NCS3 where the progenitor regions are separated by 100 kb on the 
mastercircle map. These examples of mitochondrial mutants found in plants may 
provide a useful conceptual model for the analysis of pathogenic mtDNA mutations in 
humans (section 1.5).
1.4.3 Mitochondrial DNA rearrangements in animals
Deletions in mitochondrial DNA occur in animals as diverse as mice, Drosophila and 
C. elegans (Boursot et al, 1987; Volz-Lingenhohl et al., 1992; Melov e ta l, 1994). A 
mutant strain of Drosophila subobscura has been isolated from the wild which 
possesses a heteroplasmic mtDNA population in which approximately 80% of the 
molecules contain a 4.9 kb deletion (Beziat et al., 1993). The deletion was equivalent 
to more than 30% of the genome, and encompassed subunits of complex I, complex 
III, and several tRNAs. The mutant displays no overt whole-organism phenotype; it 
is comparable to the wild-type strain for fertility (both number of eggs laid and 
number of offspring produced), its lifespan is normal, and its flight capacity is 
unaffected (Volz-Lingenhohl et al., 1992). The mutation is genetically stable. There 
is some variation in the proportions of mutant to wild-type mitochondrial DNA 
between tissues, with a small decrease in the proportion of mutant mtDNA in the male 
abdomen as compared to thorax and head, and a substantial decrease in the female 
abdomen (Beziat et al., 1997). When comparing levels of mtDNA to nuclear DNA, 
the mutant was found to have an elevated proportion of mtDNA (1.5x) as compared to 
the wild-type (Beziat et al., 1993). Given that the number of mitochondria per cell is 
reportedly unchanged, the authors suggest that the upregulation of mtDNA copy
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number may be a mechanism to compensate for deficiency of intracellular energy or a 
low redox state.
An anlysis of steady-state levels of mitochondrial transcripts showed no change as 
compared to wild-type in the levels of transcripts from genes not involved in the 
deletion. The genes which are deleted in the mutant genome have transcripts present 
at -35% (ND5) - -65% (cyt b) of the wild-type level. The fusion transcript was 
present at an intensity approximately equivalent to that of ND1 (involved in the 
deletion), which was -45% of wild-type (Beziat et al, 1993). Thus, the transcript 
levels are not directly proportional to the copy number of the mtDNA. The authors 
suggest that the relatively low level of the fusion transcript could be due either to a 
reduced rate of transcription of mutant mtDNA molecules, or instability of the 
transcript. The authors also suggest that '’overtranslation" of wild-type transcripts 
may protect them from degradation leading to an elevated proportion of transcripts 
relative to the proportion of the wild-type and deleted genomes. However, this would 
suggest that the translation mechanism can preferentially utilise transcripts which are 
in short supply, since the undeleted region of the genome produces transcripts present 
at the same steady-state levels as in wild-type flies.
The authors have also assessed the activity of the respiratory complexes in different 
tissues (head, thorax and male/female abdomen). Complex I activity is decreased in 
the mutant in all tissues. Complex III activity is reduced in thorax (muscle tissue- 
enriched fraction) and the female abdomen (germ cell-enriched). Neither complex IV 
activity, nor ATP synthase activity were compromised with respect to the wild-type 
strain (Beziat et al., 1997). Thus, the biochemical defects were apparently localised 
to the molecular defect, and in a tissue- and sex-dependent manner. The authors 
suggest that loss of tRNAs has not affected translation, as complex IV activity is 
normal. However, it is also conceivable that there is overcapacity of protein synthesis
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within the mitochondrial system, or that a mechanism to extend the lifespan of 
functional subunits exists.
C. elegans has been presented as a suitable animal model in which to study the 
mechanism by which mitochondrial DNA deletions accumulate with age. Melov et 
al., (1995) utilised a PCR screen to assay 900 animals from 3 different strains of C. 
elegans for age-associated deletions of the mitochondrial genome. Two of the strains 
were wild-type, whilst the third was an age-1 mutant displaying an increased lifespan. 
The age-1 mutation is a single gene defect producing a phenotype of stress-resistance; 
biochemically the organisms have increased levels of Cu/Zn superoxide dismutase 
and catalase in older animals, compared to wild-type, the maximum lifespan is 
doubled, whilst the mean lifespan is increased by 65%. The primers used for PCR 
spanned a 6.3 kb region, roughly half the genome, which encompassed subunits from 
all 4 complexes to which the mitochondrial genome contributes. Many amplified 
products were generated which were non-mitochondrial in origin; however, the 
authors did not amplify any of these molecules from suitable controls and maintain 
that they are not artifacts. Of the products which were shown to be mitochondrial by 
southern blotting, at least 10 discrete deletions were detected in this region of the 
mitochondrial genome. None of the rearranged molecules were present at sufficient 
levels to be detected by southern blotting, raising questions about their significance.
In the wild-type strains there was a statistically significant difference in the frequency 
of deletions detected at the mean lifespan (day 9) when compared to young animals 
(day 3). It should be noted that the number of deleted mtDNA molecules observed 
varies greatly from day to day in all 4 experiments reported. Furthermore, in 1 of 3 
experiments with the wild-type strains a statistically significant increased in deleted 
mitochondrial DNA molecules compared with day 3 animals is already present at day 
5. The authors postulate that the observed variability could be due to death of cells
with elevated levels of deleted mitochondrial DNA, or elimination of deleted
39
mitochondrial DNA via some mechanism. Despite the variation in data, making the 
authors' conclusions questionable, there is a trend which suggests that the age-1 
mutant, although it does exhibit deletions, develops them later and at a lower 
frequency than the wild-type (Melov et al., 1995). This would indicate that an 
elevation in the level of antioxidant enzyme synthesis protects against damage to 
mtDNA.
Melov et al, have also analysed the breakpoints of some of the deletion junctions. Of 
6 breakpoints reported, 5 involved direct repeats of 4-8 bp, whereas the 6th occurred 
between 2 sites which exhibited 18/25 bp homology (Melov et al, 1994, 1995). Of 
the 4 breakpoints reported in the earlier paper, 6/8 sites involved tRNAs. The authors 
suggest that stem-loop structures may therefore be involved in the deletion process 
(Melov et al, 1994).
The third animal model I shall discuss is a mouse model for cardiomyopathy, which 
has been associated with mitochondrial DNA deletions (Adachi et al, 1993, and 
references therein). Doxorubicin (DOX) is a glycoside antibiotic which can cause 
cardiotoxicity and heart failure in humans as well as several animal models, including 
mouse. One suggested mechanism is that DOX causes production of free radicals 
which attack mtDNA, leading to mitochondrial DNA deletions. Adachi et al, 
assayed for a 4 kb mtDNA deletion induced in cardiomyocytes by doxorubicin 
administration in a dosage- and time-dependent manner. They also tested for 
protection from mtDNA deletion by the free radical scavenger coenzyme Q10 at 2 
dosage levels of DOX. The incidence of myocardial mtDNA deletion did correlate 
with DOX administration in both a dosage- and time-dependent manner (3 time points 
of 4, 8, and 12 weeks treatment). Coadministration of Q10 with DOX did 
significantly decrease the incidence of mtDNA deletions detected. The authors 
propose that the mtDNA deletion is involved in cardiomyopathy (Adachi et al, 1993).
However, the PCR protocol used to amplify the mtDNA was not quantitative, so the
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level to which the deletions accumulated is not known. The physiological 
significance of the data has not been shown.
1.5 Rearrangements of mitochondrial DNA in humans
Mitochondrial disorders are predominantly encephalomyopathies due to the high 
energy requirements of brain and muscle tissues (reviews by Schon et al., 1994; 
Shoubridge, 1994; Larsson and Clayton, 1995; Papa et al., 1996). Because these 
tissues are largely non-dividing in the adult the founder population of mitochondrial 
DNA with which they are endowed is critical. If the founder population is 
heteroplasmic and includes mutated mitochondrial DNA molecules, these will persist 
in the organ; they cannot be lost through mitotic segregation unlike in rapidly dividing 
tissues such as blood or stem cells. Biochemically, most mitochondrial diseases 
present with respiratory chain deficiency and lactic acidosis. Biopsies of skeletal 
muscle typically display a pathology of ragged red fibres (RRF), which are 
characterised by the proliferation of morphologically and biochemically abnormal 
mitochondria. Common clinical manifestations include the ocular myopathies 
(ophthalmoplegia and ptosis), skeletal muscle weakness, seizures, dementia, and 
stroke-like episodes.
1.5.1 Diseases
Deletions of mitochondrial DNA were first reported in association with mitochondrial 
myopathies by Holt et al., 1988. The relationship between clinical presentation and 
molecular defect was clarified by Zeviani et al., 1988, in a report which linked 
mtDNA deletions with Keams-Sayre Syndrome (KSS) specifically, as opposed to the 
other mitochondrial myopathies and encephalomyopathies which they investigated. 
Since then, deletions have also been reported in cases of sporadic Progressive 
External Ophthalmoplegia (PEO) (Holt et al., 1989; Moraes et al., 1989) and
41
autosomal dominant PEO (Zeviani et al., 1989). Although heteroplasmy normally 
refers to one mutant mtDNA species and one unmutated species, in autosomal 
dominant PEO (adPEO) multiple forms of deleted mtDNA coexist with wild-type 
mtDNA. In this disorder, a nuclear mutation predisposes the affected individual to 
deletions in mtDNA. Partial duplications of mtDNA in mitochondrial 
encephalomyopathies were first reported by Poulton et al., (1989a, b) in 2 KSS 
patients with diabetes mellitus. The symptoms exhibited in the myopathies which are 
associated with mtDNA rearrangements thus range from the relatively mild ocular 
myopathy PEO to the relatively severe KSS. KSS by definition has 3 invariant 
symptoms, ophthalmoplegia, pigmentary retinopathy, and onset before age 20, with at 
least one of the following symptoms: cardiac conduction block, cerebellar syndrome, 
cerebrospinal fluid >100 mg/dl. Other frequently associated clinical features include 
deafness, proximal limb weakness, endocrinopathies and renal tubular dysfunction.
Other disorders which have since been found to be associated with mtDNA 
rearrangements include Pearson's bone marrow/pancreas syndrome (Rotig et al., 
1989), (onset is in infancy/early childhood and presents with sideroblastic anemia and 
exocrine pancreatic dysfunction); adult onset diabetes mellitus and deafness 
(AODMD) (Ballinger et al., 1992); inclusion body myolitis (IBM), a sporadic 
inflammatory myopathy (Oldfors et al., 1993); diminished male fertility (Kao et a l,
1995).
Two other mutations which are associated with a similar range of phenotypes in vivo 
include the nuclear defect which leads to mitochondrial DNA depletion, and one of 
several point mutations in the tRNA1^ 11^ 11) gene. The former is characterised by 
respiratory chain defects, mitochondrial proliferation and severe depletion of mtDNA 
in the affected tissue. Thus, in vivo, mitochondrial proliferation can occur 
independently of mtDNA replication. In cases of later onset, mtDNA depletion
exhibits a segmental pattern in muscle tissue, and can display 70-90% reduction in
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mtDNA (Larsson and Clayton, 1995, Schon et al., 1994). Thus an absolute reduction 
of wild-type mtDNA can result in mitochondrial dysfunction. The mutation at 
nucleotide (nt) 3243 in the tRNALeu(UUR) gene typically presents as MELAS 
(Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes). 
Although roughly 1/2 of PEO patients possess mtDNA deletions, of the remaining 
half approximately 1 in 3 has the nt 3243 MELAS mutation. These cases are 
clinically indistinguishable from each other apart from their molecular genetic 
etiology; most mtDNA deletions are sporadic in origin, whereas most point mutations 
are inherited through the maternal lineage. In addition, diabetes and deafness have 
been associated with this same point mutation (van den Ouweland et al., 1992).
1.5.2 Correlation of phenotype with genotype in human diseases
Over 100 mtDNA rearrangements, including many different deletions and potential 
duplications, have been linked to mitochondrial degenerative diseases; the two 
replication origins are not involved in the majority of these rearrangement events in 
that all rearranged molecules contain at least one copy of each origin. The molecular 
mechanism responsible for these rearrangements has not been determined, and several 
possibilities have been proposed, e.g., slipped mispairing between distant repeats 
during mtDNA replication, homologous recombination, or breakage and ligation as a 
result of the activity of an enzyme such as a topoisomerase or a catenane resolvase. 
Over 95% of mtDNA deletions occur within the major arc - the section defined by the 
Heavy- and Light-strand origins, which encompasses ~ 2/3 of the mitochondrial 
genome. All large-scale rearrangements have encompassed tRNA genes as well as 
protein-coding genes. A 4,977 bp deletion which spans nt 8,482-13,460 and is 
bordered by 13 bp direct repeats has been observed so frequently it has been dubbed 
the common deletion (Schon et al, 1989). Although the majority of rearrangements 
detected have been sporadic in origin, and were therefore thought to be somatic
mutations, germ-line transmission was first documented by Poulton et al., (1991), and
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subsequently demonstrated by others (Rotig et al, 1992; Ballinger et al, 1992). It 
may be significant that partial duplications have been detected in germ-line 
transmission more frequently than would be predicted purely on the basis of the 
number of rearrangements reported (Rotig et al, 1992; Ballinger et al, 1992; Dunbar 
etal., 1993).
Genetic rearrangements of mtDNA are linked to specific diseases, albeit with a broad 
clinical spectrum. The rearranged molecules of mtDNA have only been detected 
when coexisting at the cellular level with unmutated mtDNA, a condition known as 
heteroplasmy. It is generally held that the specific tissue-distribution of the mutant 
molecule in the affected individual contributes to the phenotype. It is controversial as 
to whether the relative proportions of mutant to wild-type molecules contribute 
significantly to clinical presentation (discussed in detail in section 1.5.3), but the 
concept of a threshold at which mitochondrial energy output becomes insufficient to 
meet cellular demand is often used. Attempts to quantitate this threshold will be 
discussed with regard to rearrangements in section 1.5.3; it is useful to consider that 
in cellular model systems a threshold of approximately 90% mutant mtDNA has been 
observed for several tRNA point mutations, above which protein synthesis is impaired 
and respiratory activity compromised (Moraes et al., 1993; Attardi et a l, 1995). This 
implies that 10% wild-type mtDNA is sufficient to complement the remaining mutant 
molecules, or that 10% of the wild-type mtDNA normally found in the cell is 
sufficient for cellular requirements in these cell systems.
A threshold is a useful conceptual tool for interpreting the phenomena observed in
mitochondrial diseases. Identical deletions have been reported in individual cases of
KSS, CPEO, and Pearson's Syndrome. Survivors of Pearson's syndrome may develop
KSS later in childhood (Larsson et al., 1990). Thus the same genetic defect may
manifest as a different disease, and in cases of maternal transmission, the same
genetic defect may be present in apparently unaffected relatives. Within the affected
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tissue it would appear that a certain amount of the rearranged molecule must be 
present in a focal manner (either intramitochondrial or intracellular) to produce a 
phenotype. This threshold amount may depend on multiple factors, including the 
nuclear background. Each individual patient will possess a slightly different nuclear 
background which may contain alleles that alter their susceptibility to the 
mitochondrial genetic lesion. Nuclear background has been shown to influence the 
segregation of mutant and wild-type mtDNA in cybrids harbouring molecules with 
the MELAS 3243 mutation (Dunbar et al., 1995). As a result of mitotic segregation 
(see section 1.3.5.2), the proportion of rearranged mtDNA can exceed the critical 
threshold for a given tissue in a focal lesion despite the overall proportions of mtDNA 
for the tissue being within the limits capable of sustaining cellular function.
Some tissues will present with a clinical symptom at a lower proportion of mutant 
mtDNA than others. An example is the typical progression of AODMD; progressive 
sensory neural hearing loss commonly presents in the second decade of life, usually 
followed by the development of type II diabetes mellitus in the third or fourth decade. 
This may imply that auditory neural tissue has a greater reliance on the oxidative 
energy supply than the pancreas, or alternatively that it is more sensitive to oxidative 
damage caused by dysfunctional mitochondria. Northern analysis of cells derived 
from a patient with a tRNA point mutation provided evidence that fibroblasts and 
muscle tissue process the mitochondrial polycistronic transcript differently (Bindoff et 
al, 1993). The intermediate species 'RNA 19', (identified by King et al., 1992), 
accumulated to very high levels in skeletal muscle, but was only slightly elevated in 
fibroblasts compared with controls. Therefore, an abnormal transcript resulting from 
a mtDNA mutation could disrupt RNA processing differently, depending on cell type. 
In mice heterozygous for deletion of the nuclear gene which encodes mitochondrial 
transcription factor A (mtTFA, see section 1.3.2), which led to a partial depletion of 
mtDNA, compensation for decreased transcription by regulation of mRNA stability
and translation occurred to varying extents in different tissues (Larsson et al., 1998).
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Larsson et al., observed that in these mice skeletal muscle was normal with respect to 
respiratory activity and transcript levels. However, heart tissue displayed decreases in 
the level of mRNA, the protein level of at least one mitochondrially-encoded subunit, 
and in the respiratory activity of complexes I, III, IV, and V. Thus, cardiac tissue may 
be more sensitive to the disruption of mitochondrial gene expression than skeletal 
muscle tissue.
To draw analogies from other mitochondrial diseases discussed above, gross 
rearrangements of mtDNA could lead to mitochondrial dysfunction in several ways. 
One possibility is that the production of abnormal transcripts might interfere with 
RNA processing. Alternatively, a relative depletion of some of the normal transcripts 
could be disruptive in itself. Another possibility is that an imbalance in encoded 
tRNAs could disrupt mitochondrial translation. A possibility which is specific to 
these diseases is that the creation of a novel chimeric gene at the site of the mtDNA 
rearrangement encodes a novel peptide which is disruptive to normal mitochondrial 
function. It is conceivable that the mode of disruption may be specific, in that the 
chimeric peptide disrupts assembly/activity of the respiratory complex in which the 
subunit it most closely resembles would have inserted. It is also possible that the 
mechanism could be more general, and the presence of any abnormal hydrophobic 
peptide is disruptive to mitochondrial function, perhaps by insertion into the inner 
membrane, or by sequestering mitochondrial chaperones.
As discussed in the section on CMS (section 1.4.2.1), a novel chimeric protein in 
plant mitochondria leads to mitochondrial dysfunction in a tissue-specific manner. 
Mammals express tissue-specific isoforms of some nuclear-encoded components of 
the respiratory chain (reviewed by Lomax and Grossman, 1989), and it is possible that 
these play a role in the phenotype of mitochondrial diseases. The presence of 
isoforms indicates a requirement for specialisation of the protein function or, in the
case of 'silent' isozymes with identical coding sequences, a specialisation of the
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regulatory function. One example is that of cytochrome c, the substrate for 
cytochrome c oxidase. It has been shown in mouse that a testis-specific isoform, 
differing at 13 of 104 amino acid residues from the somatic isoform, is expressed 
early in mouse development, and is present only in germ cells (Virbasius and 
Scarpulla, 1988). A testis-specific cytochrome c has also been found in rat, rabbit, 
and bull (Kim and Nolla, 1986). The development of male gametes is affected in 
organisms as diverse as mammals and plants in diseases which involve 
rearrangements of the mitochondrial genome. A second example involves subunits of 
the COX complex. At least three nuclear subunits (Via, Vila, and VIII) exist as 
tissue-specific isoforms, which are restricted to contractile muscle tissue (Schlerf et 
al., 1988). Tissue-specific isoforms of protein subunits could reflect a higher energy 
requirement of these tissues, or serve as a target for the disease mechanism.
1.5.3 Distribution of rearranged mtDNA within muscle fibres
Many studies have now been done to analyse the distribution and expression of 
rearranged mtDNA in skeletal muscle. No strict correlation has been found between 
the proportion of COX deficient fibres and the total fraction of rearranged mtDNA in 
muscle tissue as detected by Southern blotting (Oldfors et al, 1992). In situ 
hybridisation has demonstrated a large focal accumulation of rearranged mtDNA, 
predominantly in the subsarcolemmal region of RRFs, where mitochondrial 
proliferation occurs (Mita et al, 1989; Shoubridge et al, 1990; Collins et al, 1991; 
Hammans et al, 1992b; Prelie et al, 1994). The rearranged mtDNA is transcribed in 
RRFs, as evidenced by the detection of mRNAs from the undeleted region of the 
mitochondrial genome at levels corresponding to the proportion of rearranged 
molecules detected (Mita et al, 1989; Shoubridge et al, 1990; Oldfors et al, 1992; 
Hammans et al, 1992b; Moslemi et al, 1996). A 6-fold overall increase in 
mitochondrial mRNA levels has been estimated in RRFs (Shoubridge et al, 1990;
Hammans et al, 1992b). This figure tallies with the 4-6 -fold increase in the amount
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of total mtDNA in RRFs estimated by quantitative PCR (Sciacco et al., 1994). In situ 
hybridisation of longitudinal sections indicates the segmental nature of the elevated 
expression of the rearranged mtDNA molecules (Shoubridge et al, 1990). In adPEO, 
although multiple species of deleted molecule are present in affected patient tissues, 
only one form of deleted molecule can be detected in each affected segment using 
single fiber PCR (Moslemi et al, 1996). This suggests that affected fiber segments 
contain clonal populations of mtDNA produced by single somatic deletion events. 
Linkage analysis has implicated at least three autosomal loci in the generation of 
mtDNA deletions in adPEO (Suomalainen et al, 1995; Kaukonen et al, 1996). It 
should be noted that 3 patients in which the deletion encompasses the heavy-strand 
promoter region were found to have elevated light-strand transcription in RRFs, as 
expected, given the accumulation of rearranged mtDNA, but heavy-strand transcripts 
were only detected at low levels (Moraes et al, 1991; Hammans et al, 1992b).
The proportion of wild-type mtDNA in RRFs is agreed to be low, but the absolute 
amount is in question. Some studies have indicated that wild-type mtDNA and the 
corresponding transcripts are present at normal levels (Shoubridge et al, 1990;
Collins et al, 1991), whereas others have indicated that the unrearranged molecules 
and the corresponding transcripts are present, but at decreased levels in both 
cytochrome c oxidase-deficient fibres and RRFs (Hammans et al, 1992b; Mita et al, 
1989; Oldfors et al, 1992; Prelle et al, 1994). Two of the above studies have found 
variaton between and within patients such that wild-type transcripts were sometimes 
elevated in affected fibres (Collins et al, 1991; Oldfors et al, 1992). Differences of 
opinion can partly be attributed to differences in methodology (such as what range is 
considered 'normal' in Type I fibres). Utilising PCR on single fibres one study 
detected no wild-type mtDNA in some COX-deficient fibres (Moslemi et al, 1996).
In fibres normal for COX activity most studies have shown normal levels of wild-type
mtDNA, with little or no rearranged mtDNA (Mita et al, 1989; Shoubridge et al,
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1990; Hammans et al, 1992b; Oldfors et al, 1992; Prelie et al, 1994). Using semi- 
quantitative PCR 2/7 non-RRFs tested contained 18% and 27%, respectively, 
rearranged mtDNA molecules (Shoubridge et al, 1990). The authors presume these 
to be fibres intermediate in character, i.e., cytochrome c oxidase-deficient, but not 
progressed to RRF. However, a subsequent study utilising quantitative PCR has 
detected ~15-75% rearranged molecules in fibres normal for cytochrome c oxidase 
activity (Sciacco et al., 1994). One of four patients in this study (all of whom had the 
common deletion) consistently showed a higher proportion of rearranged mtDNA in 
cytochrome c oxidase-normal fibres. This suggests 2 possibilities; 1) nuclear 
background is integral to clinical presentation, or, 2) loss of COX activity is not an 
absolute indicator of mitochondrial dysfunction. If partially duplicated molecules 
were present in these patients, for example, the actual proportion of rearranged 
molecules would have been underestimated by the authors by the protocol used.
Sciacco et al, 1994, conclude that the accumulation of the rearranged molecules 
precedes the biochemical phenotype, and have postulated a threshold of 85% 
rearranged mtDNA in muscle fiber segments before COX activity is impaired, and 
mitochondrial proliferation is observed. However, Shoubridge et al, 1994, argue that 
although there is a correlation between the accumulation of deleted mtDNA and the 
abnormal COX phenotype, COX deficiency does not necessarily correlate to the 
accumulation of deleted mtDNA. Thus it is argued that a deficiency in OXPHOS 
may be a signal to induce mitochondrial proliferation (Shoubridge et al, 1990; 
Hammans et a l , 1992b). This does not exclude the possibility that, as other authors 
have inferred, a (local) reduction in the absolute levels of wild-type mtDNA may be 
critical to pathogenesis.
A decrease in COX activity is frequently used as a biochemical marker for 
mitochondrial dysfunction, and if detected in parallel with increased succinate
dehydrogenase (SDH) activity is considered an indicator of RRFs (mitochondrial
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proliferation in tandem with loss of mtDNA-dependent mitochondrial function). 
However, Holt et al., 1989, showed that some RRFs do exhibit COX activity. 
Reichmann (1992) demonstrated that enzyme activity (SDH and COX) can be highly 
variable along individual fibres in patients (which would reflect the variable 
distribution of mutant mtDNA molecules), although some fibres lack COX activity 
altogether (Taanman et al., 1996). It was also shown that one CPEO patient (whose 
deletion spanned at least one COX subunit) had high levels of SDH and COX activity 
in RRFs compared to her own normal fibres (Reichmann, 1992). Thus, some of the 
disagreement on mutant versus wild-type mtDNA distribution could also be attributed 
to erroneous categorisation of fibres based on this enzyme assay.
Polarographic analysis has suggested that in patients whose deletions encompass no 
subunit of the cytochrome c oxidase complex, the biochemical defect can be limited 
to complex I (NADH dehydrogenase; ND) (Morgan-Hughes et al., 1990; Hammans et 
al., 1992a). Additionally, within RRFs, a more profound reduction in COX activity 
has been observed in patients with deletions involving cytochrome c oxidase subunits 
than in those where cytochrome c oxidase subunits are not involved (Hammans et a l , 
1992b). This provides indirect evidence that translation of a proportion of transcripts 
from deleted mtDNA occurs in some patients. As all of the deletions in question 
(5/21 and 4/20, respectively) also involve the loss of genes encoding tRNAs, and one 
also included the 2 rRNAs, this would necessitate intraorganellar complementation 
for protein synthesis to occur. If this is the case, it raises the question of why the 
tRNAs (and rRNAs) would be present at sufficient levels to complement at a genomic 
ratio of wild-type to mutant that would be inadequate to observe complementation of 
the mRNAs (the ND subunits within the deleted region of the mtDNA). It is 
conceivable that an abnormal ND chimeric peptide could interfere with normal 
subunit assembly/function of the complex.
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Immunohistochemistry has been used to confirm that some mitochondrial translation 
occurs within RRFs (Mita et al., 1989; Prell et al., 1994; Taanman et al., 1996). All 3 
studies assayed subunits of cytochrome c oxidase, and subunits encoded by both 
deleted and non-deleted genes were detected. The first study detected low levels of 
COXII protein (the gene is not within the deletion), the second study detected COXII 
and III (COXIII was deleted in 8/8 patients, COXII in 2/8), the third study detected 
low levels of COXI and II (COXIII was deleted). Whereas Mita et al., (1989) 
consider the low level of detected protein as evidence of a deficiency in mitochondrial 
translation, Taanman et al., (1996) suggest additionally that limiting amounts of the 
subunit encoded by the deleted region of the mutant genome may prevent assembly of 
the remaining mitochondrially encoded subunits (making them less stable). However, 
the data presented by Prell and co-workers suggests that loss of oxidative function 
cannot be attributed directly to the loss of mitochondrially-encoded subunits in all 
cases. They suggest further that expression of the deleted genomes may be 
functionally dominant. The nuclear-encoded subunit COXIV is overexpressed in 
RRFs (Prell et al., 1994; Taanman et al., 1996) and it has also been suggested that the 
imbalance of nuclear to mitochondrially-encoded subunits could alter the assembly of 
complex IV (Prell et al., 1994). However, Taanman et al., (1996) have shown that 
RRFs lack the nuclear-encoded subunits COXVa, Vb, and Vic; thus, the common 
interpretation of COXIV immunoreactivity as indicative of normal levels of the 
nuclear-encoded subunits of complex IV is not reliable.
As discussed previously, the rearranged mtDNA molecules are transcriptionally 
active. This has been shown conclusively by the detection of the abnormal transcript 
encoded by the chimeric gene in 2 KSS patients, at levels proportional to the level of 
rearranged mtDNAs (in muscle tissue and in derived fibroblast clones) (Nakase et al., 
1990). However, a study which looked at transcripts in muscle tissue from one KSS 
patient found a 10-fold increase of the intermediate processing product 'RNA 19'
(Heddi et al., 1993). It also appears that levels of individual transcripts, whether
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derived from genes internal or external with regard to the deleted region, are not 
strictly proportional to the amount of the respective mtDNA (e.g., the mRNA for 
COXI, a gene external to the deletion, is at lower levels than the chimeric transcript 
across the deletion, whereas the mRNA for ND5, which is internal to the deletion, is 
decreased by 30% from the control level, whereas deleted mtDNA constitutes 74% of 
the total). Heddi et al., (1993) observed an accumulation of unprocessed transcripts 
in skeletal muscle of a young, unaffected son of a KSS patient and speculate that an 
RNA processing defect could be involved in KSS pathogenesis.
1.5.4 Effects on translation of pathological mtDNA rearrangements
The perturbation of steady-state RNA levels reported by Heddi et al., (1993) might be 
expected to manifest as an imbalance of the encoded protein subunits. One study has 
looked at translation in mitochondria isolated from muscle biopsies of 3 CPEO 
patients, each of whom had a different site of deletion in the mutant population of 
mtDNA (Sudoyo et al., 1993). The rate of protein synthesis was within the range of 
10 normal controls. However, the relative amounts of the mitochondrial translation 
products were radically different from the controls. This observed perturbation of the 
proportions of the subunits did not correlate directly with the site of the deletion, nor 
with the overall amount of deleted mtDNA. As an example, COXIII protein levels 
were disproportionately high in one patient in whom the deleted region of mtDNA 
included the COXIII gene, and COXIII protein levels were relatively decreased in 
another patient although the gene encoding COXIII was not deleted. As a trend, it 
would appear that levels of the larger proteins are decreased and the smaller proteins 
increased compared with controls; however, Sudoyo et al, (1993) discounted 
increased proteolytic activity in the mitochondria of patients as a cause of the 
abnormal patterns of mitochondrial protein synthesis. A novel mitochondrial 
translation product was observed in one patient, but the authors did not sequence the
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abnormal junction and could not therefore judge whether this could be a chimeric 
protein.
Whilst Sudoyo et al., (1993) analysed protein synthesis in mitochondria isolated from 
patient tissues, other groups have focused on cellular model systems. Nakase et al., 
1990, reported the results of an assay of mitochondrial translation in SV40- 
transformed fibroblast clones derived from a KSS patient. Clone fl was essentially 
homoplasmic for undeleted mtDNA, whereas clone f4 had approximately 60% 
deleted mtDNA. The figure showing the PAGE of 35S Met-labelled translation 
products from the two clones is open to some interpretation. The authors detected no 
novel band in the region of the gel where the fusion protein is predicted to run. 
Additionally, the authors observed no qualitative difference in the patterns of 
translation products between the two clones. They concluded that this is indicative of 
functional segregation of the abnormal and wild-type mitochondrial genomes, and 
that the transcripts from deleted genomes are not translated. As this paper is 
frequently cited with regard to the first point, it is worth considering the data 
presented in some detail. No indication of statistical error is given, nor any mention 
of repeated observations, therefore it is possible that the data presented are the result 
of a single experiment and should be regarded with due caution. As the authors 
acknowledged, the results could be specific to the one clone analysed. It is also 
possible that, since the control cell-line was patient-derived there were subtle defects 
of translation also present in the "control" mitochondria.
The first observation I would make is that, contrary to the authors' assertions, there 
does appear to be both a quantitative and a qualitative difference between the 
mitochondrial translation products of the two clones. The methods section of Nakase 
et al, (1990) indicates that equal amounts of mitochondrial protein were loaded in the 
two lanes; however, there is clearly a lower level of signal from the heteroplasmic 
clone. If this is not a loading error, it indicates either that mitochondrially synthesised
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proteins are less abundantly synthesised or less stable. Another qualitative difference 
is that, although the majority of protein bands appear less intense from the f4 clone 
than fl, the ATPase 6 band (the lowest molecular weight band identified on the gel) is 
more intense in the f4 lane.
Nakase et al., (1990) have quantitated the 35S signal from the protein bands for the 
three subunits of cytochrome c oxidase. The genes for subunits II and III are within 
the deleted region, whereas the gene for subunit I is completely external to the 
deletion. The authors normalised the raw data for subunits II and III respectively, and 
calculated the predicted ratios for the other two subunits in each case (COXI and III, 
or COXI and II, respectively) on the assumption that the proteins would be present in 
stoichiometric amounts to the DNA which encodes them. In both cases, COXI was 
not present at the high levels they predicted, and they concluded that this is indicative 
of no translation of transcripts from the deleted mitochondrial DNA molecules. 
However, if one approaches the data presented differently, by normalising for the 
level of the subunit which is not expected to change, i.e., COXI, one finds that there is 
evidence of translational cooperation between the two genomes. The proportion of 
radioactivity incorporated into COXI in the f4 clone/fl clone is 37%; the same 
calculation for COXII and COXIII is 46% and 60% respectively. If only transcripts 
from wild-type mtDNA are translated, then the three subunits should have been 
present at the same proportions as in the control clone. If all transcripts are translated 
equally (deleted and non-deleted) there should have been a higher proportion of 
COXI protein than COXII or III. Yet, the observation was that proteins encoded by 
the deleted genes were present at a higher proportion than the COXI subunit relative 
to the control cell line. This would appear to support the data of Sudoyo et al.,
(1993), that the presence of rearranged mtDNA leads to a disturbance of the 
mitochondrial translation pattern.
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With respect to the presence or absence of a fusion protein encoded across the 
rearrangement break point, the fact that no prominent, discrete band was detected by 
Nakase et al., (1990) is accepted. However, if the abnormal protein were present at 
low levels, it could be present in the smear between COXII and III, as this is within 
the author's predicted size range for the fusion protein's apparent molecular weight. If 
it were co-migrating with COXIII it would explain the anomalously high signal for 
the band relative to COXI. Alternatively, if the putative fusion protein were 
migrating with an even lower apparent molecular weight it could be co-migrating 
with ATPase 6, which would explain the extremely intense signal for that band 
compared to the control lane. These possibilities warrant a thorough reinvestigation, 
using other cell clones and other gel systems for resolution of the mitochondrial 
translation products.
Bourgeron et al, (1993), also analysed clonal lines established from a Pearson's 
patient with deleted mtDNA. In fibroblast cells they found that the proportion of 
rearranged mtDNA decreased with time unless the medium was supplemented with 
uridine. In supplemented medium the proportion of rearranged mtDNA increased 
from 60% to 90% within 10 cell doublings, and the authors reported no change in 
total mtDNA content. Thus, the presence of the deleted mitochondrial DNA is 
inferred to be detrimental to cellular respiration, at least within the original nuclear 
background. In EBV-transformed lymphocytes the authors reported a stabilisation at 
-60% rearranged mtDNA, with normal respiratory enzyme activities. Northern 
analysis shows a pattern of transcript abundances which does not strictly correlate 
with the proportions of wild-type and deleted mtDNA, but translation was reportedly 
normal for both total amount and pattern of products synthesised. In this case, 
although the putative fusion protein was reportedly undetected, it is predicted to be 
only ~4.7 kDa and may not have been visible by the gel system used.
55
Spelbrink et al., (1994) also studied lymphoblast cell-lines derived from a Pearson's 
patient, which had 70% deleted mtDNA. By comparing the amounts of nuclear- and 
mitochondrially-encoded COX subunits synthesised to the amounts assembled, they 
concluded that normal respiratory activity was achieved in these cells due to 
overcapacity of mitochondrial gene expression in the wild-type cell. The 
transcription pattern of the patient-derived cell line (as in Bourgeron et al., 1993) was 
not directly proportional to mtDNA, and is similar to that observed in the Drosophila 
model discussed in section 1.4.3. Likewise, an increase in the total mtDNA content is 
observed (Spelbrink et al., 1994, 1997). They reported that the predicted fusion 
transcript was not detected (data not shown). A specific decrease in the synthesis of 
mitochondrial proteins encoded by the deleted region of mtDNA was observed. This 
supports the conclusion that, at intermediate levels of deleted mtDNA, reduced gene 
dosage and a reduction in steady-state levels of the corresponding mRNAs can lead to 
decreased synthesis of specific subunits before the tRNA concentration becomes rate- 
limiting. However, due to the overproduction of subunits, reduction in the synthesis 
of a subunit does not necessarily result in a reduction of the concentration of the 
corresponding enzyme complex.
Low levels of doxycycline, an inhibitor of mitochondrial translation, were 
administered in order to partially inhibit mitochondrial protein synthesis (Spelbrink et 
al., 1997). They found that the proportion of deleted mtDNA declined steadily with 
time. Long-term treatment led to virtual depletion of deleted mtDNA, which was 
stable following the removal of the drug. Short-term administration (5-6 weeks) 
reduced the proportion of deleted mtDNA to ~ 5% of total mtDNA; withdrawal of 
doxycycline at this point was followed by reamplification of the deleted mtDNA 
molecules to ~ 50-60% of total mtDNA. These results support the hypothesis that 
deleterious mutations such as large mtDNA deletions can accumulate to a threshold 
level above which they would confer a phenotypic disadvantage on the cell. This
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threshold can be altered by manipulating the respiratory capacity of the cell, and in 
this particular cell system the smaller mtDNA molecule has a replicative advantage.
In order to distinguish the phenotypic features which may be attributable to the 
presence of the rearranged mitochondrial DNA from the possible contribution of the 
nuclear genome, Hayashi et al, 1991, introduced mitochondria derived from a CPEO 
patient’s fibroblasts into p° HeLa cells. The mtDNA was heteroplasmic for a 5.2 kb 
deletion, which created 2 chimeric genes (due to the overlapping nature of the ATP6/8 
genes); a) ATPase 8/ND5 encoding a predicted fusion protein of 77 amino acids, and 
b)ATPase 6/ND5 encoding a predicted fusion protein of 141 residues. Cybrid clones 
which were heteroplasmic for deleted mtDNA consistently displayed a propagational 
advantage over the smaller molecules in uridine-supplemented medium, up to an 
equilibrium of 75-85% deleted mtDNA, in all 3 clones and their derivatives over 10 
weeks following cellular fusion. The observed threshold for deleted mtDNA content 
was reduced to ~50% if cells were cultured in medium containing galactose rather 
than glucose, suggesting that higher levels of rearranged mtDNA compromised the 
respiratory efficiency of the cells.
The authors reported that the increase in deleted molecules was accomplanied by a 
decrease in wild-type mtDNA such that, contrary to the observations in situ of 
diseased muscle fibres, the total mtDNA content was unchanged. However, the two 
clones compared were, respectively, homoplasmic for the wild-type mtDNA and a 
heteroplasmic clone containing 11% wild-type mtDNA. A Southern blot of Pvull 
digested DNA probed with labeled total mtDNA gave a ratio of 1.12 for mtDNA 
content in the heteroplasmic clone relative to the homoplasmic clone. Although the 
authors concluded that this indicated the total amount of mtDNA per cell to be 
relatively unchanged, when the large deletion and high proportion of deleted mtDNA 
is taken into account, the data actually suggest a significant increase in copy number 
of mtDNA molecules in the heteroplasmic clone. Given that the signal for total
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mtDNA was 10% higher in the heteroplasmic clone, the fact that the deletion covers 
nearly one-third of the genome, and that the deleted molecules constituted nearly 90% 
of the mtDNA population, this suggests an increase of over 50% in copy number in 
the heteroplasmic clone.
Hayashi et al., (1991) reported that transcription, including that of the fusion 
transcript, was proportional to mtDNA content of the clones. Mitochondrial 
translation products were analysed by 35S-Met labelling and bands corresponding to 
both of the putative fusion proteins were identified in clones harbouring 55% and 
61% deleted mtDNA, although the amino acid sequences of the proteins were not 
determined to confirm their identity. This finding indicates translational cooperation 
between the two types of mtDNA molecule in this cell system. Clones containing 
proportions of deleted mtDNA exceeding 60% displayed decreased COX activity and 
a reduction in mitochondrial translation. The perturbation in the proportions of 
proteins translated observed by Sudoyo et al., (1993) in vivo did not occur in this cell 
system. Electron micrographs of mitochondria from a clone harbouring 75% deleted 
mtDNA show a uniform loss of COX activity, accompanied by swelling and 
disorganisation of the inner membrane.
1.5.5 Large-scale duplications of mitochondrial DNA
The first report of a mtDNA mutation which was proposed to be disease-associated 
was the observation of dimeric molecules in tumour cells (Clayton and Vinograd, 
1967; Clayton and Smith, 1975). In these molecules two complete copies of the 
mitochondrial genome were joined in tandem array. Partially duplicated molecules of 
mtDNA have since been shown to be associated with a range of diseases, such as KSS 
(Poulton et al, 1989a, b), renal tubulopathy and cerebellar ataxia (Rotig et al, 1992), 
and diabetes mellitus and deafness (Ballinger et al, 1992,1994). Maternal
transmission of partially duplicated molecules has been documented (Ballinger et al,
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1992, 1994; Rotig et al., 1992; Dunbar et al, 1993). Reinvestigation of cases initially 
reported as deletions of mtDNA has shown that partial duplications of mtDNA are 
prevalent in KSS, but not in 'pure myopathies' (Poulton et al, 1993, 1994). A 
partially duplicated mtDNA molecule is essentially a tandem dimer with a partial 
deletion in one copy of the genome, and it is possible for more than one form of a 
partially deleted molecule to coexist with the wild-type genome. Poulton and 
coworkers first documented families of rearranged molecules consisting of partially 
duplicated molecules, deletion monomers, and deletion dimers (two deletion 
monomers joined head-to-tail), and these molecular forms have since been 
demonstrated by other groups (Poulton et al., 1993; Brockington et al., 1995; 
Manfredi et al., 1997). The abnormal junctions in the various species of rearranged 
molecules when sequenced have been shown to be identical, indicating that all 3 
forms of the partially deleted molecules have arisen from one initial rearrangement 
event.
Several studies have now looked at the distribution of these various molecular species 
in patient tissues (Poulton et al., 1995; Brockington et al., 1995; Fromenty et al., 
1997). Blood can contain up to 85% partially duplicated mtDNA, whereas deleted 
molecules are not detected (Holt et al., 1989; Brockington et al., 1995). The 
correlation of partially duplicated molecules (Poulton et al., 1989; Rotig et al, 1992; 
Dunbar et al., 1993; Ballinger et al., 1992, 1994; Poulton et al., 1994) rather than 
deleted mtDNA alone (Holt et al, 1989) with diabetes mellitus, may be significant. 
One publication which has included post-mortem data for the pancreas reported that 
in that one KSS patient -40% of mtDNA was rearranged, and about 1/4 of this was 
partially duplicated, the remainder of the rearranged species in the pancreas being 
deletion monomer/dimer (Poulton et al, 1995). It is possible that in other cases of 
"mitochondrial" diabetes, the pancreas contains a mixed population of rearranged 
molecules.
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Sequential biopsies and single fiber analysis from patients indicates that the partially 
duplicated species may be a transient form in skeletal muscle, and/or a progenitor of 
the deleted monomer/dimer species (Poulton et al, 1993; Poulton et al., 1995; 
Manffedi et al., 1997). PCR of individual COX" fibres from a patient with adult onset 
myopathy and a mixed population of mtDNA (-40% partially duplicated, -1%  
deleted species) presented a mixed picture (Manffedi et al., 1997). The authors 
reported that the majority of fibres tested possessed "nondeleted" mtDNA (i.e., wild- 
type and partially duplicated) at a level several fold lower than found in COX+ fibres, 
but 3/25 fibres contained "nondeleted" mtDNA at levels equivalent to COX+ fibres. 
This suggests that respiratory dysfunction might precede depletion of "nondeleted" 
mtDNA, and would imply a dominant negative effect on respiratory function of the 
presence of rearranged mtDNA. PCR amplification of deleted mtDNA was not 
reported in this study, so it is not possible to relate proliferation of deleted mtDNA to 
respiratory dysfunction in these fibres. The authors also report that all COX" fibres 
showed reduced COXII antibody staining. However, the nuclear subunit tested was 
COXIV (see sect. 1.5.3) so it is not possible to distinguish between loss of 
mitochondrial translation, and general lack of COX subunits. Only a proportion of 
COX- fibres stained excessively with SDH; this also indicates that respiratory 
deficiency precedes mitochondrial proliferation (as SDH staining is used generally as 
an indicator of mitochondrial volume [Reichmann, 1992]).
In cardiac muscle, duplicated molecules appear to be more stable than in other long- 
lived post-mitotic tissues, such as skeletal muscle and brain (Fromenty et al, 1997). 
These authors reviewed postmortem data which indicates that the overall mutant load 
of mtDNA (duplicated and deleted molecules) correlates with the severity of the 
cardiac conduction defect (Poulton et al., 1995; Brockington et al., 1995; Fromenty et 
al., 1997). This indicates that duplications can be pathogenic.
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A high proportion of deleted mtDNA has been shown to correlate with decreased 
cellular respiration and decreased/abnormal mitochondrial protein synthesis in cell 
culture. By contrast, few reports of cultured cells harbouring partially duplicated 
mtDNA are available. In one report, duplicated mtDNA was rapidly lost from both 
uncloned and cloned patient fibroblast lines (Poulton et al, 1993); in contrast, 
partially duplicated mtDNA from different patients was reported to be stable in 
cultured myoblasts (Dunbar et al, 1993; Brockington et al, 1995). Unfortunately, 
media conditions were not reported in these 3 papers, so it is unknown whether 
uridine supplementation had any effect, or whether cell type was a determining factor.
In the first detailed cell-culture study to address the latter point (Holt et al, 1997), 
enucleated cytoplasts from one such patient with partially duplicated mtDNA (Dunbar 
et al, 1993) was fused with a p° osteosarcoma cell-line (p° 143B) and also with a p° 
lung carcinoma cell-line (p° A549). The two recipient cell-lines displayed quite 
different phenotypes; all clones analysed from the lung carcinoma cell line became 
homoplasmic for wild-type mtDNA, regardless of uridine supplementation. As the 
mitochondria introduced into the recipient A549 cell line were virtually homoplasmic 
for partially duplicated mtDNA, the authors suggest this is evidence that homologous 
recombination is active in this nuclear background. In the osteosarcoma background, 
further mtDNA rearrangements were observed on at least two occasions; in both of 
these cases a partially triplicated mtDNA molecule was produced. In the presence of 
uridine supplementation, random drift occurred such that mitochondria which were 
heteroplasmic could mitotically segregate to 100% wild-type, 100% partially 
duplicated, or -100% partially triplicated. Thus, no systematic replicative advantage 
can be said to be gained by the presence of additional copies of the Heavy-strand 
replication origin. Serial transfer of homoplasmic partially duplicated mitochondria 
into p° 143B cells could lead to mtDNA depletion, whereas serial transfer of wild- 
type mtDNA did not. A modest but statistically significant respiratory deficiency was
observed in the osteosarcoma cybrids due to increased lactate:pyruvate ratios.
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The observed similarities in the clinical features of patients with partial duplications 
and deletions of mtDNA suggest that duplications are in some way pathogenic (Holt 
et al, 1997; Brockington et a l, 1995). It is frequently observed that deleted 
molecules rather than duplicated molecules correlate with mitochondrial proliferation 
in RRF, and, therefore, that deleted mtDNA is more pathogenic than duplicated 
mtDNA. A popular hypothesis is that up to a given proportion of deleted mtDNA, 
translational cooperation with coexisting wild-type mitochondrial DNA molecules 
masks any defect. However, above a critical threshold, competition for the rare 
tRNAs leads to a loss of mitochondrial protein synthesis, and respiratory dysfunction 
(Hayashi et a l, 1991). I would argue that this sequence of events probably occurs 
within RRFs, but it may not be the primary defect. The evidence presented in this 
section indicates that the mitochondrial proliferation which is observed in RRF occurs 
in response to preexisting mitochondrial dysfunction.
It has been suggested that partially duplicated mtDNA molecules are pathogenic only 
insofar as they are the progenitor molecules of deleted mtDNA (Poulton et al, 1993, 
1994); however, there are patients in whom the only species of rearranged mtDNA 
identified is duplicated molecules (e.g., Dunbar et al, 1993). Partially duplicated 
mitochondrial DNA could be problematic to the mitochondrion for several reasons: 1) 
an imbalance of tRNAs leads to translational interference. This seems unlikely in that 
the mitochondria tolerate a relative excess of the 2 tRNAs which are encoded adjacent 
to the mitochondrial rRNAs, but this could relate to the "threshold" effect; 2) an 
imbalance of protein subunits could disrupt the kinetics of enzyme complex assembly. 
This seems possible, given the polarographic data discussed earlier; 3) the chimeric 
gene transcript interferes with normal mitochondrial function, possibly by disrupting 
processing of the polycistronic transcript; 4) translation of the novel chimeric protein 
encoded by the rearranged mtDNA. An abnormal polypeptide in the mitochondria
could disrupt cellular respiration in several ways, e.g., by interfering with normal
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translational mechanisms, disrupting complex assembly, or by inserting into the inner 
membrane, making it "leaky" to protons or other molecules, and disrupting the 
electrochemical gradient essential to OXPHOS. It is of course possible that any of 
these hypotheses may be applicable to certain cell-types only, and that all or at least 
more than one of the above mechanisms contributes to pathogenesis. As discussed in 
section 1.4.2, different cases of CMS in plants may be attributable to causes as 
divergent as an alteration of the transcriptional pattern (Brassica) and the presence of 
a fusion peptide (CMS-T maize, and Petunia).
1.5.6 The fusion peptide hypothesis
In the three model systems discussed in detail in section 1.4 (CMS-T in maize, CMS 
in Petunia, and NCS isolates of maize), the presence of a fusion peptide encoded by a 
chimeric gene generated by a rearrangement of the mitochondrial genome is inferred 
to be pathogenic. In both cases of CMS protein interaction with the membrane is 
implicated. In CMS-T maize, a tissue-specific factor may also be involved. 
Furthermore, the absence of a detectable fusion protein in vivo does not exclude a role 
for the putative polypeptide. In the CMS Petunia strain discussed in section 1.4.2, a 
novel protein of apparent molecular weight 25 kDa is easily detectable by PAGE; 
however, this protein is the processed carboxy terminal portion of the chimeric gene 
product. The unprocessed chimeric protein is detectable only by 
immunoprecipitation, and the processed amino terminal extension has not been 
detected by any immunological method. Analysis of transgenic plants which express 
the 25 kDa protein suggests, moreover, that the undetected amino terminal extension 
is involved in the generation of the CMS phenotype.
In yeast, it has been shown that the presence of an abnormal respiratory chain subunit 
(subunit 6 of complex III) can produce a petite phenotype when the absence of that 
same subunit yields no growth defect (Schmitt and Trumpower, 1991). This suggests
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that the presence of an abnormal protein in mitochondria, and not simply the loss of 
function of the normal subunit, can cause dysfunction. Respiratory dysfunction in 
this case may be due to interference with complex assembly; western analysis found 
that some other subunits of the affected complex were absent or present in reduced 
amounts. However, overexpression of subunit 9 of the same complex can suppress 
the phenotype, perhaps due to some interaction between the two subunits. By 
analogy, the proliferation of mtDNA in diseased tissue in humans may be a nuclear 
response to mitochondrial dysfunction; not only is this a crude mechanism for 
increasing the levels of mRNA, but the overexpression of other subunits may act as a 
compensatory mechanism for the presence of abnormal subunits in some cases, or 
early in pathogenesis.
The evidence for the presence of a fusion protein in cases of rearranged mtDNA in 
humans may be summarised as follows: (1) transcription of rearranged mtDNA has 
been demonstrated in vivo; (2) translation occurs in ragged red fibres; (3) the chimeric 
gene transcript is translatable by the mitochondrial machinery in at least one cell- 
culture system; (4) cases of mitochondrial pathology associated with partially 
duplicated (but no deleted) mitochondrial DNA molecules have been reported; (5) 
polarographic data indicates that the respiratory deficiency is associated with the 
genetic lesion. It is likely that some biochemical deficiency is the signal to induce 
mitochondrial proliferation.
An abnormal protein would be encoded in most cases of rearranged mtDNA. In one 
of the studies which showed a polarographic defect specific to the complex affected 
by the molecular rearrangement, the sequence is reported for the rearrangement 
breakpoint found in the mtDNA of the 4 patients (Hammans et al., 1992a). The 
chimeric gene would encode a putative fusion protein consisting of all but the final 8 
residues of the ND4 subunit followed by 6 abnormal residues encoded by the ND6
gene (antisense). The presence of an abnormal protein in the mitochondria could
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contribute to respiratory deficiency in multiple ways, as discussed in section 1.5.2. 
The overlap in the phenotypes associated with the MELAS mutation and that of 
mtDNA rearrangements could extend to the mechanism of pathogenesis. 
Misincorporation/ premature termination at Leu (UUR) codons (Flierl et al., 1997) 
would generate abnormal peptides in the mitochondria, creating a situation analagous 
to that hypothesised for rearranged mtDNA.
Thus, there is reasonable cause to speculate that the presence of an abnormal protein 
could be a factor contributing to mitochondrial dysfunction in these cells. A direct 
test of this hypothesis is therefore warranted.
1.6 Aims of the project
The aim of the project was to test the hypothesis that abnormal proteins, encoded in 
affected individuals by chimeric mitochondrial genes, contribute to mitochondrial 
dysfunction and pathogenesis. The long-term aim of the project was to create 
transgenic mice expressing a chimeric mitochondrial gene product, to assess whether 
such a protein would be pathogenic in an organism. The suitability of mice as models 
for human disease is dependent on the nature of the disease under investigation 
(Erickson, 1989). With regard to this project, the three main points raised by 
Erickson are all relevant: variation in biochemical pathways between humans and 
mice (species-specific differences in oxidative phosphorylation capacity have been 
shown, (Van den Bogert et al., 1993), variation in neurodevelopmental pathways 
between humans and mice, and the possibility that the rate of the pathological process 
in diseases associated with mitochondrial DNA rearrangements may be dependent on 
absolute time rather than physiological time. However, only by creating the mouse 
models could one address these questions.
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The more limited, specific aim of this PhD project was to generate mouse cell-lines 
expressing chimeric mitochondrial peptides and assess the phenotype of the cell-lines 
produced. The strategy which I have adopted is to relocate the chimeric gene to the 
nucleus, and to target the encoded protein to the mitochondria. This makes it possible 
to analyse specifically, and in a controlled fashion, the effect of a chimeric protein on 
the cellular environment. The use of a controlled expression system should result in 
production of the abnormal protein at a level which can be detected by conventional 
methods. By selecting and characterising both low- and high-expressing cell-lines, a 
possible threshold effect of the chimeric protein level can be investigated. In 
addition, by using an inducible promoter, the phenotype can be ascribed precisely to 
the expression of the protein. If the expression of the protein is found to be highly 
detrimental to the cells, an inducible promoter should enable one to maintain the cell- 
line. Although positional effects of the transgene insertion site may affect expression 
of the transgene within a specific clone, by comparing the phenotype of multiple cell- 
lines all carrying the same transgene one can reduce the possibility of having created 
any observed phenotype by chance.
The molecular models used for the experimental work described in this thesis are two 
rearranged mitochondrial genes, characterised by Poulton et al., (1989 a, b) each 
derived from a rearranged COXI gene. The chimeric genes were identified in two 
KSS patients, and are described in section 1.7.1. As the long-term aim of the project 
is to create a mouse model for Keams-Sayre syndrome, mouse mtDNA and mouse­
cell lines were used for this work. As no mitochondrial transformation system was 
available for mammalian cells, nuclear versions of the chimeric mitochondrial genes 
had to be created. The nuclear version of the full-length COXI gene required 43 point 
mutations to convert the nucleotide sequence from the mitochondrial to the universal 
genetic code. Additionally, it was necessary to insert a transit-peptide coding region 
5' to the nuclear constructs, to enable mitochondrial targetting of the encoded protein.
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A further consideration was to determine the apparent molecular weight of the 
chimeric peptides by SDS-PAGE analysis, as this was not known.
The work described in my thesis has been subdivided into three chapters. Chapter 3 
describes the mutagenesis and subcloning required to create the nuclear versions of 
COXI and the patient-analagous constructs. Chapter 4 describes the use of an in vitro 
translation system and a prokaryotic expression vector to assay the available antisera 
for monitoring expression of the synthetic genes, and to ascertain the apparent size of 
the novel chimeric peptides by SDS-PAGE. Chapter 5 describes the generation and 
analysis of mouse cell-lines transfected with the patient-analagous constructs.
1.7 The molecular models
1.7.1 Pathology of patients 1 and 2
In this section are described the two Keams-Sayre syndrome patients reported by 
Poulton et al., (1989a, b), that are used as molecular models for the experimental 
work described in my thesis. Both patients exhibited clinical features representative 
of the syndrome - "ptosis, external ophthalmoplegia, retinopathy, ataxia, proximal 
muscle weakness and diabetes mellitus." In addition, patient 1 was "deaf and had a 
cardiac conduction defect," whilst patient 2 "was mentally retarded and had stroke­
like episodes." Both patients had had muscle biopsies taken, and although patient 1 
exhibited ragged red fibres, patient 2 did not (however, this patient was biopsied early 
on in the progression of the illness).
Partial duplication of mtDNA was demonstrated in both patients using Southern 
hybridisation (Poulton et al., 1989a). Southern blotting was performed on BamHI- 
digested mtDNA extracted from whole blood in both patients, and additionally EBV-
transformed lymphocyte lines, muscle, urinary epithelium, and fibroblasts in Patient I.
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The blot was probed with total mtDNA, and the relative proportions of normal to 
abnormal mtDNA measured densitometrically. Partially duplicated molecules were 
only detectable by Southern blotting in the blood and muscle tissue samples. 
Densitometry indicated that in Patient I muscle 20% of mtDNA was present in the 
duplicated form, whilst in blood 32% of mtDNA was present in the duplicated form. 
In Patient II 43% of mtDNA was present in the duplicated form in blood. Using PCR, 
rearranged molecules were detected in all tissues tested for Patient I. It must be noted 
that the PCR products generated did not distinguish between amplification from a 
template molecule which is a partially duplicated mtDNA and one that is partially 
deleted (i.e., the latter molecule lacking the "normal" copy). Given the detection 
limits of Southern blotting, it is possible that deleted molecules were also present in 
patient tissues.
In order to investigate whether there had been a single event or multiple events which 
generated the abnormal mtDNA molecules, DNA was extracted from single hairs and 
granulocyte clones. PCR was performed to amplify the mtDNA sequences across the 
abnormal junction, and the products were subcloned for sequencing. 3 of 5 
recombinants obtained from cloned granulocytes, and 5 of 16 recombinants obtained 
from individual hairs contained an insert indicating that they arose from rearranged 
mitochondrial DNA molecules. All recombinant plasmids generated had similar 
insert sizes. Of those sequenced, a single rearrangement breakpoint was detected for 
each patient, although the possibility of additional variants, with minor sequence 
differences was not ruled out.
In both patients the COXI gene has been interrupted by fusion to another gene (figure 
1.3). In patient 1, nt 6130 is joined to nt 15056 (from the cyt b gene). The abnormal 
junction in patient 2 is formed at a point where the two genes have 3 bp identity, so 
the actual breakpoint has occurred between nt 7354-7357, and nt 15914-15917
(tRNA^ gene). Analysis of the sequence in the immediate vicinity of the abnormal
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a) patient 1
Reference Sequence - cytochrome c oxidase I - (bp 6120-6193)
ATCATAATCGGAGGCTTTGGCAACTGACTAGTTCCCCTAATAATCGGTGCCCCCGATATCGCGTTTCCCCGCATA
I M I G G F G N W L V P L M I G A P D M A F P R M
Patient Sequence at abnormal junction
ATCATAATCGGTACGGATCATTTCTCTACTCAGAAACCTGAAACATCGGCATTATCCTCCTGCTTGCAACTATAG
I M I G T D H F S T Q K P E T S A L S S C L Q L *
Reference Sequence - cytochrome b - (bp 15045-15119)
GAGGCCTATATTACGGATCATTTCTCTACTCAGAAACCTGAAACATCGGCATTATCCTCCTGCTTGCAACTATAG
G L Y Y G S F L Y S E T W N I G I I L L L A T M
b) patient 2
Reference Sequence - cytochrome c oxidase I - (bp 7347-7370)
GTCCTAATAGTAGAAGAACCCTCC
V L M V E E P S
Patient Sequence at abnormal junction 
GTCCTAATAGTCTTGTAAACCGGA 
V L M V L *
Reference Sequence - tRNAt*ir - (bp 15906-15929)
AATACACCAGTCTTGTAAACCGGA
Figure 1.3 Sequence data for patients 1 and 2
Sequence data for the cloned PCR products obtained from patients 1 and 2 (Poulton etal., 
1989b). The sequences of wild-type mtDNA from the breakpoint regions are indicated above 
and below the sequence which spans the abnormal junction in each clone. The inferred amino 
acid sequences (mitochondrial genetic code) of the wild-type and encoded chimeric peptide are 
also given. In patient 1 bp 6130 of COXI adjoins bp 15056 of cyt b and in patient 2 bp 7357 of 
COXI adjoins bp 15917 of tRNAthr. COXI sequence is underlined.
junction reveals in the case of patient 1 that there is some sequence similarity (7/10 
matches), although not in alignment with respect to the breakpoint. As noted by the 
authors the "GAGG" sequence implicated in nuclear DNA rearrangements (Picolli et 
al., 1984) is present on both strands. In the case of patient 2, the sequence "CCTC" 
(the converse of "GAGG") is found on one of the parental strands near the breakpoint. 
Also, there is some sequence similarity (7/13 matches) between the two parental 
strands.
The DNA sequence of the recombinant plasmids obtained for each patient indicates 
that a truncated and terminally altered form of COXI is encoded by the partially 
duplicated mtDNA in each case. In patient 1 this chimeric peptide consists of the 
amino terminal 76 residues encoded by the COXI sequence, which are joined to 20 
residues encoded by cyt b, out of frame. In patient 2, as already stated, there are 3 
homologous base pairs between the two genes over which the rearrangement 
occurred. I shall refer to the breakpoint as occurring at base number 7357 in COXI, 
adjoining base number 15917 in tRNA^; this results in a chimeric peptide consisting 
of the first 485 residues from COXI followed by one abnormal amino acid before a 
stop codon is generated.
These two KSS patients were chosen as the molecular models for the study primarily 
because, in both cases, the mtDNA rearrangement clearly involved a duplication. 
Therefore, the hypothesis that rearranged mtDNA is associated with pathogenesis 
through a depletion of mitochondrially encoded constituents seemed an unlikely 
explanation in these two cases. There are several possible interpretations of the 
manner by which partially duplicated molecules could be pathogenic (discussed in 
section 1.5.5). However, it was (and remains) plausible that the novel protein 
encoded by the rearranged genes contributed to pathogenesis in these individuals.
This hypothesis has become more likely since the reevaluation of 10 KSS patients
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thought previously to harbour only deleted mtDNA, but now demonstrated to possess 
partially duplicated molecules as well (Poulton et al., 1994).
1.7.2 Complex IV - cytochrome c oxidase
As the chimeric mitochondrial genes chosen as models for this project are subunits of 
cytochrome c oxidase, a few details about the function and composition of the 
enzyme are presented. Complex IV is the terminal enzyme of the electron transfer 
chain in aerobic bacteria as well as in eukaryotic mitochondria (Capaldi, 1990). In 
mitochondria, it catalyses the transfer of electrons from reduced cytochrome c to 
molecular oxygen, coupled to proton translocation across the mitochondrial inner 
membrane from the matrix to the inter-membrane space (the bacterial enzyme is a 
component of the plasma membrane).
The crystal structure of the oxidised form of bovine cytochrome c oxidase has been 
determined (Tsukihara et al., 1996). It exists as a dimer, each monomer consisting of 
13 different subunits. The transmembrane region of the complex has 28 a  helices per 
monomer; COXI itself has 12 transmembrane domains, and no substantial 
extramembrane region. Subunits II and III both associate with the transmembrane 
region of COXI, with no direct contact to each other. The structure of the bacterial 
enzyme has been described, and the three subunits common to both complexes show 
structural similarities (Iwata et al., 1995; Tsukihara et al., 1996). These 3 
mitochondrial subunits (COXI, COXII, and COXIII) are encoded by mtDNA in 
mammals, and together they perform the catalytic functions of the enzyme.
In eukaryotes, additional subunits of the complex, which appear to have no direct role 
in electron transfer or proton translocation, are encoded by the nuclear genome 
(Capaldi, 1990). They are assumed to have roles in the regulation of COX assembly
and/or activity. Yeast and mammalian COX are reported to have 9 and 10 nuclear-
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encoded subunits, respectively (Taanman and Capaldi, 1992; Capaldi, 1990). 3 of the 
nuclear-encoded subunits in mammals have tissue-specific isoforms which are 
designated 'heart' or 'liver' for historical reasons. The COXVIa heart isoform is 
expressed in heart and skeletal muscle, whereas the liver isoform is expressed in all 
tissues, although at a low level in contractile muscle (Schlerf et al., 1988). 7 of the 10 
bovine nuclear-encoded subunits have transmembrane domains (including all 3 which 
have tissue-specific isoforms), whilst 3 associate peripherally with the complex 
(Tsukihara et al., 1996).
The assembly of cytochrome c oxidase in cultured human cells has been studied 
(Nijtmans et al., 1998). Two stable assembly intermediates of the complex were 
identified by 2-dimensional PAGE and western blotting. It would appear that 
assembly of complex IV is initiated by the association of the mitochondrially-encoded 
subunit I with the nuclear-encoded subunit IV. Although intuitively one might 
suppose that subunits I, II and III would interact first (given that these subunits are 
homologous to the entire bacterial enzyme), this first assembly intermediate may be 
an evolutionary adaptation to ensure involvement of the nuclear genome. However, 
as discussed in section 1.5.3, the actual amount of subunit IV does not appear to be 
rate-limiting in assembly of the complex (Taanman et al., 1996). It would appear that 
other nuclear-encoded subunits (such as Via, Vila or Vllb) may have a regulatory 
role in the assembly of cytochrome c oxidase (Nijtmans et al., 1998).
1.7.3 Nomenclature of cytochrome c oxidase subunits
The nomenclature in usage for the subunits of cytochrome c oxidase varies within 
organisms, and the alternatives in use differ between organisms. To reduce the 
possibility of confusion, I have adopted the use of COX, with the subunit denoted by 
a roman numeral, to refer to the protein subunit for all organisms. The identical
nomenclature is used for the respective gene, except in plants (because this format is
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not used), for which I have adopted the use of cox, with the subunit denoted by a 
roman numeral. However, all oligonucleotides and plasmids generated during this 
work, which contain a reference to cytochrome c oxidase in the name, use CO rather 
than COX (e.g., the universal code equivalent of COXI is called n-COI).
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Chapter 2 
Materials and methods
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2.1 E. coli strains
The E. coli strains used in this work are all derivatives of E. coli K12.
Strain Genotype Reference/Source
XL 1-Blue RecAl endAl gyrA96 thi-\ hsdR 17 supEAA relAl 
lac[F’ proAB lacNZ(M\5 TnlO (TetR)]
Stratagene
CJ236 F+ LAM- dut-l ung-\ relAl spoTl thi-1 CmR Joyce and 
Grindley (1984)
CB51 dam-3, ara-lA, thi-l, A(lac-pro) SmR Iain Hunter
M15 Nals Strs rif*, lac- ara- gal- mtl- F- recA+ uvr+ Qiagen
2.2 Mammalian cell lines
Mammalian cell-lines used in this work, other than those which were generated in the 
course of this study and are described in chapter 5.
LTK- A mouse cell-line with fibroblast-like morphology derived from cell-
line L-M, which was derived from connective tissue from a 100 day old male C3H/An 
mouse. The European Collection of Animal Cell Cultures (ECACC) reference 
number is 85011432.
NIH 3T3 A mouse cell-line with fibroblast morphology derived from a Swiss 
NIH embryo. The ECACC reference number is 93061524.
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2.3 Plasmids
Plasmids used in this study, other than those whose construction is described 
elsewhere in this thesis, are listed below.
Name Use Source
pBluescript II SK+, KS+ E. coli cloning vector Stratagene
pQE32 E. coli expression vector Qiagen
pMamneo Mammalian expression vector Clontech
2.4 Oligonucleotides
Oligonucleotides used in this study, grouped according to their application. All 
oligonucleotide sequences are given 5' to 3'. Reference coordinates for 
oligonucleotides corresponding to mouse mtDNA sequence are according to Bibb et 
al., 1981, Oligonucleotides which are mutagenic will not be identical to the published 
sequence. Coordinates for oligonucleotides corresponding to the antisense strand are 
listed in reverse.
2.4.1 Oligonucleotides used for the mutagenesis of the mouse COXI gene
Oligonucleotides used for the mutagenesis of the mouse COXI gene as depicted in
CfQ 3.7.a. Nucleotides which determine the code-corrections are underlined.
A GGTTGAGAATAACCAACGATTAATG 5357-5333
B GTACCCACCATTCCCGCCCAGGCTC 5419-5395
C CAAAGCCTCCAATCATCATTGGCATTACCATGAAGAAAATCATAACAAAAG
5563-5512
D GGCTCCGATCATTAGTGGGACAAGCCAGTTTC 5594-5564
E GGTAGGAGCCAAAAACTCATATTATTCATTCGTGGGAATGCCATATCTGG
5644-5595
F CTCCTGCTTCTACCATTGATGATG 5691-5668
G GTAGACTGTCCATCCTGTTCCTG 5714-5692
H GTTTGATACTGTGTCATGGCTGG 5869-5847
I TAAGTACGGACCAGACAAATAGTGGA 5895-5870
J CTGTTAGTAGCATAGTAATGCC 5961-5940
K GCCCAAAGAACCAGAACAG 6045-6027
L CAATAGACATCATTGCCCATACCATTCCCATATAGC 6168-6133
M CTACTGTGAACATGTGGTGGGCCCATACAA 6213-6184
76
N GCGATAATCATAGTGGCTG 6265-6247
0 GGTTGCAAGCCAGCTAAA 6305-6288
P CCTAAGGCCCATAGCATAGCTGGAGACCATTTAA 6355-6322
Q ATAATGGGAACCAGTGAACAAATCCTGCCATGATAG 6525-6490
R GAAGTGGGCTTTTGCCCATGTGTC 6569-6546
S GAAGAATGTCATGTTTACTCCTACGAACATGATGGC 6605-6570
T GCGTCGTGGCATTCCTG 6644-6628
U TAAATGATCCCATAGAAGAGACAGTGTTCCATGTGG 6705-6670
V GCAAAGGCCTCCCAAATCATAAAGATC 6757-6731
W CATACGATACTGACATTACTTCTCGTTTTGAA 6789-6758
X CCATGAAGCCATTCTAAATTTGTTGAAG 6817-6790
L' GCGAATAGACATCATTGCCCATACCATTCCC 6170-6140
Q' CAAATCCTGCCATGATAGC 6507-6489
2.4.2 Oligonucleotides used to repair unprogrammed mutations
Oligonucleotides used to repair unprogrammed mutations as described in chapter 3, 
depicted in fig. 3.7.b and 3.16.
J 1(repair)
Q ''(repair) 
S 1(repair) 
Rpr/1178/A 
Rpr/1178/B
GTAATGCCTGCCGCTAGTACTGGTAG
GAACCAGTGAACAAATCCTGCCATG
CATGTTTACTCCTACGAACAT
GCGGTGCACAAATCCTGCCATGATAGC
GCGGTGCACTGGTTCCCATTATTT
2.4.3 Oligonucleotides used for sequencing COXI
S+l GAGGATTTAAACCTCTG 
S+2 CTTGTCCCACTAATGATC 
S+3 CCACTATTTGTCTGGTC 
S+4 CTTTCTAGGCTTTATTG 
S+5 CTATCAATGGGAGCAGTG 
Y CATAGGTTGGTTCCTCG
Z GATATGAGATTGGCTTG
2.4.4 Universal sequencing primers
Reverse primer 
Ml3 -20 primer
AACAGCTATGACCATG
GTAAAACGACGGCCAGT
5947-5922
6518-6494
6596-6576
6512-6489
6507-6527
5269-
5571-
5871-
6170-
6468-
6858-
6923-
■5285
•5588
5887
■6186
6485
6842
6907
2.4.5 Oligonucleotides used to create the transit peptide coding region
Oligonucleotides used to create the COXIV transit peptide coding region as depicted 
in fig. 3.8.
TPl GCGGTCGACCAGAAT
TP2 GTTGGCTTCCAGAGCGCTGAGCCTGATTGG
TP3 CAAGAGAGCCATTTCTACTTCGGTGTGCCTTCGAAGCG
TP4 CGCTTCGAAGGCACACCGAAGTA
TP5 GAAATGGCTCTCTTGCCAATCAGGCTCAGC
TP6 GCTCTGGAAGCCAACATTCTGGTCGACCGC
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2.4.6 Oligonucleotides used to create the Patient 1 3' coding region
Oligonucleotides used to create the Patient I 3' coding region as depicted in fig. 3.10.
PI1 GCGTGATCATTTCTCTACTCAGA
PI2 AACCTGAAACATCGGCATTATCCTCCTGC
PI3 TTGCAACTATAGGTCGACGCG
PI4 CGCGTCGACCTATAGTTGCAAGCAGGAGGATAA
PI5 TGCCGATGTTTCAGGTTTCTGAGTAGAGAAATGATCACGC
2.4.7 Oligonucleotides used for PCR-based subcloning
Oligonucleotides used for PCR-based subcloning as described in chapter 3
COI/Lsp GCGTTCGAATGTTCATTAATCGTTGG 5328-5345
COI/PI3' GGGATCCGTACCAATCATCATTGGCATT 5546-5537
5'TP/Xba ATATCTAGACAGAATGTTGGCTTCCAG
PI3'/ZIF-1 GGTCCTCGGGGTCGCCTAGTTGCAAGCAGGAGGA
Z IF - 2 TATCTCGAGTCAATCCAGGTCCTCGGGGTCGCC
COI/WT3'/Xho CGCCTCGAGTTATTTTACTTTTACATAGGT 6872-6852
2.4.8 Oligonucleotides corresponding to pMamni# sequences
pMam/5 'MCS GCTATCATCACAAGAGC 1501-1517
pMam/3'splice TCAGTTCCATAGGTTGG 1728-1712
2.5 E. coli growth media and culture
2.5.1 Media
L-Broth: 10 g Tryptone, 5 g yeast extract, 5 g NaCl, made up to 1 litre with
dH20 , adjusted to pH 7.0 with NaOH.
L-Agar: As L-Broth with the addition of agar to 1.5%.
2xYT Broth: 10 g Tryptone, 10 g yeast extract, 5 g NaCl, made up to 1 litre with 
dH20 , adjusted to pH 7.0 with NaOH.
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2.5.2 Antibiotics
Ampicillin Stock (lOOOx)
Carbenicillin Stock (lOOOx)
Chloramphenicol Stock (lOOx)
Kanamycin Stock (lOOOx)
Streptomycin Stock (lOOOx)
Tetracycline Stock (lOOOx)
2.5.3 Growth conditions
L-broth was used for growth of most E. coli strains. 2 x YT was used for single­
stranded DNA preparation. Incubation was at 37 °C (unless specified otherwise), 
with vigorous shaking. For long term storage,
0.75 ml of overnight culture was added to 0.75 ml of 30 % glycerol, mixed by 
inversion, quick frozen and stored at -70 °C.
2.5.4 Transformation of K  coli
Competent E. coli cells were prepared using the calcium chloride procedure 
(Sambrook et al., 1989). For storage 100 pi aliquots had sterile glycerol added to 15 
% and were then frozen in an ethanol/dry ice bath before storage at -70 °C in screw 
top 1.5 ml Eppendorf tubes. After heat shock (1 minute at 42 °C), 1 ml of L-Broth 
was added to each tube and the bacteria allowed to recover at 37 °C for 45 minutes 
before plating onto appropriate selective media.
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2.5.5 Indicators
For blue/white selection of transformants 50 pi of 100 mM IPTG (Isopropyl-B-D- 
thiogalactopyranoside) and 50 pi of 50 mg/ml X-Gal (5-bromo-4-chloro-3-indolyl-B- 
galactoside) were spread onto 90 mm diameter L-agar plates and allowed to dry 
before spreading the transformed bacteria. The plates were incubated at 37 °C for 12- 
lb hours. To intensify blue/white colour selection, plates were sometimes placed at 4 
°C for one hour prior to picking colonies.
2.6 Mouse cell growth media and culture
2.6.1 Cell culture media
The mouse cell lines NIH 3T3 and LTK- were maintained in Dulbecco's Modified 
Eagle's Medium (DMEM) containing 10% foetal calf serum (FCS).
Derivatives of these cell lines transfected with pMamweo, pM/PI, or pM/PIZ were 
maintained in supplemented medium referred to as "superglu".
DMEM-Superglu DMEM + 10% FCS supplemented to a final concentration of 2
mM glutamine, 50 pg/ml uridine, and 1 mM sodium pyruvate.
2.6.2 Cell culture conditions
Cells in routine culture were maintained in 25 cm2 plastic tissue culture flasks under 
10 ml of the appropriate medium at 37 °C in an atmosphere containing 5% C 02. The 
cells were passed every 3-4 days. In order to pass the cells the medium was aspirated
off and the cells were washed with 10 ml phosphate buffered saline (PBS) which was
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Ca+2 and Mg+2 free. The PBS was also aspirated off and the cells were detached by 
treatment with 1 ml trypsin-versene (0.025% trypsin, 500 pM EDTA, 0.0015% 
phenol red in PBS) for 1 minute. The cells were dislodged by tapping the flask and 
were dispersed in 9 ml of fresh medium. Fresh cultures were initiated with 1/10 to 
1/30 dilutions made up to 10 ml with fresh medium.
2.6.3 Selective medium conditions
Geneticin (G-418 sulfate, Gibco BRL) was used in selections at a final concentration 
of 600 pg/ml for NIH 3T3 cells; 800 pg/ml for LTK- cells.
Dexamethasone was used at a final concentration of 0.2 pM where appropriate.
Ethidium bromide for the generation of p° derivative cell lines was used at a final 
concentration of 50 ng/ml (Desjardins et al., 1985).
Derivatives of NIH 3T3 and LTK- cell lines transfected with pMamweo, pM/PI, or 
pM/PIZ were incubated in galactose medium when appropriate to experimental 
conditions as specified in chapter 5.
Galactose medium DMEM without glucose, 25 mM galactose, 10% FCS.
2.6.4 Transfection of mouse cell lines
All transfections were performed with DOTAP (Boehringer Mannheim), a cationic 
lipid which forms unilamellar vesicles (liposomes) in aqueous solution. The 
liposomes form complexes with DNA which, upon fusion with a cellular membrane, 
release the DNA into the cytoplasm of the cell. The manufacturer’s protocol was
followed precisely. The cells were transfected with circular plasmid DNA, prepared
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using Qiagen midiprep columns (Qiagen). Cells were incubated overnight (15-16 
hours) with the transfection reagent. The medium was aspirated off, cells were 
washed with PBS, then fresh medium was applied. After 24 hours recovery, the 
transfected cells were placed under selection with Geneticin G418-sulfate at a 
concentration of 600 pg/ml, the concentration previously determined as the lowest 
which caused cell death of untransfected NIH 3T3 cells, with no resistant colonies 
remaining after 2 weeks. After 2 weeks in selective media, colonies were cloned 
using sterile metal cloning rings coated with vaseline, by detaching the cells with 
trypsin and gentle pipetting up and down, and transfer to 6 well dishes where they 
were incubated in appropriate media.
2.6.5 Galactose assay for respiratory competence
Initially, the test media I used contained DMEM (without glucose), 10% dialysed 
Foetal Calf Serum (dFCS), 25 mM galactose. However, all cell-lines tested died 
rapidly in this medium, presumably due to unsupplemented factor(s) lost during the 
dialysis of the dFCS. For the test data presented in section 5.2.7, the galactose 
medium (gal medium) consisted of DMEM (without glucose), 10% FCS, and 25 mM 
galactose. All transfected cell-lines were incubated in media containing G418. Cell- 
lines were incubated with dexamethasone (dex) to upregulate transgene expression, 
where specified by test conditions.
The assays were conducted as follows; as stated previously, the cell-lines were 
maintained in "superglu" medium, which is supplemented with constituents identified 
as required for the growth of respiration-incompetent cells. Confluent cells were 
trypsinised, counted using an automated cell counter, and 1 x 105 cells were plated in 
"superglu" in 25 cm2 flasks, for each of the four media conditions to be tested. Cells 
were allowed 3 hours to settle and adhere to the flask. Medium was then aspirated
off, and after washing with PBS, the appropriate medium was added to each flask.
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The clones were tested for any variation in adherence efficiency; this may have been 
important, given that PIZ is primarily derived from COXI, a membrane protein, and 
could conceivably be inserting into the plasma membrane when expressed at high 
levels. The media and PBS washes were centrifuged to pellet the cells which had not 
adhered within 3 hours. Very few cells had not adhered within this period, and no 
difference was observed between the clones. The four media conditions used were 
"superglu" without dexamethasone, "superglu" with dexamethasone, galactose 
without dexamethasone, and galactose with dexamethasone. These four conditions 
were intended to test the effect of transgene expression in low and high respiratory 
stress conditions. The media was changed on day 2, and the cells were harvested and 
counted using an automated cell counter after 4 days of growth.
2.7 Buffers and reagents
Church buffer 
50 x Denhardts
7 % SDS, 1 % BSA, 1 mM EDTA, 0.25 M NajHPO* pH 7.2
10 g Ficoll, 10 g polyvinylpyrolidine, 10 g BSA, made up to 1 
litre with dH20.
EDTA A 0.5 M solution was made up in dH2Oand adjusted to pH 8.0 
with 10 MNaOH.
20 x SET 
20 x SSC
50 x TAE
3 M NaCl, 20 mM EDTA, 0.4 M Tris, pH 8.0
175.3 g NaCl, 88.2 g Sodium citrate, made up to 1 litre with 
dH20.
242 g Tris base, 57.1 ml glacial acid, 100 ml 0.5 M EDTA (pH 
8.0), made up to 1 litre with dH20.
5 x TBE 54 g Tris base, 27.5 g boric acid, 20 ml 0.5 M EDTA (pH 8.0), 
made up to 1 litre with dH20.
TE 10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0).
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2.8 Nucleic acid isolation
2.8.1 Double-stranded plasmid DNA
Both large and small scale preparations of double-stranded plasmid DNA were 
performed by alkaline lysis. Single colonies of E. coli were picked with a sterile 
toothpick, and grown overnight in L-broth at 37 °C with constant shaking. Minipreps 
of 1.5 ml of culture were prepared either with stock solutions according to the 
protocol in Sambrook et al., 1989 or using the Promega Magic miniprep kit and 
following the manufacturer's instructions. Maxipreps of 100 ml of culture were 
prepared with stock solutions and purified by CsCl density gradient centrifugation 
according to Sambrook et al., 1989. For transfections into mammalian cells, DNA 
was extracted from 30 ml of overnight bacterial cell culture using Qiagen Midiprep 
columns (Qiagen).
2.8.2 Single-stranded phagemid DNA
Single-stranded DNA was prepared essentially according to the 1989 protocol 
recommended by Stratagene for use with pBluescript phagemids, and the method is 
described below. The bacterial strain used was XL 1-blue, the phagemid from which 
single-stranded DNA was prepared was pBluescript II SK+, and the helper phage was 
VCSM13.
50 ml of 2 x YT media was inoculated with 5 ml of fresh overnight E. coli culture and 
incubated for 1 hour at 37 °C with vigorous shaking, prior to helper phage infection. 
The optimal multiplicity of infection (moi) was not constant throughout the work
described; an moi of 10:1 (phage to cells) was used in early experiments,
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subsequently an moi of 1:1 was found to be optimal. 30 minutes after infection 
kanamycin was added to a final concentration of 25 |Lig/ml, and incubation was 
continued for a further 6 hours. The culture was spun at 11,000 g for 5 minutes to 
remove bacterial cells, and the supernatant was transferred to a fresh tube.
Phagemids were precipitated by the addition of 12.5 ml of 2.5 M NaCl, 20%PEG 
solution (PEG-8000), inverting to mix, allowing to stand at room temperature for 15 
minutes, then spun at 11,000 g for 20 minutes. The pellet was resuspended in 1 ml of 
media, to which 250 pi of PEG solution was added, and reprecipitated as above. The 
pellet was resuspended in 500 j l l I  digestion buffer as described below, and incubated 
at 65 °C for 45 minutes. An equal volume of buffer-saturated phenol/chloroform was 
added, the mixture was vortexed for 1 minute, then spun in a microfuge for 1 minute. 
The aqueous phase was removed and reextracted until there was no interface left. An 
equal volume of chloroform was added, vortexed for 1 minute, then spun in a 
microfuge for 2 minutes. The aqueous phase was removed to a fresh tube and DNA 
was precipitated by adding 1/10 volume 3 M sodium acetate and 2 volumes cold 
absolute ethanol. The mixture was left on ice for 15 minutes, then spun for 20 
minutes 11,000 g, 4 °C. The pellet was washed with cold 80% ethanol. The dry 
pellet was resuspended in 50 pi TE.
Phagemid digestion buffer: 20 mM Tris, pH 8, 1 mM EDTA, 200 pM proteinase K,
0.1% SDS
2.8.3 Mouse cell DNA extraction
High molecular weight DNA was prepared from ~ 5 x 106 trypsinised cells which 
were washed with PBS and pelleted at 550 g for 5 minutes. Two protocols were used.
1 - Nucleon kit (Scotlab) as per manufacturer’s protocol. Briefly, the cells were lysed 
in a TE buffer containing 150 mM NaCl and 1% SDS, the optional RNAse A 
treatment was used, and deproteination was performed with sodium perchlorate. The
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DNA was extracted with a Silica suspension, and precipitated by centrifugation at 
1700 g for 2 minutes, then washed with 70% EtOH.
2 - Cells were resuspend in 300 pi digestion buffer (as described below) and 
incubated overnight at 55 °C, with shaking. The solution was extracted with an equal 
volume of buffered phenol, and twice with 2FC (as described below) (mixed by 
inverting tubes, and spun at 10,000 g in a microfuge for 10 minutes). 30 jllI 10 M 
NH4OAc and 330 jllI cold EtOH were added and the solution was mixed vigorously. 
This was spun immediately at 10,000 g for 2 min in a microfuge. The precipitate was 
washed with 70 % EtOH, respun, aspirated, and allowed to air dry. DNA was 
resuspended in 115 pi TE, and heated for 15 min at 65 °C.
Digestion buffer 50 mM Tris, pH 8, 100 mM EDTA, 100 mM NaCl, 1 % SDS.
Proteinase K was added to 10 pg/ml just before use.
2FC 50 ml phenol, 50 ml chloroform, 0.1 g hydroxyquinoline, 1 ml isoamyl
alcohol, sufficient 1 M Tris, pH 8 to layer overtop. The solution was 
mixed well, and left overnight before use. pH of solution should be 8.
2.8.4 Mouse cell RNA extraction
Cells were incubated in "superglu" medium supplemented with dexamethasone and 
G418 for approximately 40 hours prior to harvesting (the untransfected 3T3 cells did 
not have G418 in the medium). Total RNA was prepared from mouse cells by two 
alternative protocols, both of which used a guanidium thiocyanate denaturing 
solution, phenol extraction, and isopropanol precipitation. In both cases ~ 107 cells 
were lysed in situ using guanidium thiocyanate denaturing solution. The RNA pellet 
obtained was resuspended in 0.5% SDS and heated at 60 °C for 10-15 minutes.
1 - The method of Chomczynski and Sacchi, (1987), which was followed precisely.
2 - RNAzol B (Biogenesis Ltd.), following the manufacturers protocol precisely 
(which is based on the method above).
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2.9 In vitro manipulation of DNA
2.9.1 Restriction digests and sub-cloning
Restriction enzyme digestion of plasmid DNA was carried out using the conditions 
recommended by manufacturers. Typically 0.5-2 pg of DNA were digested in 20 pi 
containing the recommended enzyme buffer and 5-10 units of enzyme. After 1 hour 
at the appropriate temperature the incubations were placed on ice. For sequential 
digests the first restriction enzyme was either heat inactivated or removed by Magic 
DNA Cleanup Columns (Promega) before the second digestion. Sub-cloning of DNA 
into plasmid vectors was performed essentially as described by Sambrook et al., 
(1989).
2.9.2 Extraction of DNA fragments from agarose gels
Three methods were employed to extract DNA from agarose gels, as follows.
(1) Low melting point agarose (Sambrook et al., 1989).
(2) Spin-X columns (Sigma) as per manufacturers instructions. The tube 
containing the agarose slice was frozen at -20 °C before being centrifuged at 
maximum speed in a microfuge for 15 minutes.
(3) Electroelution onto NA45 membrane (Schleicher & Schuell) as per 
manufacturers protocol.
For methods 1 and 2 - The bands of interest were cut from agarose gels under 
ultraviolet illumination with a sterile scalpel blade. For method 3, NA45 paper was
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inserted into the gel immediately below the band so that the DNA would run onto the 
paper during electrophoresis.
2.9.3 Radio-labelling of nucleic acids
2.9.3.1 Labelling of DNA fragments by random priming
25 ng of gel-purified DNA was labelled using the Prime-it kit (Stratagene), with 50 
p.Ci of a -32P-dCTP. The unincorporated label was removed using Nuctrap columns 
(Stratagene) as recommended by the manufacturer. Before hybridisation the probe 
was denatured by boiling for 5 minutes, then spun down and kept on ice before 
adding to the hybridisation tube.
2.9.3.2 End-labelling of oligonucleotides
15 pmol of oligonucleotide was end-labeled with 50 pCi of y-32P-ATP using 10 units 
of polynucleotide kinase. The unincorporated label was removed by spinning the 
labeled oligonucleotide in TES buffer through a sephadex G-25 column at 1580 rpm 
for 4' at 15 °C.
TES 10 mM Tris-HCl (pH 8.0), 100|iM EDTA, 20 mM NaCl
2.9.4 Sequencing of plasmid DNA
The Sequenase Version 2.0 (United States Biochemical Corporation) kit was used.
No modifications to the protocol were made. Where compressions were detected, the 
dITP labeling and termination solutions were used, as recommended by the 
manufacturer. The radiolabel used was 35S. In early experiments, single-stranded
DNA template was prepared; subsequently,
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double-stranded plasmid DNA was used employing a rapid alkaline denaturing 
protocol as recommended in the USB protocol and described below.
5 pi of template DNA (prepared using the Magic Miniprep columns, Promega) was 
added to 5 pi of dH20 . To denature the DNA, 1 pi of 2 M NaOH was added and the 
mixture was incubated at 37 °C for 20 minutes. To neutralise the solution, 1.65 pi of 
2 M sodium acetate, pH 4.5 was added, and the DNA was precipitated with 30 pi of 
cold EtOH at -70 °C for 15 minutes. After spinning at maximum speed in a 
microfuge at 4 °C for 30 minutes, the pellet was washed with 70% EtOH. The pellet 
was resuspended in 2 pi of Sequenase reaction buffer, 1 pi of primer, and 7 pi of 
dH20 . Annealing was performed by heating the mixture to 65 °C for 2 minutes, then 
cooling slowly (15-30 minutes) to room temperature. It was then spun briefly, and 
kept on ice for sequencing.
2.9.5 PCR
2.9.5.1 Typical parameters of PCR
Typical PCR reaction components:
5 pi of each primer oligonucleotide (20 pM stock)
5 pi of 2 mM dNTP mix
5 pi of 10 x reaction buffer 
0.5 pi of DNA polymerase (5 u/pl)
20 ng template DNA 
dH20  to 50 pi
Typically PCR conditions were:
Step 1 94 °C for 5 min (initial denaturation)
Step 2 60 °C for 30 sec -1 min
Step 3 72 °C for 30 sec - 3 min
Step 4 94 °C for 30 sec - 1 min
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(Steps 2-4 were repeated for 30 cycles)
Step 5 60 °C for 5 min
Step 6 72 °C for 10 -15 min
Specific parameters depended on both the machine used and the size of the amplified 
fragment.
2.9.5.2 Cloning of PCR products
Pfu DNA polymerase (Stratagene) was used due to the reduced frequency of 
mutations introduced by this enzyme compared with Taq DNA polymerase (Cline et 
al., 1996). After 5 pi of the reaction had been run on an agarose gel to check that a 
product of the desired size had been amplified, the rest of the amplified product was 
purified using Magic PCR cleanup columns (Promega).
2.9.5.3 PCR screening of bacterial transformants
A numbered bacterial colony was touched with a sterile toothpick. This was then 
dipped into 50 pi of dH20  in an eppendorf tube and overlaid with mineral oil. The 
samples were denatured for 5 minutes at 94 °C and placed on ice. The rest of the PCR 
reaction components (as specified in section 2.8.5.1) were added to a final volume of 
100 pi. Taq polymerase was used. 10 pi of each reaction was run on an applicable 
percentage agarose gel.
2.9.5.4 PCR of genomic DNA prepared from mouse cell lines
Typical PCR reaction components:
5 pi of each primer oligonucleotide (20 pM stock)
5 pi of 2 mM dNTP mix
5 pi of 10 x Taq buffer
0.5 pi of Taq DNA polymerase (5 u/pl)
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1 pg template DNA 
dH20  to 50 pi
The PCR conditions were generally:
Step 1 94 °C for 5 min (initial denaturation)
Step 2 60 °C for 45 sec
Step 3 72 °C for 1 min 30 sec
Step 4 94 °C for 45 sec
(repeat steps 2-4 for 30 cycles)
Step 5 60 °C for 45 sec
Step 6 72 °C for 10 min
10 pi of the product was run on an appropriate percentage agarose gel.
2.9.6 Site-directed mutagenesis
Site-directed mutagenesis using single-stranded template was performed essentially 
according to the protocol recommended by Stratagene for use with pBluescript 
phagemids (1989), apart from the amendments detailed in section 3.2.2, (e.g., the 
DNA polymerase used initially was Klenow, subsequently Sequenase (USB) was 
used), the annealing procedure, and the temperature and duration of the primer 
extension reaction.
Protocol for site-directed mutagenesis:
100 ng of oligonucleotide was phosphorylated in 40 pi total volume, using T4 
polynucleotide kinase, at 37 °C for 30 minutes. 50 ng of each mutagenic 
oligonucleotide was added to 1 pg of single-stranded DNA template in 1 x ligation 
buffer* (the total volume depended on the number of mutagenic oligonucleotides in 
the reaction). Annealing was performed by incubating the oligonucleotide/template 
mixture at 65 °C for 10 minutes, then allowing it to cool gradually from 65 °C to room 
temperature in the heating block. The primer extension reaction was carried out in 1
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x ligation buffer*, 125 fiM dNTP mix, 1 mM rATP, 100 (ig/ml Gene 32 protein 
(Pharmacia), 1.5 units DNA polymerase, 4 units T4 DNA ligase. The primer 
extension reaction was initially executed at room temperature for 3-4 hours as per the 
protocol, but the procedure was later amended to an incubation of 15 °C overnight.
1/4 of the total synthesis reaction was used in each transformation.
* Initially, the ligation buffer used was as per the recipe provided with the protocol, 
which is given below. Subsequently, the ligation buffer provided by the manufacturer 
with the ligase was substituted.
10 x ligation buffer: 500 mM Tris-Cl, pH 7.5, 70 mM MgCl2, 10 mM dithiothreitol
2.10 Gel electrophoresis
2.10.1 Agarose gels
0.7-4 % agarose gels were used for separating plasmid and PCR-derived DNA 
depending on the size of the expected fragments. The gels were normally run in 1 x 
TAE at 100-150 Volts and contained 0.1 pg/ml of ethidium bromide. Low melting 
point (LMP) agarose gels were run in 1 x TAE at 50 V.
5 x Loading Buffer (agarose) 0.25 % Bromophenol blue, 0.25 % Xylene cyanol FF,
10 mM EDTA (pH 8.0), 15 % Ficoll.
2.10.2 Agarose formaldehyde gels
Total RNA was analysed in 1% agarose formaldehyde gels as per Sambrook et al., 
1989. After running, the entire gel was washed three times for 20 minutes in 1 x 
TAE; during the second wash it was stained with ethidium bromide (1 jig/ml).
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2.10.3 Polyacrylamide gels
Products of DNA sequencing reactions were separated on denaturing polyacrylamide 
gels; 6% acrylamide (acrylamide:bisacrylamide, 19:1), 7M urea, in TBE. 
Polymerisation was initiated by the addition of 1 ml of 10% ammonium persulphate 
and 35 pi of TEMED to 100 ml of 6% acrylamide/urea solution. Conventional 
spacers were used to give a flat gel. Sequencing gels were allowed to polymerise 
overnight before use. They were prerun for 1 hour at 60 W. Samples were denatured 
at 90 °C for 2 minutes in the buffer supplied by USB with the Sequenase kit, and 
quenched on ice, immediately prior to loading with the aid of a shark's tooth comb. 
Gels were run for the required amount of time (until the bromophenol blue had 
reached the bottom of the gel for short runs, approximately 4 hours for a long run) at 
60 W. The gels were fixed in 10% acetic acid/10% methanol for 30 minutes, then 
dried onto Whatmann 3 MM paper under vacuum. Autoradiography was carried out 
without intensifying screens at room temperature.
2.10.4 SDS-Polyacrylamide gels
Protein samples were separated by SDS-PAGE, using the discontinuous gel method 
(Laemmli, 1970).
Separating gel - 0.375 M Tris-HCl, pH 8.8, acrylamide as below.
Stacking gel - 0.125 M Tris-HCl, pH 6.8, 4.0 % acrylamide.
Depending on the size-range needing separation, 12 to 17.5 % acrylamide 
(acrylamide:bisacrylamide, 37.5:1) separating gels were used. Gels were run at 4 °C 
using minigel kits as per the manufacturer's protocol (Biorad). The samples were run
in at 100 V, then voltage was increased to 200 V once samples had entered the
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separating gel. Gels were run until the band of bromophenol blue had reached the 
bottom of the gel. The gels were either stained using Coomassie R-250 brilliant blue, 
or electroblotted for western blots.
For staining, the gels were placed in dH20  containing 30 % methanol, 10 % glacial 
acetic acid and 0.1 % Coomassie R-250 brilliant blue for 30 minutes. Destaining took 
approximately 2 hours in frequent changes of dH20  containing 30 % methanol and 10 
% glacial acetic acid. The gels were then left in dH20  overnight before being 
transferred to 3MM paper and dried down at 80 °C under vacuum for 45 minutes.
5 x SDS-PAGE Running Buffer 15 g Tris base, 72 g Glycine, 5 g SDS, made up
to 1 litre with dH20.
5 x SDS-PAGE Sample Buffer 1.25 ml 0.5 M Tris-HCl, pH 6.8, 1.0 ml
glycerol, 2.0 ml 10 % (w/v) SDS, 0.5 ml 2-p 
mercaptoethanol, 0.25 ml 0.05 % (w/v) 
bromophenol blue, 5.0 ml dH20
2.11 Nucleic acid hybridisation
2.11.1 Screening of bacterial colonies by colony hybridisation
Colonies were patched out onto duplicate 90 mm agarose plates in a grid (120 
colonies per plate). One plate was retained as a master plate. The other plate was 
used for colony lifts. 2 replica lifts were performed for each oligonucleotide being 
used to screen the colonies.
Pre-wetted Hybond-C filters (Amersham) were inverted onto the plate used for the 
lifts, oriented by punching a needle through the filter in several places, then replaced 
on LB/Amp plates colony side up, and incubated at 37 °C until the colonies were 1 
mm in diameter.
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Lysis of the bacteria and plasmid DNA denaturation were performed as per the 1989 
protocol recommended by Stratagene for use with pBluescript phagemids; the filters 
were placed on 3MM (Whatmann) paper soaked in 0.5 M NaOH for 5 min, blotted 
dry 5 min, the filters were placed on 3MM paper soaked in 1 M Tris-HCL, pH 7.5 for 
2 min, blotted dry 2 min, and the filters were placed on 3MM paper soaked in 1.5 M 
NaCl, 0.5 M Tris-HCl (pH 7.5) for 10-15 minutes, blotted dry 2 min. The DNA was 
UV crosslinked to the membranes.
Hybridisation was performed using oligonucleotide hybridisation buffer, as described 
below (prehybridisation for one hour, hybridisation overnight). Membranes were 
washed sequentially in oligonucleotide wash buffer (see below) twice at 5x, lx  and 
twice at 0.1 x. The final wash was carried out at a few degrees below the calculated 
Tm for each mutagenic oligonucleotide used as a probe in final wash buffer using the 
formula below. %G+C refers to the percentage of G and C residues in the 
oligonucleotide, n refers to the total number of residues in the oligonucleotide. 
Obviously there would be no mismatch between a successfully mutated target 
sequence and the mutagenic oligonucleotide; however, use of this formula enabled the 
selection of oligonucleotides as probes with a wide differential between successfully 
mutated target DNA and unmutated DNA.
Tm = 81.5 + 1/2(%G+C) + 16.61og[Na+] - 600/n - %mismatch
Oligonucleotide hybridisation buffer:4 x SET, 5 x Denhardf s solution, 0.02 M sodium 
phosphate buffer, pH 6.8, 5 % dextran sulphate, 10 (ig/ml each of poly A and 
poly C, 0.1 % SDS, 100 pg/ml denatured, sonicated salmon sperm DNA
Oligonucleotide wash buffer: 5 x / l x / 0 . 1 x  SET, 0.02 M sodium phosphate buffer, 
pH 6.8, 0.1 % sodium pyrophosphate, 0.1 % SDS
Sodium phosphate buffer, pH 6.8: 100 ml each of 1 M Na2HP04 and NaH2P 0 4
were prepared. The pH of the two solutions was ascertained. Whichever was 
closest to pH 6.8 was brought to pH 6.8 by addition of the other solution.
95
2.11.2 Northern blots
Blotting was performed both by electroblotting and by capillary action, as specified in 
the relevant figure legends in section 5.2.3. The membrane used was Boehringer 
nylon membrane. RNA was cross-linked to the membrane by baking at 80 °C for 2 
hours. Church buffer was used for both prehybridisation, and hybridisation of the 
blots with the random-primed probes, at the temperature specified in the respective 
figure legends. Washes were performed at high stringency by sequentially washing at 
1 x SSC at room temperature, 1 x SSC at 68 °C, then twice at 0.1 x SSC at 68 °C (all 
wash buffers contained 0.1% SDS).
2.11.3 Slot blots
To 120 jllI aliquots of DNA was added 40 pi of 1 M NaOH. This was vortexed for 10 
minutes at room temperature. Biodyne membrane (PALL) was presoaked in 1 x TAE 
for 30 minutes at room temperature. 160 pi of 10 x TAE was added to samples. The 
samples were vortexed, spun down for 2 minutes, then put on ice. Samples were 
loaded onto the blotting apparatus without vacuum. Vacuum was applied, then 1 drop 
of 5 x TAE was added from a pasteur pipette to each well. DNA was cross-linked to 
the membrane by UV irradiation using a Stratalinker (Stratagene).
2.12 Western blots
The western blots described in this work were predominantly performed using PVDF 
membrane (Bio-Rad) used as per the manufacturer's protocol, although initially 
Hybond-C membrane (Amersham) was used. Proteins from unstained gels were 
transferred to the membrane in SDS-PAGE Blot Buffer, at 100 mA overnight at room 
temperature, or 200 mA for 2 hours at 4 °C. The PVDF membrane was allowed to
dry in order to fix the protein. The membrane was moistened with 100% ethanol and
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Ponceau-S stained (Sigma) to allow detection of the protein markers. The blot was 
then rinsed with TBS-T. The ECL western blotting protocol (Amersham) was 
followed using TBS-T (0.1 %) with the following three amendments; no wash step 
was included between the blocking step and incubation with the primary antibody, 
2.5% w/v non-fat milk was added to the primary antibody solution, although 
normally the blot was incubated with the primary antibody for one hour as per the 
Amersham protocol, initially a protocol was used which recommended an incubation 
period of 3 hours-ovemight. All antisera used are described fully in section 4.1.2. 
Primary antibody dilutions varied; the monoclonal antibody Z1F11 was normally 
used at a 1/2000 dilution, the polyclonal rabbit antisera at 1/1000. The secondary 
antibodies (HRP-conjugates) were used at a dilution of 1/2000. Preabsorbtion of the 
patient 1 - analagous oligopeptide to the rabbit 3 antiserum (fig. 4.7) was performed 
by incubating the antiserum with 1 pg/ml of the oligopeptide in blocking solution at 
room temperature for 2 hours before it was applied to the membrane.
SDS-PAGE blot buffer 3.25 g Tris-HCl, 14.4 g glycine, 200 ml methanol,
made up to 1 litre with dH20 .
TBS-T 8 g NaCl, 2.42 g Tris base, adjust to pH 7.6 (~3.8 ml 1
M HC1), add dH20  to 1 litre.
Tween-20 was added to 0.1 %.
Ponceau-S 0.5% Ponceau-S, 1% glacial acetic acid in dH20 .
2.13 Cell labelling with mitochondrial dyes and Z1F11
Cells were plated onto coverslips in a petri dish and incubated in the appropriate 
medium until they had grown to -70% confluent. Labelling with MitoTracker dyes 
(Molecular Probes, Inc.) was performed according to the manufacturer's protocol. 
Three concentrations of each dye were used; CMXRos at 100 nM, 200 nM, 500 nM 
and CXXRos-H2 at 200 nM, 500 nM and 1000 nM. Cells were incubated in situ with
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the dyes for 30 minutes, then in fresh medium for 30 minutes. Cells were washed in 
PBS, then fixed with freshly prepared 3.7% paraformaldehyde in PBS at room 
temperature for 10 minutes. Cells were washed with PBS, then permeabilised with 
0.5% Triton-X-100 in PBS for 15 minutes at room temperature. Cells were washed 
with PBS then the coverslips were rinsed with 0.05% Tween in PBS (PBS-T). Cells 
were incubated with Z1F11 at 1/100 dilution in PBS-T for 1 hour in a humidified 
chamber. Cells were washed with PBS, rinsed with PBS-T, then incubated with 
FITC-labelled goat anti-mouse IgG (H+L) antibody at 1/100 dilution in PBS-T for 20 
minutes. Cells were washed with PBS. Cells were treated with SlowFade-Light 
(Molecular Probes, Inc.) as per the manufacturer's protocol to extend the time of 
fluorescence emission of the fluorescein label. The mounting medium used was 
Mowiol (Harco).
2.14 Immunoprecipitation
Immunoprecipitation of PIZ was performed using 5 x 106 cells washed in PBS and 
pelleted. The cells were lysed in 1 ml RIPA buffer, with 2% aprotinin and 1 mM 
PMSF, then vortexed and left on ice for 5 minutes. This was then spun in a microfuge 
at maximum speed, 4 °C for 10 minutes. The supernatant was transferred to a fresh 
tube. 100 pi of 50% protein A-sepharose was added, and the tube was slowly rotated 
for 2 hours at 4 °C. This was spun down as before, and the supernatant transferred to 
a fresh tube. The antiserum was added (50 pi Z1F11), and the tube was slowly 
rotated overnight at 4 °C. 50 pi 10% protein A-sepharose, which had been 
preincubated with rabbit anti-mouse IgG*, was added to the mouse monoclonal 
fraction. This was rotated for 30 minutes at 4 °C. It was spun down (2 min), and the 
supernatant discarded. The pellets were washed twice with 1 ml NET:N, pH 8.0, and 
once with 1 ml TBS. The pellets were resuspended in 30 pi reducing sample buffer 
and vortexed, incubated for 5 minutes at 95 °C, and spun. The supernatant was then
ready to be loaded on an SDS-polyacrylamide gel.
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*For binding the mouse monoclonal, the protein A-sepharose had been preincubated 
with rabbit anti-mouse IgG overnight, and washed 3x with NET:N buffer, pH 8.8.
NET:N 150 mM NaCl, 5 mM EDTA, 50 mM Tris (pH 8.0 or 8.8), 0.05% 
NP40.
RIPA buffer 150 mM NaCl, 50 mM Tris, pH 8.0, 1% NP40, 0.5% sodium 
deoxycholate, 0.1% SDS.
2.15 Purification of poly histidine-tagged fusion proteins
For screening transformants, the rapid screening of small scale expression cultures 
protocol was used (Qiagen). Cells were resuspended in buffer B (described below). 
The Ni-NTA resin (Qiagen) slurry/lysate mixture was washed with buffer C, before 
eluting bound protein using buffer C with a final concentration of lOOmM EDTA to 
chelate the Ni 2+ ions.
buffer B 8 M urea, 0.1 M NaH2P 04, 0.01 M Tris, pH 8.0. 
buffer C as buffer B, but pH 6.3.
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Chapter 3
Creation of nuclear cytochrome c oxidase I constructs
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3.1 Introduction
3.1.1 Overview of strategy
In order to investigate the relationship between the expression of a chimeric peptide in 
mammalian mitochondria and a disease-related phenotype (as discussed in section 
1.6), the first stage of my project required the creation of a nuclear version of the 
mouse COXI gene (n-COl). A nuclear version was necessary because no reliable 
procedure for the transfection of animal mitochondria was (or is) available, whereas 
transfection of DNA targetting the nuclear genome is a standard procedure. The 
engineering of a nuclear version entailed alteration of the coding sequence from the 
mammalian mitochondrial genetic code to the universal code, using site-directed 
mutagenesis. The code corrections required for a mouse mtDNA sequence to be 
compatible with cytosolic translation are adenine to guanine transitions (for the 
mitochondrial codons Met (ATA) and Trp (TGA)). In order that the n-COI protein 
could be targeted to the mitochondrial compartment it was necessary to subclone a 
sequence encoding a transit peptide 5' to the code-corrected gene. The mouse 
cytochrome c oxidase subunit IV (COXIV) transit peptide was selected for the 
following reasons: (i) it targets a subunit of the same enzyme complex in the same 
organism (the mouse), (ii) it conforms to the stereotypic structural requirements for 
appropriate processing of a leader sequence (Hendrick et al., 1989), (iii) the sequence 
of the translational start site contains the elements essential for efficient translation in 
eukaryotes (Kozak, 1986), (iv) the sequence of a cDNA for this subunit was available 
(Grossman & Akamatsu, 1990), (v) the yeast COXIV transit peptide was sufficient 
for importation of an attached cytosolic protein into the matrix of yeast mitochondria 
(Hurt et al., 1985). Figure 3.1 shows the nucleotide and amino acid sequence of the 
portion of the COXIV gene encoding the transit peptide. The full length, code­
corrected, mitochondrially targetted n-COI protein was intended to be used as a
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a)
ATGTTGGCTTCCAGAGCGCTGAGCCTGATTGGCAAGAGAGCCATTTCTACTTCGGTGTGCCTTCGA 
M L A S R A L S L I G K R A I  S T S V C L R
b)
- 3 +4
Kozak optimal sequence ACC ATG G 
AGA ATG TMouse COXIV
Figure 3.1 Sequence of COXIV transit peptide
a) Nucleotide and amino acid sequence of the mouse cytochrome c oxidase subunit IV 
mitochondrial targetting peptide, as determined from the sequencing of cDNA (Grossman and 
Akamatsu, 1990). Amino acid residues indicated by Hendrick eta l., (1989), as conserved for 
appropriate processing of the leader sequence are underlined.
b) The optimal sequence for translational initiation by eukaryotic ribosomes as defined by site- 
directed mutagenesis studies on the rat preproinsulin gene is shown (Kozak, 1986), and 
compared to the relevant section of the mouse COXIV gene (Grossman and Akamatsu, 1990). 
A purine at position -3 is essential for efficient translation, with an adenine optimal. If an 
adenine is present at -3, a T at position +4 is translated at ~l/2  the rate of a construct with a G 
at position +4. The Cs at positions -2 and -1 were not shown to enhance translation when the 
constructs tested had an A at position -3 and a T at +4. Although the T at position +4 is not 
optimal for translational initiation in the cell system used by Kozak (1986), it was decided to 
use the native sequence of COXIV rather than altering the leucine codon to a valine.
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M  1542 n t--------------------- ►
n-COI /W W W W W I
-♦-235 n t - ^
PI E H S S S S S S S K 3
♦ -2 3 5  n t - ^
PIZ i M E S S S S S ^ a H
■♦-------------------- 1452 n t ----------------- ►
Figure 3.2 Nuclear cytochrome c oxidase I constructs
n-COI - the nuclear version of COXI
PI - Patient I construct
PIZ - epitope tagged version of the Patient I construct
PII - Patient II construct
K \ \ \ \ \ V \ 1  mouse COXI-derived sequence
FxTH mouse COXIV-derived sequence (transit peptide - 22 aa)
Y7X human cyt ^-derived sequence (out of frame - 20 aa)
g  DNA encoding the Z1F 11 epitope tag (7 aa)
|  human tRNA ^ -derived sequence (1 aa)
control for expression studies with the chimeric versions of n-COI depicted in fig. 3.2, 
and described below.
The chimeric mouse genes which I set out to construct were the equivalent of the 
chimeric COXI genes found in the partially duplicated mitochondrial genomes of 
KSS patients 1 and 2 (Poulton et al., 1989) discussed in section 1.6. The first 
construct (designated PI for Patient I) consists of the 5' region of n-COI, plus a 3' 
region derived from the human cyt b gene, read out of frame (see fig. 3.2). In the 
mutant mitochondrial genome of KSS patient 1, COXI is joined to cyt b out of frame. 
If I had used the homologous mouse cyt b sequence to construct the chimeric mouse 
genes, a stop codon would have been generated after 6 abnormal residues rather than 
the 20 abnormal residues encoded by the chimeric gene found in the patient's mutant 
mitochondrial DNA (fig. 3.3). Also, as explained below, it was necessary for the 
mouse construct to encode the same carboxy-terminal protein sequence as the patient 
chimeric gene in order to utilise the antipeptide sera raised by J.Poulton and co­
workers for analysing KSS patient 1 tissues. Therefore it was decided to use the 
human cyt b coding sequence for generating the PI construct. The second construct 
(designated PII for Patient II) would encode all but the final 33 amino acids of COXI, 
plus a single novel codon derived from the tRNAThr coding sequence.
In order to analyse the expression of the three constructs based on n-COI, it was 
anticipated that a specific antibody would be necessary. No antibodies raised against 
mouse COXI were available. These would not have been useful for intra- 
mitochondrial analysis of the full-length n-COI anyway, due to the presence of 
endogenous COXI. In collaboration with Dr. J. Poulton rabbits were immunised with 
a peptide encoded by the cyt b region of the patient 1 chimeric gene. This should 
have generated Pi-specific antibodies, because the cyt b region of the chimeric gene is 
read out of frame. However, it was decided also to "tag" the three n-COI constructs
with a 3' terminal epitope to facilitate expression analysis. The epitope that was
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(a) Human cyt b sequence (nt 15056-15121)
Y G S F L Y S E T W N I G I I L L L A T M A
TACGGATCATTTCTCTACTCAGAAACCTGAAACATCGGCATTATCCTCCTGCTTGCAACTATAGCA
T D H F S T Q K P E T S A L S S C L Q L *
(b) Mouse cyt b sequence (nt 14448-14513)
Y G S Y T F M E T W N I G V L L L F A V M A  
TATGGATCATATACATTTATAGAAACCTGAAACATTGGAGTACTTCTACTGTTCGCAGTCATAGCC 
M D H I  H L *
Figure 3.3 Sequence comparisons of human and mouse frame-shifted cyt b
This figure depicts the region of the cytochrome b gene relevant to the discussion in section 
3.1.1.
(a) gives a portion of the sequence of human cytochrome b. The top line shows the cyt b 
amino acid sequence, the middle line is the nucleotide sequence, and the bottom line is the 
amino acid sequence of the patient I 3' region, as specified by the frame-shifted cyt b 
nucleotide sequence.
The amino acid sequences are translated using the mitochondrial genetic code.
(b) gives the sequence of the corresponding portion of the mouse cytochrome b. The top line 
shows the cyt b amino acid sequence, the middle line is the nucleotide sequence, and the 
bottom line shows the predicted amino acid sequence if the nucleotide sequence were 
frameshifted as in the human patient 1. Translation of the top line uses the mitochondrial 
genetic code, translation of the bottom line uses the universal genetic code.
chosen is a seven amino acid epitope from the Herpes Simplex Virus - 1 65K DNA- 
binding protein (65KDBP, encoded by the gene UL42), for which the sequence is 
GDPEDLD. This epitope was chosen because the monoclonal antibody designated 
Z1F11, which was reactive against 65KDBP, was available (courtesy of Dr. H. 
Marsden and co-workers), and had been characterised (Schenk et al., 1988; Murphy et 
al., 1989). The antibody was reported to recognise both the denatured protein on 
western blots and the native protein for the purpose of immunoprecipitation. The 
epitope had also been used previously as a tag for immunofluorescence-labelling of 
transgene-encoded proteins in a mammalian cell culture system (personal 
communication, Dr. R.Sutcliffe).
3.1.2 Oligonucleotide-directed mutagenesis
Oligonucleotide-directed mutagenesis is a technique which permits the programmed 
change of DNA sequence by in vitro procedures (Zoller and Smith, 1982). The 
technique requires the use of a cloning vector capable of generating single-stranded 
DNA. In general, bacteriophage M l3 or M13-based phagemid vectors are used. 
pBluescript SK+ (supplied by Stratagene), a phagemid, was chosen as the cloning 
vector, because it was reported to be less prone to deletion of insert DNA than Ml 3, 
as well as more efficient at packaging the single-stranded DNA (due to its reduced 
size), and also because the polycloning site is situated between the T3 and T7 
promoters, enabling in vitro transcription. In this technique, the mutagenic 
oligonucleotide is designed to be complementary to the single-stranded template, 
except at the site of the programmed mutation (which could be a point mutation, 
insertion or deletion of sequence). The mismatch region is usually centred between 
the two exactly matched anchor sequences. Figure 3.4 shows a schematic diagram of 
the basic technique, using a phagemid vector to create a single point mutation. The 
mutagenic oligonucleotide is hybridised to the single-stranded template and then
extended using a DNA Polymerase (I initially used Klenow fragment) in the presence
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In vitro
In vivo
4a 4b
Figure 3.4 Oligonucleotide-directed mutagenesis with single-stranded DNA as template
1. A 5’ phosphorylated oligonucleotide encoding a single mismatch is annealed to the single­
stranded template DNA. 2. Primer extension using DNA polymerase. 3. Ligation of the nascent 
strand to form a closed heteroduplex molecule. 4. Replication/mismatch repair of the plasmid 
produces two possible daughter molecules. 4a is identical to the original plasmid. 4b contains 
the programmed mutation on both strands.
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of T4 DNA ligase. This produces a double-stranded closed-circular DNA molecule 
which contains a mismatch at the site of mutation. Following transformation of a 
suitable host bacterial cell, the heteroduplex molecule will give rise to both mutant 
and wild-type progeny cells.
The diagram shown in fig. 3.4 implies that 50% of the daughter molecules will 
contain any given programmed mutation. However, E.coli contains a methyl-directed 
mismatch repair system which favours the repair of a non-methylated DNA strand 
over a methylated strand. In the host cell this system protects against mutation by 
preferentially repairing newly synthesised DNA which has not yet been methylated. 
Similarly, the non-methylated, in vitro synthesised strand is preferentially repaired by 
the cell, thus reducing the proportion of mutant progeny (Kramer et al., 1984). The 
presence of any uncopied template or partially replicated molecules in the 
transformation reaction can also reduce the proportion of mutant progeny (Zoller and 
Smith, 1983). Klenow fragment is used as the DNA polymerase because it should 
lack the 5'-3' exonuclease activity. However, if any such residual activity is present in 
the enzyme preparation used, the mutagenic oligonucleotide is susceptible to 
digestion. Zoller and Smith (1984) developed a mutagenesis method using 2 primers 
to circumvent this problem. By having an accessory non-mutagenic primer upstream 
of the mutagenic oligonucleotide, which can be extended and covalently joined to the 
5' end of the mutagenic oligonucleotide, the probability is increased that the 
mutagenic oligonucleotide will not be displaced by exonuclease activity. However, in 
practice, less than 10% of colonies obtained by oligonucleotide-directed mutagenesis 
contain a typical programmed mutation. Therefore, strand selection techniques have 
been designed to enrich the yield of mutants which were used in the project at specific 
stages (Kunkel, 1985; Vandeyar et al., 1988).
108
3.1.3 Strand selection methods
One technique to increase the proportion of mutants obtained is the Kunkel procedure 
(Kunkel, 1985). This requires the sequential use of two E. coli strains. The template 
strand is prepared in a bacterial strain which is deficient in both dUTPase (dut) and 
uracil-n-glycosylase (ung). The enzyme dUTPase converts dUTP to dUMP, so a 
deficiency causes an increase in the cellular pool of dUTP leading to its incorporation 
in DNA at thymine sites. The second enzyme, uracil-n-glycosylase, would normally 
remove uracil residues incorporated into DNA. After the in vitro mutagenesis 
reaction using standard dNTPs, transformation of the heteroduplex molecules into an 
ung+ strain will remove the uracil from the template strand, thus blocking its 
replication and making it susceptible to cleavage by nucleases. The preferential 
destruction of the template strand increases the proportion of progeny containing the 
desired mutation. One drawback to this technique is that dut-, ung- strains are less 
viable than standard E. coli strains due to the increased potential for mutation of the 
host genome.
The converse of this approach is to include a modified nucleotide in the in vitro 
synthesis of the second strand, such as 5-methyl-dCTP or dCTPaS. The heteroduplex 
can then be nicked with an endonuclease (e.g., Mspl and Neil respectively) which 
cleaves the non-modified strand preferentially, and exonuclease III digestion will then 
remove the parental strand (Vandeyar et al., 1988, Eckstein/Amersham system).
Other systems are now widely available.
3.1.4 The use of PCR in oligonucleotide-directed mutagenesis
Another version of oligonucleotide-directed mutagenesis utilises the polymerase 
chain reaction. As with the technique already described, the programmed mutations
are incorporated in the oligonucleotide sequence. Several variations of the technique
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exist (see fig. 3.5). Mutagenic primers are used in PCR to create changes in the target 
sequence whilst amplifying the fragments which are then cloned by standard methods. 
Mutagenesis of an internal site will necessarily generate two fragments, because each 
oligonucleotide used for priming DNA synthesis forms an end of a product. The 
products can then be subcloned, either with a blunt end ligation at the junction formed 
by the two internal primers, or by "sticky-ended" ligation, if a suitable restriction site 
is present or can be generated. Although "sticky-ended” ligation is more efficient 
than blunt ended, the problem with the second strategy is that not all endonucleases 
are capable of efficient digestion near to the end of a fragment. Sequential PCR 
overcomes this by designing primers that overlap. This produces 2 PCR fragments 
which, when denatured and reannealed, can form the template for a second round of 
PCR. The product of this reaction can then be subcloned as a single fragment.
The major advantages of a PCR-based method for oligonucleotide-directed 
mutagenesis are the simplicity of the technique (there is no need to use special vectors 
and procedures for preparing single-stranded DNA), speed, and the high frequency of 
mutation incorporation. However, it is more costly than the procedure described in 
section 3.1.2 because 2 oligonucleotides are required for each mutagenic target site. 
Additionally, 2 primers external to the target sequence are required for amplification 
by PCR (although these could be standard primers such as M l3 forward/reverse, 
which hybridise to vector sequence). The major drawback of a PCR-based approach 
is the fidelity of the DNA polymerase used. Taq DNA polymerase does not have a 3'- 
5' exonuclease (proofreading) activity. Thermostable DNA polymerases with 
proofreading activity are now commercially available, e.g., Pfu polymerase supplied 
by Stratagene. However, a PCR-based approach was not deemed suitable to a project 
requiring the mutagenesis of multiple sites within a single gene such as this, although 
this approach was used for other steps in the creation of the nuclear-expressible 
transgenes.
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Figure 3.5 Oligonucleotide-directed mutagenesis by PCR
(a) Mutagenesis by PCR produces two fragments which can be subcloned by a blunt end ligation at 
the central junction.
(b) Mutagenesis by PCR produces two fragments which can be subcloned by a cohesive end 
ligation at the central junction.
(i) PCR of the template sequence is performed using two external primers, and two internal 
primers. The mutation is programmed by one of the internal primers for methods (a) and (b).
(ii) PCR yields two products, (a) digestion with restriction enzymes A and C enables directional 
subcloning of the two fragments into the vector, with a blunt end ligation at the junction of the 
fragments, (b) digestion with restriction enzymes A, C, and S enables directional subcloning of the 
two fragments in a vector.
A, C - flanking restriction sites. F, R - forward and reverse primers. B - blunt end junction of 
primers. M - point mutation introduced. S - sticky-end restriction site.
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Fig. 3.5 continued
(c) Mutagenesis by sequential PCR is executed in two stages, producing a single fragment for 
subcloning.
(i) PCR of the template sequence is performed using two external primers, and two internal 
primers. The mutation is programmed by both internal primers for method (c).
(ii) PCR yields two products, (c) denaturing and annealing of the two products yields a 
mixture of molecules, including the two shown in (iii).
(iii) The reannealed product with the free 3' OH ends can serve as a substrate for DNA polymerase.
(iv) PCR of the new template sequence is performed using two external primers. Digestion with 
restriction enzymes A and C enables directional subcloning of a single fragment.
A, C - flanking restriction sites. F, R - forward and reverse primers. M - point mutation introduced.
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3.2 Results
3.2.1 Subcloning of mouse COXI into pBluescript II SK+
Plasmid p5.0 (a gift from Dr. K. Fischer-Lindahl) contains the region 3565-8420 of 
the mouse mitochondrial genome, cloned as a BamHl/Pstl fragment in pUC. The 
2,448 bp Lspl fragment from this plasmid contains the entire coding sequence of 
COXI, as well as 107 nt of 5' and 800 nt of 3' flanking DNA. Following digestion 
with Lspl, the 5' overhanging ends of the fragment were endfilled using DNA 
polymerase I Klenow fragment, and subcloned into the Smal site of pBluescript SK+. 
EcoRY  digestion of plasmid DNA prepared from 12 recombinant colonies (as 
ascertained by blue/white colour selection of colonies grown in the presence of X-gal 
and IPTG) enabled assessment of the presence of an insert, and the orientation of the 
mouse mitochondrial DNA insert within the vector multiple cloning site (MCS). An 
EcoRY  site is present in the MCS of pBluescript II SK+, and a single EcoRY  site is 
present in the insert DNA, at nt 42 of COXI. In one orientation the 2 restriction 
fragments produced are 3.15 kb and 2.35 kb respectively, in the other orientation the 
fragments are 5.35 kb and 0.15 kb. 9 transformants contained the insert in the "sense" 
orientation for COXI, i.e., transcription from the /I-galactosidase promoter would 
produce mRNA containing the coding sequence of COXI (the remaining 3 
transformants contained no detectable insert). One transformant containing the mouse 
mitochondrial DNA insert was selected for use, and designated pLR (fig. 3.6).
3.2.2 Mutagenesis of mouse COXI
The pBluescript vectors are phagemids which can be used to prepare single-stranded 
DNA. The vector contains a 454 nt intergenic region from an fl filamentous phage 
(fllG), which is M13-related. This region encodes all of the ds-acting functions
necessary for single-stranded DNA synthesis and packaging. The orientation of the
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fllG  region in the vector determines whether the '+' o r s t r a n d  is synthesised. The 
use of pBluescript vectors for single-stranded DNA preparation requires an F+ E. coli 
host, because the sex pili encoded by the F plasmid are used by filamentous helper 
phage as the route of infection. The engineered helper phage encode trans-acting 
factors for the preferential packaging of phagemid DNA. pLR contains the 
mitochondrial DNA insert in the orientation which produces single-stranded DNA 
containing the sense strand of COXI. Therefore, all oligonucleotides designed for the 
site-directed mutagenesis are based on the antisense sequence (see fig. 3.7.a for a 
depiction of the plan; the sequences of the oligonucleotides are listed in full in section 
2.4.1).
I devised a strategy using 24 oligonucleotides to create 43 point mutations in the 
COXI coding sequence which would enable correct cytosolic translation. Each 
oligonucleotide encoded between 1-5 programmed mutations. Where possible, they 
were designed to anneal precisely adjacent on the template, so that they could be 
ligated together prior to the addition of DNA polymerase. The "rules" used for 
oligonucleotide design were as stated in Sambrook et ol., e.g., 8-10 nt anchor 
sequence 5' of mutation (to prevent displacement by DNA polymerase), 7-9 nt 3' of 
mutation (to prevent exonucleolytic degradation), minimal length of the 
oligonucleotide while meeting the other criteria (in order to maximise the difference 
in thermal stability between a perfectly matched/mismatched hybrid for later 
screening). Also, C/G base pairing was preferred at termini to increase 
primer/template hybrid stability. Up to 14 oligonucleotides were used per primer 
extension reaction. Following transformation, 102-103 colonies were patched out in a 
grid format and colony lifts were screened with two 32P end-labelled oligonucleotides 
of similar melting temperature (Tm) from the primer extension reaction. Final wash 
conditions were calculated to preserve hybrids between the oligonucleotide probes 
and the correctly mutated DNA, but not with the wild-type DNA, which would have
1-5 mismatches depending on the oligonucleotide used. If obtained, colonies positive
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pBluescript II SK+ 
(3.0 kb)
lacZ
transcription
COI (1.5 kb)
L*/Sm *Sm*/L*
2.4 kb ►
500 bp
Figure 3.6 Plasmid pLR
Map of Plasmid pLR. The 2.4 kb mouse mitochondrial DNA Lspl fragment 
containing the COXI gene is subcloned into the Smal site of pBluescript IISK+. 
Restriction enzyme sites are as follows: E - EcoBM, L - Lspl, Sm - Smal.
* denotes site destroyed in subcloning.
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'TGATTATTCTCAACCAATCACAAAGATATCGGAACCCTCTATCTA
A
rTATTCGGAGCCTGAGCGGGAATAGTGGGTACTGCACTAAGTATTTTAATTCGAGCAGAA 120
B
TTAGGTCAACCAGGTGCACTTTTAGGAGATGACCAAATTTACAATGTTATCGTAACTGCC 180
rATGCTTTTGTTATAATTTTCTTCATAGTAATACCAATAATAATTGGAGGCTTTGGAAAC 240
C ><
TGACTTGTCCCACTAATAATCGGAGCCCCAGATATAGCATTCCCACGAATAAATAATATA 300  
D >< E
AGTTTTTGACTCCTACCACCATCATTTCTCCTTCTCCTAGCATCATCAATAGTAGAAGCA 360
F
GGAGCAGGAACAGGATGAACAGTCTACCCACCTCTAGCCGGAAATCCAGTCCATGCAGGA 420  
>< G
GCATCAGTAGACCTAACAATTTTCTCCCTTCATTTAGCTGGAGTGTCATCTATTTTAGGT 480
GCAATTAATTTTATTACCACTATTATCAACATGAAACCCCCAGCCATAACACAGTATCAA 540
H
ACTCCACTATTTGTCTGATCCGTACTTATTACAGCCGTACTGCTCCTATTATCACTACCA 600  
>< I
GTGCTAGCCGCAGGCATTACTATACTACTAACAGACCGCAACCTAAACACAACTTTCTTT 660
GATCCCGCTGGAGGAGGGGACCCAATTCTCTACCAGCATCTGTTCTGATTCTTTGGGCAC 720
CCAGAAGTTTATATTCTTATCCTCCCAGGATTTGGAATTATTTCACATGTAGTTACTTAC 780
TACTCCGGAAAAAAAGAACCTTTCGGCTATATAGGAATAGTATGAGCAATAATGTCTATT 840
L
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GGCTTTCTAGGCTTTATTGTATGAGCCCACCACATATTCACAGTAGGATTAGATGTAGAC 900
M
•  9  0  0  0  0
ACACGAGCTTGCTTTACATCAGCCACTATAATTATCGCAATTCCTACCGGTGTCAAAGTA 960
N
TTTAGCTGACTTGCAACCCTACACGGAGGTAATATTAAATGATCTCCAGCTATACTATGA 1020  
O P
•  •  •  •  •  •
GCCTTAGGCTTTATTTTCTTATTTACAGTTGGTGGTCTAACCGGAATTGTTTTATCCAAC 1080
TCATCCCTTGACATCGTGCTTCACGATACATACTATGTAGTAGCCCATTTCCACTATGTT 1140
•  •  •  •  •  •
CTATCAATGGGAGCAGTGTTTGCTATCATAGCAGGATTTGTTCACTGATTCCCATTATTT 1200
Q
•  • • • • •
TCAGGCTTCACCCTAGATGACACATGAGCAAAAGCCCACTTCGCCATCATATTCGTAGGA 1260
R >< S
•  •  •  •  •  •
GTAAACATAACATTCTTCCCTCAACATTTCCTGGGCCTTTCAGGAATACCACGACGCTAC 1320
T
TCAGACTACCCAGATGCTTACACCACATGAAACACTGTCTCTTCTATAGGATCATTTATT 1380
U
TCACTAACAGCTGTTCTCATCATGATCTTTATAATTTGAGAGGCCTTTGCTTCAAAACGA 1440
V ><
GAAGTAATATCAGTATCGTATGCTTCAACAAATTTAGAATGACTTCATGGCTGCCCTCCA 1500  
W >< X
CCATATCACACATTCGAGGAACCAACCTATGTAAAAGTAAAATAA 1545
Figure 3.7.a COXI - mutagenesis strategy
The nucleotide sequence of the mouse COXI gene is shown. Bold type indicates nucleotides 
programmed for mutation. Underlining indicates the span of the complementary 
oligonucleotide to effect the A>G transition. The letter centered below this line is the reference 
letter for the oligonucleotide. The arrowheads ('>' and '<') are used to indicate the endpoints of 
the respective oligonucleotides where two mutagenic oligonucleotides are juxtaposed. The 
sequences of all the oligonucleotides are listed in section 2.4.1.
i l l
i) 595- 620
L P V L A A 6 I T
mouse COXI 5 1CTACCAGTGCTAGCCGCAGGCATTAC 3 '
L P V P  P Q A L
pLR8 5 1CTACCAGTACCA CCACAGGCATTAC 3 '
oligo J'repair 3 ' GATGGTCATGATCGGCGTCCGTAATG 5 '
L P V L A A G I T
pLR9 5 1CTACCAGTACTAGCCGCAGGCATTAC 3 '
ii) 1167-1191
code- M A G F V H H F
corrected 5 ' CATGGCAGGATTTGTTCACTGGTTC 3 '
COXI
M A G L  F T G S  
pLRlO 5 ' CATGGCAGGAT TGTTCACTGGTTC 3 '
oligo Q"repair 3 ' GTACCGTCCTAAACAAGTGACCAAG 5 '
iii) 1249-1269
code- M F V G V N M
corrected 5 1ATGTTCGTAGGAGTAAACATG 3 ?
COXI
M F V R V N M
pLRlO 5 ' ATGTTCGTAAGAGTAAACATG 3 '
oligo S'repair 3 ' TACAAGCATCCTCATTTGTAC 5 1
M F V G V N M
pLRll  5 ' ATGTTCGTAGGAGTAAACATG 3 '
Figure 3.7.b Mutagenesis strategies to repair unprogrammed mutations
This figure shows the 3 unprogrammed mutations which occurred during the course of 
mutagenising COXI, the oligonucleotides which were designed to repair those mutations, and 
the product of the mutagenesis repair reaction. The nucleotide sequence is given for the region 
specified within the mouse COXI gene (numbered as in part (a) of this figure). The amino acid 
translation is shown above the nucleotide sequence. Programmed mutations (already executed) 
are indicated by underlining and bold font as in figure 3.7.a. The unprogrammed mutations are 
shown in bold font. Affected amino acid residues are also indicated in bold font As the 
unprogrammed mutations shown in (i) and (ii) both involve a point deletion, both result in a 
frame-shifting of the encoded protein, thus all the residues encoded after the respective point 
deletions are shown in bold.
118
for both oligonucleotides were sequenced (up to 12 per primer extension reaction), 
and the clone with the most programmed mutations, but no unprogrammed mutations, 
was selected for the next round of mutagenesis.
During the initial phase of site-directed mutagenesis I attempted to use the Kunkel 
procedure, which was originally designed for use with bacteriophage M l3 
recombinants. Using pLR I observed poor growth in E. coli strain CJ236 (dut-, ung-) 
and obtained no transformants in the ung+ or ung- strains with the primer extension 
reaction mix using CJ236-derived template DNA. However, as I was successful in 
obtaining clones with multiple changes from the use of a mutagenesis and screening 
procedure in E. coli strain XL 1-blue, I did not pursue optimisation of the Kunkel 
procedure for the pBluescript derivatives with which I was working.
After four successful rounds of mutagenesis using the protocols recommended by 
Stratagene for use with pBluescript vectors, a clone was obtained, designated pLR4, 
which required only 8 further point mutations comprised in 6 oligos (see Table 3.1 for 
a summary of the mutagenesis procedure). The DNA polymerase Sequenase™, 
which cannot displace the hybridised primer from the template as easily as Klenow 
fragment, was then used in the subsequent primer extension reactions. The use of this 
engineered enzyme achieved mutations in two rounds of mutagenesis with 3 
oligonucleotides which were previously unsuccessful. To carry out the remaining 
"problematic" mutations I then altered the protocol slightly. I hypothesised that 
secondary structure in the area to which the oligonucleotides were designed to 
hybridise could be inhibiting the annealing o f primers. In addition to denaturing the 
template by heating (as per the original protocol), I tried alkali denaturation (as used 
in sequencing of double-stranded plasmid). This proved moderately successful, in 
that I obtained further mutations using oligonucleotides which previously had been 
unsuccessful (e.g. mutagenic oligonucleotide R). I also tried parallel primer extension 
reactions using the remaining primers singly/together, as there may have been
Template Oligonucleotides Used Mutations Obtained Clone
pLR A,B,C,D,E A,B ,C,D,E pLRl
pLRl F,G,H,I,J F,G pLR2
pLR2 H,I,J,K,L,M,N,0,P,Q,R,S,T,U H,I,K,L* ,M,0,P,U pLR3
pLR3 J,L,N,Q,R,S,T,V,W ,X T,V,W,X pLR4
pLR4 $ J,L,N,Q,R,S J,N pLR5
pLR5 $ L',Q,R,S Q* pLR6
pLR6 $+ L',Q',R,S L' pLR7
pLR7 $+ Q',R,S R pLR8
pLR8 $+ Q \SJ'( repair) J'(repair) pLR9
pLR9 # Q’,S Q',S pLRlO
pLRlO# Q"(repair),S'(repair) S'(repair) pLRll
Table 3.1 Summary of the oligonucleotide-directed mutagenesis procedure
The sequence of mutagenic events which occurred to code-correct the mouse COXI gene are 
presented in tabular form. Symbols used: * - a subset of the programmed mutations for this 
oligo was achieved (see text for details). $ - Sequenase™ used as the DNA polymerase rather 
than Klenow fragment. + - Alkali treatment used rather than heat to denature the template. # - 
Amersham oligonucleotide-directed in vitro mutagenesis system used. ' - indicates an 
oligonucleotide which was redesigned for mutagenesis, but corresponds to the general region 
indicated on figure 3.7.a by the letter, (repair) - indicates that the mutation encoded by the 
oligonucleotide is not one of the transitions originally programmed, but to correct an 
unprogrammed mutation which occurred during the mutagenesis procedures.
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misannealing and priming by an oligonucleotide at an incorrect site, or hybridisation 
occurring between oligonucleotides (although no obvious sequence similarity 
between them is evident). However, the use of single primers produced no mutants 
(see section 3.1.2). During the course of the mutagenesis, I redesigned 2 
oligonucleotides (L and Q) when a subset of the programmed mutations for the 
respective oligonucleotides was successful, but other changes remained. In the case 
of Q, the mutation at nt 1188 of the COXI sequence was initially successful, but the 
transition at nt 1170 was not (which is the 3' proximal change encoded by the 
oligonucleotide). For primer L it was the 5' proximal change (nt 831) encoded by the 
oligonucleotide which was unsuccessful with the original mutagenic oligonucleotide; 
it is therefore possible that 5'-3' exonuclease activity displaced part of the 
oligonucleotide.
After a further four mutagenesis procedures as described above I had obtained a clone 
(pLR8), which still required 3 programmed mutations (in oligonucleotides Q' and S) 
as well as a further mutation event to repair unprogrammed changes (in the region of 
oligonucleotide J) (fig. 3.7.b). After the next round of mutagenesis all 3 
oligonucleotide primers were used to screen the progeny, but only clones positive for 
single mutations were found. A clone (designated pLR9) was chosen which had been 
correctly repaired using the mutagenic oligonucleotide J' repair. However, the region 
of COXI which was the target sequence for mutagenic oligonucleotides Q' and S was 
apparently resistant to mutagenesis. Because it seemed unlikely that these last few 
changes could be achieved without a selection procedure, the Amersham 
oligonucleotide-directed in vitro mutagenesis system was purchased.
The Amersham kit makes use of the Eckstein selection technique described 
previously, combined with a filtration step to remove single-stranded template DNA 
which has not undergone second strand synthesis. Using the kit, 2 clones were
obtained which had both of the programmed mutations encoded by oligonucleotide S.
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However, both also contained unprogrammed point mutations within the region of 
oligonucleotide S. Clone AmS+5 had a G-A transition at nt 1258, while clone 
AmS+12 had a C-G transversion at nt 1254. Both of these unprogrammed point 
mutations fall between the programmed mutations which were successfully corrected 
using the oligonucleotide. It may be that the two rare point mutations were selected 
for because they were able to disrupt the secondary structure in the region thus 
enabling the mutagenic oligonucleotide to bind, although why they were not then 
subsequently corrected by the same process as the programmed point mutations, is not 
clear. One of these 2 clones also had the code correction programmed by 
oligonucleotide Q', so this clone was chosen as pLRlO to undergo a final repair 
mutagenesis. Two repairs were necessary: (i) the repair at nt 1258, because the G-A 
transition caused a codon change from glycine to arginine, and (ii) correction of a 
single nucleotide deletion in a group of three thymine residues (1177-1179) in the 
region of oligonucleotide Q. The deletion (which had occurred in a previous round of 
mutagenesis) generates a ffameshift and a premature stop codon at nt 1214. As oligo 
Q' did not repair this deletion, a new oligonucleotide Q" repair was designed which 
had ~12 nt anchor sequences to either side of the point deletion; the S' repair oligo 
had 10 nt anchor sequences (both repair strategies are depicted in fig. 3.7.b). Using 
the Amersham kit, a very rare mutagenesis event (5 ug of starting template yielded 
only 9 transformants) produced 2 clones which were code-corrected for the S' repair, 
but none of which had the thymine insertion. One of these clones with the repair at nt 
1258 was designated pLRl 1, and was used as the template for PCR-based 
oligonucleotide-directed mutagenesis to repair the remaining deletion (the repair is 
described in section 3.2.6).
3.2.3 Creation of additional coding regions
As explained in section 3.1.1, in addition to the introduction of point mutations for the
purpose of code correction, it was necessary to subclone the coding sequence for a
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transit peptide to target the proteins encoded by the n-COI based constructs to the 
mitochondrial compartment. It was also necessary to subclone the human cyt b 
region which encodes the 3' section of the PI construct, and to add the epitope tag 
described above.
3.2.3.1 Transit peptide-encoding region
Using the reported sequence of the mouse COXIV cDNA (Grossman and Akamatsu, 
1990), I designed six oligonucleotides which, when annealed, were to form the 
complete double-stranded sequence encoding the transit peptide and restriction sites 
suitable for subsequent recloning (fig. 3.8). Sail was chosen as the 5' restriction site 
because it was compatible with all 3 vectors chosen for the project (the mammalian 
expression vector pMamneo has only 3 unique sites in the MCS, limiting the choice). 
At the 3' end of the coding sequence Lspl was chosen, because the restriction site for 
Lspl is formed by the juxtaposition of the final 5 nt of the COXIV transit peptide 
sequence and the first nucleotide of the start codon of COXI, whilst maintaining the 
correct reading frame. The sequence of the junction is shown here - CTT CGA / 
ATG - with the Lspl site emphasised in bold print. The oligonucleotides were 5' 
phosphorylated, annealed in equimolar amounts, ligated, and digested with Sail. A  
sample of the annealed oligonucleotides was run on a gel at this point to check for 
appropriate double-stranded product formation. The remaining oligonucleotide 
mixture was then deproteinised with phenol/chloroform, ethanol precipitated, and 
subcloned into pBluescript SK+, which had been digested with EcoKV/Sail. Twelve 
transformants were analysed by restriction digests; Lspl to test if the site was present 
in the insert, Safl/Xbal to test whether the insert was of the correct size. Eight clones 
met these criteria, one of which (designated pTP/cx4) contained the correct insert 
when sequenced. However, it had not inserted into the polylinker as designed. The 
restriction site of the insert fragment had not been digested, and a short sequence of
DNA (which was the product of a successful Sail digestion of another insert
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fragment) had annealed to the Sail site in the vector. This enabled a blunt-ended 
insertion event in the reverse orientation to the original design (fig. 3.9).
3.2.3.2 Patient I 3’-encoding region
The human cyt b coding sequence which encodes the Patient I-specific ORF was 
created in a similar fashion to the transit peptide-encoding sequence. It was necessary 
to choose suitable restriction sites in the design of the oligonucleotides in order to 
subclone the fragment that would be generated. Sail was chosen as the 3' restriction 
site for the simple reason given above, whilst the choice of Bell as the enzyme for the 
5' site of the fragment was more complicated. As shown in table 3.2, the sequence of 
the first 3 codons in the Patient I 3' region encode threonine, aspartic acid, and 
histidine. In bold, I have emphasised the 4 nt which are the 5' protruding end formed 
by digestion with Bell or BamHl at an appropriate site. Alteration of the coding 
sequence to a Bell site would not have changed the coding sense, but there is no Bell 
site in pBluescript SK+ to make use of during the sequential subcloning of the 
sections of the PI construct. Conversely, there is a BamHl site in the polylinker of 
pBluescript SK+, but alteration of the coding sequence to this restriction site would 
have changed the coding sense of the third codon. Therefore, I devised a subcloning 
strategy which utilises both of these enzymes to facilitate sucloning without changing 
the coding sequence (see table 3.3, and section 3.2.4 for the execution of the 
procedure).
Five oligonucleotides were used to encode the 20 amino acid residues, stop codon, 
and two restriction sites for subcloning as depicted in fig. 3.10. The oligonucleotides 
were treated as in section 3.2.3.1 and subcloned into pBluescript SK+ (digested with 
SaWEcoKV). Twelve transformants were analysed by double digest (SaB/Xbal) to 
check the size of the insert. Clones which contained the correct size insert were
analysed by single digest (Bell) for the presence of the cloning site. This required
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pBluescript II SK+ 
(3.0 kb)
TP/cx4
LS
 76 b p  ►
Figure 3.9 Plasmid pTP/cx4
The plasmid encoding the transit peptide of the mouse cytochrome c oxidase subunit IV, subcloned 
in pBluescript II SK+. Restriction sites are as follows: E - EcoRM, L - Lspl, S - Sail, X - Xhol,
Xb - Xbal. * - denotes a site destroyed in subcloning.
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DNA sequence Amino acid sequence Restriction Site
a ACG GAT CAT Thr Asp His
b ACT GAT CAT Thr Asp His Bell
c ACGGATCCT Thr Asp Pro BamHl
Table 3.2 The coding sequence of the first three novel amino acids of the PI3' region
Row (a) of Table 3.2 shows the DNA sequence and the corresponding protein sequence for 
the first three novel residues of the Patient 13' region.
Row (b) shows what the corresponding sequences would be if a BelI site was created.
Row (c) shows what the corresponding sequences would be if a BamHl site was created. 
The bases making up the restriction site are underlined. The 5' protruding end generated by 
digestion with either restriction enzyme is indicated by bold font.
DNA site Sequence Procedure
a Annealed PI 1/PI5 5-CGT GAT CAT ..-3’ 
3'-GCA CTA GTA...-5'
digestion with BcB
b PCR product 
COI/PI3’
5'-...ACG GAT CCC-3' 
3 -...TGC CTA GGG-5’
digestion with 
BamHl
c Patient I 
Sequence
5’-...ACG GAT CAT..-3' 
3-...TGC CTA GTA...-5'
Ligation
Table 3.3 The strategy adopted for subcloning the P D f region
Table 3.3 shows how both Bel I and Bam HI were used to facilitate the subcloning of the Patient 13' 
region and the COI fragment without altering the coding sequence.
Row (a) shows the double-stranded DNA sequence (of the relevant codons) from the 5’ section of the 
PI3* region generated by the annealing of oligonucleotides PI1 and PI5. This contains a Bell site, thus 
maintaining the histidine codon.
Row (b) shows the double stranded DNA sequence (of the relevant codons) generated by PCR using 
oligonucleotide COI/PI3' as the 3' primer to amplify the region of COI found in the Patient I construct 
and tag it with the cyt b junction. This contains a BamHl site.
Row (c) shows the Patient I sequence, which is generated when the products in rows (a) and (b) are 
digested with the appropriate restriction enzyme and ligated together. The final sequence translates 
as Thr Asp His, the same sequence as is found in the patient.
The bases making up the restriction sites are underlined. The complementary products created by 
restriction enzyme digestion which are then annealed together to create the junction found in the 
finished product are emphasised in bold print.
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transformation of the plasmid DNA into E.coli strain CB51, which is dam-, to enable 
digestion of prepared plasmid DNA with Bell, a methylation-sensitive restriction 
enzyme. Seven clones were chosen for sequencing, of which one (designated pPI3') 
had the correct sequence. Although it had inserted into the poly linker in the 
orientation which was planned (the insert fragment had been digested with Sail and 
successfully ligated into the Sail vector site), a short piece of extraneous DNA (the 3' 
product of iSa/I-digestion of the insert DNA) was inserted between the EcoKV vector 
site, and the blunt end of the insert DNA (fig. 3.11).
3.2.4 Subcloning PI - the Patient I construct
As the Patient I construct encodes only the first 227 nt of COXI, the requisite point 
mutations for the conversion of this construct to the universal code had been achieved 
after one successful round of mutagenesis. In order to subclone the 5' terminal 
portion of the code-corrected COXI, I used a PCR strategy. The 5' primer was 
designed to include an Lspl site such that COXI could be joined to the COXIV transit 
peptide coding sequence whilst keeping the coding sequence in frame (see section
3.2.3.1 for the sequence at the junction). The 3' primer was engineered to contain a 
BamHl site in the 8 nt of human cyt b sequence that it encoded (table 3.3). Digestion 
with BamHl, as explained in section 3.2.3.2, generates an overhang compatible with 
BcR for joining the PCR fragment to the PI3' coding region. The PCR product was 
digested with BamHl and subcloned into pBluescript SK+ (digested with 
EcoKV/BamHl) to produce pPIpcr, a plasmid containing only the «-COXI PCR 
fragment necessary for the construction of the entire PI construct (see fig. 3.12).
To assemble the Patient I coding sequence in pBluescript SK+ from the 3 plasmids 
which contained the COXIV transit peptide coding region, the relevant section of n- 
COI, and the segment of human cyt b coding sequence, (pTP/cx4, pPIpcr, and pPI3'
respectively), the following procedures were performed (for a summary of the
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pBluescript II SK+ 
(3.0 kb)
Sm
Xb
PI3
S Be
 67 b p  ►
Figure 3.11 Plasmid pPI3'
The plasmid encoding the 3' region of the Patient I construct, derived from the human cyt b 
coding sequence, subcloned in pBluescript II SK+. Restriction sites are as follows: Be - Bell, 
E - EcoKV, S - Sail, Sm - Smal, Xb - Xbal. * - denotes a site destroyed in subcloning.
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(a)
pBluescript II SK+ 
(3.0 kb)
lacZ
transcription
E*
227 bp ►
Figure 3.12 PCR of the code-corrected COXI fragment for construction of plasmid pPIpcr
(a) PCR of COXI fragment to generate sites for subcloning. The template DNA was plasmid pLRl; 
the PCR primers used were oligonucleotide COI/Lsp as the 5' primer, and oligonucleotide COI/PI3' 
as the 3' primer.
(b) The PCR product was digested with BamHl, and ligated into pBluescript II SK+ which had been 
digested with £coRV and BamHl. The plasmid was named pPIpcr.
Restriction sites are as follows: B - BamHl, E - EcoKV, L - Lspl, S - Sail, X - Xhol.
* - denotes a site destroyed in subcloning.
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construction see fig. 3.13). The 72 bp SaWLspl fragment from pTPcx4 was gel- 
purified using a 4% NuSieve agarose gel,and ligated into pPIpcr digested with 
SaWLspl. This clone was designated pTP/PI, and contains the sequence encoding the 
COXIV transit peptide 5' to the n-COI PCR fragment. pTP/PI was digested with 
Xhol, and the 5' overhanging ends were end-filled using DNA polymerase I Klenow 
fragment. It was then itawHI-digested and gel-purified. The isolated 300 bp 
fragment had an intact BamHl overhang at the 3' end of the fragment, compatible with 
BelI, and a blunt end at the 5' end of the gene fragment, compatible with Smal. pPI3', 
which contains the human cyt b fragment of the PI construct, had been digested with 
Smal and Bell, and the 300 bp fragment encoding the transit peptide and n-COI 5' 
region was then ligated into these sites. This produced the end construct pPI/SK+, 
which contained the entire Patient I coding sequence with mitochondrial targetting 
sequence, in pBluescript SK+ (see fig. 3.14 for the final sequence).
3.2.5 Subcloning PIZ - the epitope-tagged version of the Patient I construct
It was my intention to use the Z1F11 epitope tag (described in section 3.1.1) for 
tagging the wild-type COXI construct, PI, and the KSS Patient II construct described 
in the introduction. For the nucleotide sequence encoding the seven amino acids of 
the epitope tag I chose the codons most commonly found in the mouse nuclear 
genome, whilst ensuring the new sequence did not encode any of the restriction sites 
used in the subcloning strategy. I planned a strategy for tagging all three constructs, 
using two sequential rounds of PCR (see fig. 3.15 for a depiction of the PIZ 
construction). The primary 3' oligonucleotide PCR primer was to be construct- 
specific, each having 18 nt homologous to the last 18 nt of the PCR target sequence 
(e.g., the primary 3' oligonucleotide for PI has 18 nt homologous to the human cyt b 
sequence which encodes the 3' region of the PI construct), and 16 nt which encoded 
the 5' portion of the Z1F11 tag.
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(a) pPIpcr MCS (b) pTP/cx4 fragment
X E*
B
L
-235 bp- -76 bp-
(c) pTP/PI MCS (d) pPI3' MCS
x SmP6 bPn
-^\\\\\\\\\\\\\\\\\\\\\\m\\\\\^///////M^^^ I ------
s  T B 'Be
(e) pPI/SK+
pBluescript II SK+ 
(3.0 kb)
lacZ
\  transcription /
Figure 3.13 Construction of the Patient I coding sequence in pBluescript I I SK+
a)The MCS of pPIpcr containing the COXIPCR fragment, b) pTPcx4 fragment for subcloning 
into pPIpcr. c) pTP/PI MCS containing the COXIV transit peptide-encoding sequence plus 
COXI PCR fragment. The plasmid is digested with Xhol, endfilled, then digested with BamHI 
for ligation into plasmid pPI3\ d) pPI3' MCS containing the PI3' coding region, which is then 
digested with Smal and Bell to permit subcloning of the pTP/PI fragment into the vector to 
create the entire PI coding sequence, e) The entire coding region for the Patient I construct 
subcloned into pBluescript II SK+. The plasmid was designated pPI/SK+.
  mouse COXIV-derived sequence (transit peptide)
mouse COXI-derived sequence 
B™ 5™ 5S!a human cyt ^-derived sequence
Restriction sites are as follows: B - BamHI, Be - BelI, E - EcoBN, L - Lspl, S - Safi 
Sm - Smal, X - Xhol. * - denotes a site destroyed in subcloning.
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# # • • • •
ATGTTGGCTTCCAGAGCGCTGAGCCTGATTGGCAAGAGAGCCATTTCTACTTCGGTGTGC
60
M L A S R A L S L I G K R A I S T S V C
• • • • • •
CTTCGAATGTTCATTAATCGTTGGTTATTCTCAACCAATCACAAAGATATCGGAACCCTC
120
L R M F I N R  W L F S T N H K D I G T L
TATCTACTATTCGGAGCCTGGGCGGGAATGGTGGGTACTGCACTAAGTATTTTAATTCGA
180
Y L L F G A W A G M V G T A L S  I  L I  R
GCAGAATTAGGTCAACCAGGTACACTTTTAGGAGATGACCAAATTTACAATGTTATCGTA
240
A E L G Q P G A L L G D D Q  I Y N V I V
ACTGCCCATGCTTTTGTTATGATTTTCTTCATGGTAATGCCAATGATGATTGGTACGGAT
300
T A H A F V M I  F F M V M P M M I  G T D
CATTTCTCTACTCAGAAACCTGAAACATCGGCATTATCCTCCTGCTTGCAACTATAG 357  
H F S T Q K P E T S A L S S C L Q L *
Figure 3.14 Patient I coding sequence
Nucleotide and corresponding amino acid sequence of the Patient I coding sequence.
The Lspl restriction site, at the junction of the transit peptide-encoding region and the COXI 
coding region, is indicated by bold font in the nucleotide sequence. The first residue of the 
mature Patient I peptide, if the transit peptide is proteolytically processed appropriately, is 
indicated by bold font in the amino acid sequence.
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(a) pPI/SK+ template sequence
J k  .................... ..............
-*-76 bp—^ -------------- 235 bp--------------- **-56 bp-**
(b) PCR product from (a) as template for the second amplification reaction
i k  ..........................................................
(c) PCR product from (b) subcloned in pBluescript II SK+.
pBluescript II SK+ 
(3.0 kb)
lacZ
transcription
Xb
30
Figure 3.15 Construction of the epitope tagged version of the Patient I construct
a) The first round of PCR amplifies the target sequence and tags it with a 3' Z1F11-specific 
sequence, in frame. Additionally, the 5' cloning site is altered from Sail to Xbal. The template 
DNA is pPI/SK+; oligonucleotide 5'TP/Xba is the 5' primer, and oligonucleotide PI3YZ1F11 
is the 3' primer, b) The second round utilises a 3' primer homologous to the Z1F11 sequence, 
which encodes the remainder of the epitope tag, stop codon, and Xhol restriction site for subcloning. 
The template DNA is the PCR product from step (a); oligonucleotide 5'TP/Xba is the 5’ PCR primer, 
oligonucleotide Z1F-2 is the 3' PCR primer, c) The PCR product from step (b) is digested 
with Xbal and Xhol, and ligated into XbaUXhol-digQsXQd vector. This creates plasmid pPIZ/SK+, 
the epitope-tagged Patient I construct subcloned into pBluescript II SK+.
mouse COXTV-derived sequence (transit peptide) 
mouse COXI-derived sequence (code corrected) 
human Cyt ^-derived sequence 
DNA encoding the ZIF 11 epitope tag
Restriction sites are as follows: X - Xhol, Xb - Xbal.
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To construct the tagged version of the PI product, the first round of PCR included 
pPI/SK+ as the template. A sample of the reaction product was run on a gel to 
ascertain correct product formation (377 bp), and to separate product from template 
and primers. Both the gel-purified fragment and the unpurified PCR product were 
then used as templates for the second round of PCR to synthesise PIZ. The secondary 
3' oligonucleotide had 16 nt homologous to the Z1F11 coding region in the new target 
sequence, whilst additionally encoding the remainder of the epitope tag, stop codon 
and an Xhol restriction site useful for cloning. The 5' primer used was homologous to 
oligonucleotide TP1, which encodes the 5' terminal portion of the transit peptide, but 
had an Xbal site rather than Sail. This was to enable directional cloning of the DNA 
product, as Sail and Xhol have compatible overhangs. By gel analysis, both the gel- 
purified and unpurified templates yielded a single product in the second PCR. DNA 
was extracted from the final reaction mix using Magic PCR Clean-up (supplied by 
Promega), digested with Xbal and Xhol, and subcloned into pBluescript SK+ digested 
with Xbal/Xhol, to produce pPIZ/SK+. The insert was verified by complete 
sequencing of both strands.
3.2.6 Subcloning tt-COI
As the final 3 programmed mutations had been difficult to achieve using conventional 
oligonucleotide-directed mutagenesis, I proceeded with clone pLRl 1 despite the 
nucleotide deletion (described in section 3.2.2). I devised a strategy using PCR to 
insert the missing thymine at nt 1178, whilst creating an Alw44l restriction site 
proximal to the nucleotide insertion. When creating mutations by PCR, the 
oligonucleotides are designed such that the mismatch with the target sequence is as 
close as possible to the 5' end of the oligonucleotide, in order to minimise the effect a 
mismatch will have on the Tm of hybrid formation. The Alw44l site was created by 
making a silent mutation in the coding sequence which altered the original valine
codon (GTT) to a valine codon more commonly found in the mouse nuclear genome
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a)
Planned n-COI t t g c t a t c a t g g c a g g a t t t g t t c a c t g g t t c c c a t t a t t t
sequence a i m a g f v h w f p l f
b)
Location Sequence
COI/Rprl 178/B 5 '  g c g g t g c a c t g g t t c c c a t t a t t t  3 '
pLRll 5 ' TTGCTATCATGGCAGGAT-TGTTCACTGGTTCCCATTATTT 3 '
3 ' AACGATAGTACCGTCCTA-ACAAGTGACCAAGGGTAATAAA 5'
COI/Rprl 178/A 3 '  c g a t a g t a c c g t c c t a a a c a c g t g g c g  5 '
c)
A/w44I
Sequence o f  t t g c t a t c a t g g c a g g a t t t g t g c a c t g g t t c c c a t t a t t t
pCOI/KS+ A I M A G F V H W F P L F
Figure 3.16 PCR strategy to repair the point deletion at nt 1178
a) The sequence of the code-corrected n-COI from nt 1160-1200 as it should have read, based 
on the original strategy (programmed changes are emphasised in bold print).
b) The sequences of the template and primers for repairing the point deletion at nt 1178 of the 
COXI sequence (equivalent to nt 6505 of the mouse mtDNA sequence). The double-stranded 
sequence of pLRl 1 from nt 1160-1200 is shown. Above and below pLRl 1 are given the 
sequences of the oligonucleotides used as PCR primers for the mutagenesis. COI/Rprl 178/A 
inserts the missing A/T base pair as well as creating a silent A-C transversion to create the 
Alw441 site. COI/Rprl 178/B encodes a T-G transversion for the creation of the Alw441 site. 
Note that the creation of the restriction site does not alter the coding sense.
(c) The sequence of the code-corrected n-COI from nt 1160-1200 as it reads in the final 
construct, pCOI/KS-h
The programmed changes are emphasised in bold print. (-) indicates the missing base pair. 
The Alw441 site is indicated by underlining. Both primers have a 3 nt nonsense 5' 'tail' to 
provide a restriction enzyme substrate that does not have the site immediately at the end of the 
PCR product.
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(GTG), (fig. 3.16). The design of the PCR primers allowed me to amplify n-COI in 
two segments using pLRl 1 as template, inserting the missing nucleotide and creating 
substrates for restriction enzymes to enable subcloning.
Thus, PCR was utilised for the final steps in the mutagenesis and subcloning of n- 
COI, (see fig. 3.17). Using pLRl 1 as template, the 5' primer created the Lspl site for 
the junction with the transit peptide coding region (as used in subcloning the Patient I 
construct), whilst the 3' primer inserted the missing nucleotide at nt 1178 and 
engineered the creation of the AlwAAl restriction site. The PCR product was digested 
with Lspl and subcloned into pTPcx4 which had been digested withATzoI, endfilled, 
then Lspl digested. This created pCOI5' which joins the 5' region of n-COI to the 
COXIV transit peptide sequence. This plasmid was then used as a PCR template to 
amplify the transit peptide/COI5' region, whilst pLRl 1 was used as the template for a 
PCR reaction to amplify the 3' region of n-COI, engineering the creation of the 
AlwAAl site. Both products were digested with AlwAAl, then ligated. An attempt to 
subclone the ligation product was unsuccessful (possibly due to low efficiency of one 
of the enzyme manipulations). The ligation mixture was then used as a template for 
PCR to amplify the intact n-COI coding unit.
This final PCR product was digested with Xbal and Xhol, and subcloned into 
pBluescript SK+ digested with Xbal and Xhol. Six transformants appeared to have 
the correct insert when screened by PCR. However, all of these clones grew poorly. 
Plasmid DNA prepared by three different variations of the alkaline lysis procedure 
(with solutions prepared in the lab, Magic mini-prep (Promega), and Qiagen kit) was 
always contaminated by degraded DNA, believed to be chromosomal, due to its large 
size. This may have been due to nuclease activity in dying cells. h-COXI had been 
subcloned into pBluescript SK+ such that transcription from the lac promoter read 
into the sense strand of n-COI, and such a transcript would potentially encode a lac
Z/COXI fusion protein in frame. It is surmised that this could be toxic to cells, even
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(a) Template DNA: pLRl 1
  COXI (1.54 kb)------------------------------------
1.18 kb-------------------------------------------- 362 bp-
Insertion^
Mutation
(b) The multiple cloning site of pTP/cx4
TP/cx4
s T i ts  L c X
(c) pCOI 5'
X*
— j l l l l l l l l l l l i p
S L
Figure 3.17 Construction of the nuclear cytochrome c oxidase I gene in pBluescript I I KS+
(a) PCR of n-COI 5' region to insert the deleted nucleotide at nt 1178 and engineer Lspl and 
^/w44I restriction sites for subcloning. The template used for the PCR was plasmid pLRl 1.
The primers used were oligonucleotide COI/Lsp as the 5' primer, and oligonucleotide COI/Rpr/A 
as the 3' primer.
(b) The MCS of plasmid pTP/cx4 (see figures 3.8 and 3.9), which contains the COXIV transit 
peptide-encoding sequence, is shown. pTP/cx4 was digested with Xhol, endfilled to make a blunt 
end, then Lspl digested to prepare the plasmid for subcloning.
(c) The n-COI 5’ PCR product subcloned into pTP/cx4. The PCR product from step(a) was 
digested with Lspl, and ligated into vector pTP/cx4 which had been prepared as described in 
step (b). This plasmid was designated pCOI5'.
Restiction sites used are: A - AlwAAl, L - Lspl, S - Sail, X - Xhol.
* - indicates a site destroyed in subcloning.
iiiiiiiiiiimliiiliiiiiiiniM  denotes mouse COXIV-derived sequence (transit peptide), 
denotes mouse COXI-derived sequence.
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(d) Template DNA: pCOI 5'
—|...111111
(e) Template DNA: pLRl 1
1.18 kb 362 bp-
Fig. 3.17 continued
(d) PCR of the COXIV transit peptide encoding region joined to the n-COI 5' region. The 5' cloning 
site is altered from Sail to Xbal to enable directional cloning. The template used was pCOI5\ The 
primers were oligonucleotide 5'TP/Xba as the 5' primer, and oligonucleotide COI/Rprl 178/A as
the 3' primer.
(e) PCR of the 3' portion of n-COI. A one nt change is made to create the AlwAAl restriction site 
for joining the 5' and 3' sections of n-COI together. The template used for the PCR was pLRl 1.
The primers were oligonucleotide COI/Rprl 178/B as the 5' primer, and oligonucleotide 
COI/WT3'/Xho as the 3' primer.
Restiction sites used are: A - AlwAAl, L - Lspl, S - Sail, X - Xhol, Xb - Xbal. 
i i i i i i i i i i l l l i l i i i i i i i i i i i i i i l i M i l i  denotes mouse COXIV-derived sequence (transit peptide).
denotes mouse COXI-derived sequence.
(f) Template DNA: n-COI 5' and 3' ligation product
pBluescript IIKS+ 
(3.0 kb)
lacZ
transcription
Xb
L
Fig. 3.17 continued
(f) The products of the PCR reactions described in steps (d) and (e) were both digested with the 
restriction enzyme AlwAAl. The digestion products were ligated together. This ligation mixture was 
then used as a template for PCR to amplify the entire n-COI coding unit. The primers used were 
oligonucleotide 5'TP/Xba as the 5' primer, and oligonucleotide COI/WT3'/Xho as the 3' primer.
(g) The product from step (f) was digested with Xbal and Xhol, and subcloned into pBluescript II 
KS+ digested with Xbal and Xhol. This plasmid, which contains the entire coding region for 
n-COI is designated pCOI/KS+.
Restiction sites used are: A - ^ 4/w44I, L - Lspl, X - Xhol, Xb - Xbal.
iiiininiiiiiiiilHiiiiiiiflinn denotes mouse COXIV-derived sequence (transit peptide).
WMmmmMM denotes mouse COXI-derived sequence.
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at background levels of expression, i.e., from the lac promoter without induction. The 
same fragment was therefore recloned into pBluescript KS+, which has the polylinker 
in opposite orientation to the lac promoter, so that any read-through transcription 
would produce a transcript containing anti-sense COXI RNA. Plasmid DNA was 
prepared from 6 recombinant transformants and assayed by double restriction digest 
with Xbal and Xhol to check the size of the insert. No degradation of DNA was 
observed. One clone had the correct size insert. This clone was digested with Alw44l 
to ascertain that the 5' and 3' regions of n-COI were joined correctly. Sequence 
analysis detected no unprogrammed mutations. This clone is designated pCOI/KS+, 
and is now ready for use in expression studies. It will also now be possible to 
construct the PII chimeric mouse COXI gene using pCOI/KS+ as a PCR template.
3.3 Discussion
In this chapter I have described the mutagenesis and subcloning used to generate 3 
synthetic genes: (i) the Patient I construct, PI, a chimeric version of mouse COXI 
based on a rearranged COXI gene found in the mutant mtDNA of a KSS patient, (ii) 
an epitope-tagged version of the Patient I construct, PIZ, and (iii) a full length 
universal-code version of mouse COXI. All 3 constructs have been code-corrected by 
site-directed mutagenesis to enable cytosolic translation, and all 3 constructs encode 
an amino terminal mitochondrial targetting signal from the mouse COXIV gene. The 
two Patient I constructs are the basis of the remaining work I shall describe in my 
thesis. n-COI was finally subcloned only at the end of the project, and can form the 
basis of future work in the lab.
In Sambrook et al., 1989 it is stated, in a discussion of site-directed mutagenesis, that 
"in extremely rare cases the secondary structure [may be] so great that no mutants can 
be obtained." My experience with oligonucleotide-directed mutagenesis confirms that
certain regions of DNA are much more resistant to mutagenesis than others. This
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may be because of an inherent property of the DNA (i.e., secondary structure) or 
perhaps because the sequence change creates a transcription/translation product toxic 
to the bacterial host cell. Full-length mouse COXI would, indeed, appear to be toxic 
in E. coli, since the n-COI construct, when in-frame and subject to read-through 
transcription from the lac promoter in the SK+ polylinker, was associated with loss of 
viability of the bacterial host cells. Conversely, when the n-COI insert was oriented 
in the pBluescript KS+ polylinker such that read-through transcription would produce 
an antisense COXI transcript, no impairment of bacterial viability was observed.
In general, the validity of the rules stated for primer design for oligonucleotide- 
directed mutagenesis in Sambrook et al., (1989) were supported by my own results. 
Where mutations proved difficult to achieve, redesign of oligonucleotides had little 
effect, therefore the problem seemed to be template- or mutation-dependent. The use 
of the various mutagenic oligonucleotides for screening putative mutants was 
straightforward. The empirical formula used to calculate the hypothetical Tm (see 
section 2.3.1.3) proved a reliable guide for most of the oligonucleotides used, apart 
from oligonucleotide S. This oligonucleotide, which was also involved in the only 
rearrangement of the template sequence during mutagenesis that I observed, was 
repeatedly unsuccessful as a mutagenic oligonucleotide, although it was used 
successfully as a sequencing primer. It also indicated many false positives during 
screening for mutants. When the final wash temperature was raised 10°C above the 
calculated Tm, the problem of false positives was eliminated.
With hindsight I believe the task of mutagenising a long sequence such as COXI 
would have been made easier by splitting the gene into smaller fragments. Although 
no suitable restriction site is contained in the sequence, silent mutations which do not 
alter the coding sense could have been made in order to create restriction sites (as 
employed subsequently to repair the nucleotide deletion at nt 1178).
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I would also advocate the use of PCR for site-directed mutagenesis where possible, 
rather than conventional techniques requiring single-stranded DNA as template.
There are several reasons for this: (i) the production of good quality single-stranded 
DNA is dependent on many more variables than is the production of double-stranded 
plasmid DNA (e.g., multiplicity of infection of helper phage, length of time host 
bacterial cells are cultured with the helper phage before harvesting). Even when the 
protocol has been optimised for a given clone, the yield of single-stranded DNA may 
be poor. The protocol recommended by Stratagene for single-stranded DNA recovery 
from cells containing pBluescript derivatives states "yields of single-stranded DNA 
can be dependent on the specific insert sequence...". The pLR series of clones had 
poor yields of single-stranded DNA, which hampered progress with site-directed 
mutagenesis. PCR is not subject to these problems, (ii) One major objection to PCR 
for site-directed mutagenesis given is that the relatively higher frequency of ectopic 
mutation makes sequencing necessary (Saiki et al, 1988). However, during the 
mutagenesis of COXI using single-stranded template, an ectopic mutation did occur 
in the region of mutagenic oligonucleotide J. This happened during a primer 
extension reaction which involved no mutagenic oligonucleotides which had a target 
sequence near the site in question. Thus ectopic mutation can occur with either 
technique, making the sequencing of the entire coding region exposed to the 
mutagenesis reaction essential, regardless of the mutagenesis technique used. This is 
another good reason for subcloning the target sequence into smaller fragments, which 
can be sequenced conveniently in their entirety, and can be set aside when the desired 
mutations are achieved for subsequent subcloning, (iii) The speed and accuracy of 
mutagenesis using PCR far outweigh any disadvantages the technique may have. 
Screening is not necessary as there can be no product if the amplification primer has 
not been used (unlike with single-stranded template techniques).
Having used PCR extensively for subcloning the constructs, no ectopic mutation has 
been detected using Pfu polymerase (a high temperature DNA polymerase which has
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proofreading activity). In creating the epitope-tagged version of the Patient I 
construct, 16 nt were added to the sequence in a single round of amplification, yet a 
single product was observed by gel analysis and sequencing. Although PCR can 
generate spurious products, when using plasmid DNA as a template this is rarely a 
problem that cannot be solved by altering the parameters of the polymerase chain 
reaction. If optimal conditions for yield of the desired product had produced spurious 
secondary products, gel purification could have been used to separate the desired 
product from other amplification products. However, for a project such as this which 
required 43 programmed point mutations within a single coding region, it is difficult 
to envisage how a PCR strategy could have been employed throughout. Thus, on 
balance, the correct approach was probably adopted, although a switch to the PCR 
approach at an earlier point in time may have facilitated more rapid progress with this 
project.
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Chapter 4
Expression studies of Patient I constructs in E. coli
and in vitro
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4.1 Introduction
4.1.1 Aims
There were principally two reasons for expressing the Patient I constructs in a 
prokaryotic system. Firstly, I wanted to test the available antisera to determine which 
would be most effective in analysing the mouse cell lines I was generating (discussed 
in chapter 5). A prokaryotic expression system seemed the most appropriate means of 
doing this. Secondly, if the antisera were found not to react specifically with the 
recombinant protein, the expressed protein could be used to generate new antisera to 
the recombinant protein.
An additional consideration was to observe the apparent size of the Patient I protein 
(PI) on SDS-PAGE. Although the molecular weight of the full-length bovine 
cytochrome c oxidase I (COXI) is 57 kDa, its apparent size by SDS-PAGE is 37 kDa, 
due to its extreme hydrophobicity (Hensel and Buse, 1990). The calculated molecular 
weight of the PI fusion peptide is ~13 kDa, and 13.75 kDa for PIZ (the epitope-tagged 
version). Given that these proteins are also highly hydrophobic (~50% of the residues 
are hydrophobic) it was possible that they would migrate with an apparent molecular 
weight of <13 kDa. The apparent molecular weight of the PI peptide on SDS-PAGE 
could be determined by use of a prokaryotic expression system, or by in vitro 
translation. Additionally, in vitro translation using reticulocyte lysate would confirm 
that the encoded RNA could be translated by eukaryotic cytosolic ribosomes.
However, the hydrophobic nature of the proteins meant that expression of the proteins 
might have had a toxic effect on E. coli. For example, it was possible that PI and PIZ 
could associate with the bacterial membrane, disrupting its integrity. When 
subcloning into the prokaryotic expression vector chosen, the manufacturer's (Qiagen)
manual recommends that hydrophobic regions, particularly transmembrane
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sequences, "should be removed from the recombinant protein if they are not of 
specific interest”, to minimise this potential problem. However, this was not possible, 
as the entire encoded polypeptide is of a hydrophobic nature, derived as it is from 
COXI which is an integral membrane protein. Therefore, it was anticipated that an in 
vitro transcription/translation system might be required.
4.1.2 The antisera
An antiserum which would have been desirable in the long term is an anti-mouse 
COXI. No such antibody had been reported in the literature at that time. However, 
for the analysis of the PI polypeptide, it would have been useful only had it 
recognised one or more epitope(s) contained within the 76 amino-terminal residues of 
COXI. Even for the analysis of the full-length n-COI, an anti-mouse COXI antibody 
would be of limited use. It would not discriminate between the endogenous COXI 
and the n-COI proteins once the nuclear encoded version had been imported into the 
mitochondrion and the leader peptide cleaved. Thus the antibody could not be used to 
show conclusively whether the imported n-COI functioned normally, i.e. , was 
incorporated into the inner membrane in a functional cytochrome oxidase complex.
J. Poulton and co-workers, who had analysed the mtDNA from the model KSS patient 
1, obtained a synthetic peptide based on the amino acid sequence of the putative 
patient 1-specific fusion protein (which is derived from the human cytochrome b 
coding sequence as explained in section 1.7.1, Poulton et al., 1989b). This peptide 
was then used to generate antisera. Fig. 4.1 depicts the sequence of the synthetic 
peptide.
A peptide-KLH (keyhole limpet haemocyanin) conjugate was used to immunise 3
rabbits. The antisera were tested by ELISA and western blot by K. Morten using a
BSA-peptide conjugate. 50 pi of a 10 pg/ml stock was detectable by a 1/1000
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a)  M I G  T D H F S T Q - K P E T S A L S S C L Q L
b)  C Y G T D H F S T Q K P E T S A L S
Figure 4.1 Amino acid sequence of the patient 1-specific oligopeptide
a) is the amino acid sequence of the carboxy terminus (residues 74-96) of the putative KSS 
patient 1 polypeptide and of the analagous mouse polypeptide PI. The patient 1-specific region 
which is derived from cytochrome b coding sequence is underlined.
b) is the sequence of the synthetic peptide used to generate antipeptide antisera. An amino- 
terminal cysteine residue is necessary for the in vitro synthesis of peptides to join the peptide to 
the matrix by a disulphide bond. The tyrosine residue was also included to assist in the 
manufacture of the synthetic peptide. Residue 76 in COXI is glycine; in the hypothetical KSS 
patient 1 polypeptide residue 76 is encoded at the COXI/cyt b chimeric junction and is 
unchanged as a glycine.
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dilution of the rabbit 3 antiserum in ELISA. Using a 1/500 dilution of the same 
antibody, -1 ng of the BSA-conjugate was detectable on a western blot. On the basis 
of this data, the rabbit 3 pre-immune and 3rd bleed antisera were sent to me. As is 
evident from the westerns which I have performed using these antisera (data shown in 
the results section), it does not react with the 66 kDa BSA size marker. It is therefore 
reasonable to assume that the antiserum recognises epitope(s) contained within the 
peptide sequence on western blot. Later, the pre-immune and 3rd bleed antisera from 
rabbits 1 and 2 were also made available and tested by me. All rabbit antisera were 
normally used at a 1/1000 dilution for western analysis.
Preliminary western analysis of patient tissues with the rabbit 3 antiserum had been 
done by Dr. Morten when I began analysis of the Patient I constructs in E. coli. A  
10% SDS-polyacrylamide gel was loaded with brain, heart, kidney and pancreas 
tissue extracts from the KSS patient, and control muscle tissue. This was blotted and 
probed with rabbit 3 immune serum. A strong band of apparent molecular weight -58 
kDa was seen in pancreas, which reportedly had a high proportion of duplicated 
mtDNA molecules in patient 1. No bands were reported in the range <35 kDa, the 
predicted size of the chimeric patient 1 protein being -13 kDa, however, on a 10% gel 
the protein may have run off or been very diffuse. Additionally, the antiserum 
detected a number of bands non-specifically. On a 15% polyacrylamide gel a band of 
apparent molecular weight 12 kDa was detected in patient 1 muscle tissue, but not in 
control muscle. However, this band was not detected on a subsequent blot of patient 
tissue. It is possible that this was attributable to a lack of sensitivity in the detection 
system used, to limited proteolysis, or because the original positive result was, in fact, 
an artifact. Thus, although there was no clear evidence that the antiserum could 
detect a patient 1 - related fusion peptide on westerns, the antiserum was used in the 
following analysis because it was the only one available to me.
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As explained in chapter 3, the other antiserum which was used for expression analysis 
was the mouse monoclonal antibody Z1F11. It had been raised against the HSV-1 
65K DNA-binding protein (65Kdbp), a protein essential for HSV DNA replication, 
which it recognised on western blots (Schenk et al., 1988). Using overlapping 
hexapeptides, the antigenic region of 65Kdbp recognised by the antibody was mapped 
to a 7 amino acid epitope (Murphy et al., 1989). In the latter paper, Z1F11 was used 
to immunoprecipitate the protein, and this reaction was specifically blocked by the 
presence of a heptadecapeptide (corresponding to amino acids 357 to 373 of 65Kdbp) 
which contained the 7 amino acid epitope. I created an epitope-tag coding region for 
the PIZ constructs based on the defined amino acid sequence. The antibody, of 
immunoglobulin subtype G l, was provided as ascites fluid and used at a 1/1000 - 
1/3000 dilution for westerns.
For western analysis, the ECL detection system (supplied by Amersham) was used. 
This system makes use of the enzyme horseradish peroxidase (HRP) for 
chemiluminescent detection. The primary antibody binds to the denatured protein 
which is fixed to a membrane. The secondary antibody, e.g., goat anti-mouse, then 
binds to the primary antibody. The secondary antibody is conjugated to HRP, so that 
when the HRP substrate is added, light is emitted. The reaction can be very sensitive, 
and exposure times usually range from seconds to a few minutes.
4.1.3 The prokaryotic expression vector pQE32
For expression of PI in E. coli, I chose the Qlhexpress (pQE) system supplied by 
Qiagen. There were 3 main reasons for the choice: 1) the tight regulation of 
transcription, 2) the easy and reputedly efficient procedure for protein purification,
3) other researchers in the department who could be consulted were using the system 
routinely.
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Transcription of the recombinant gene in the pQE vectors is initiated from an 
engineered promoter/operator element designed to enable a high level of protein 
expression. The element is composed of the E. coli phage T5 promoter and two 
copies of the lac operator sequence. The lacl gene, which encodes the lac repressor 
protein, is present on a second high-copy number plasmid pRep4. The high level of 
repressor expression this produces is necessary to ensure repression of transcription 
from the engineered promoter element. Expression is induced by the addition of 
IPTG, which inactivates the lac repressor protein, displacing it from the operator 
elements. The pQE vectors also contain a synthetic ribosome binding site for optimal 
mRNA recognition and binding, and translational stop codons in all 3 reading frames 
immediately following the multiple cloning site.
The pQE vectors encode a tag of 6 histidine residues (either 5' or 3f with respect to the 
cloning site) to enable affinity purification of the recombinant protein using the Ni- 
NTA (Ni2+-nitrilotriacetic acid) resin, supplied by Qiagen. The stability of the 6 x 
His/Ni-NTA interaction is maintained in the presence of non-ionic detergents such as 
Triton X-100 (0.1-1%), enabling their use for purification of membrane-associated 
proteins. Protein denaturants such as 8M urea can also be used during purification, 
because binding of the tagged protein to the resin is not dependent on protein 
structure. Elution is achieved by the addition of a chelating agent (EDTA), lowering 
of pH (causing protonation of the histidine residues), or competition with imidazole 
(which binds to the Ni-NTA and displaces the tagged protein). The 6 x His tag is 
reportedly non-immunogenic (apart from in some species of monkey) and therefore 
need not be removed when raising antisera to the recombinant protein. The tag is also 
reported usually not to interfere with the structure or function of the purified protein. 
Lastly, the QIAexpress product information reports that this system has been used 
with membrane proteins; a paper has since been published citing the use of the 
QIAexpress system for purifying a transmembrane protein with 8 membrane-spanning 
domains (Waeber et al., 1993).
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The specific vector chosen was pQE32. The pQE-30 series has the 6 x His tag 
encoded at the amino-terminus of the recombinant protein. Reportedly, placing the 
histidine tag-encoding sequence at the 5' end of the gene yields higher expression 
levels than 3' tagged constructs (Qiagen manual, S. LeGrice, personal 
communication). Because PI is a low molecular weight protein, I considered 
obtaining the Type II vector which encodes mouse DHFR (dihydrofolate reductase) as 
a carrier protein between the amino-terminal histidine tag and the recombinant 
protein. However, the manufacturer's information defined a "small" protein 
(requiring the carrier protein for stable expression) as <10 kDa, so I made use of the 
general purpose vector. pQE32 is the vector in the pQE-30 series which allowed 
subcloning of the PI constructs into the same reading frame as the 6 x His affinity tag.
4.2 Results
In section 4.1.2 it was explained that the testing of the anti-patient 1 peptide antiserum 
on western blots of patient tissues, carried out by Dr. Morten, was inconclusive, in 
that it was unclear as to whether the rabbit 3 antiserum was reacting with a patient- 
specific protein. In order that the available antisera could be tested specifically for 
their reactivity to the chimeric protein, the Patient I-analagous construct was 
subcloned into the prokaryotic expression vector pQE32. The epitope-tagged version 
of the Patient I construct was also subcloned into pQE32 to test the reactivity of the 
monoclonal antibody Z1F11 with the PIZ protein.
4.2.1 Subcloning of Patient I constructs into pQE32
Sub-cloning of the PI and PIZ constructs into the pQE vector was done in E. coli 
strain XL 1-blue, which contains the lacfi gene. This gene has a mutated promoter
causing constitutive expression of the lac repressor protein; the high levels of lacl
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protein should be sufficient for blocking expression of the recombinant protein during 
propagation.
Plasmid pPI/SK+ (the Patient I construct in pBluescript SK+, described in section 
3.2.4) was digested with Sail, and the 370 bp Patient I insert sequence was gel- 
purified. The fragment was subcloned into pQE32 which had been digested with Sail 
and dephosphorylated with calf intestinal alkaline phosphatase. Transformants were 
mini-prepped and screened by restriction digest with Sail, and 2 clones were chosen 
for sequencing. Of these, the plasmid designated pPI/Q contained the correct insert 
sequence in the appropriate orientation for protein expression (fig. 4.2.a).
Plasmid pPIZ/SK+ (the epitope-tagged Patient I construct in pBluescript SK+, 
described in section 3.2.5) was digested with^YM, and the 5' overhanging end was 
endfilled using DNA polymerase Klenow fragment. The plasmid was then Xhol 
digested, and the fragment gel-purified. The isolated 390 bp fragment had an intact 
Xhol site overhang at the 3' end of the fragment, compatible with a Sail overhang, and 
a blunt end at the 5f end of the gene fragment, compatible with Smal. pQE32 had 
been digested with Smal and Sail, and the fragment was ligated into the vector 
multiple cloning site in frame for correct translation. Transformants were mini- 
prepped and screened by restriction digest with Lspl (a single site is present in the 
insert sequence, none in the vector, see fig. 3.15), and a clone, pPIZ/Q, was selected 
for sequencing to confirm that it contained the correct insert sequence (fig. 4.2.b).
It should be noted that the prokaryotic expression vector pQE32 encodes an additional 
20 and 19 amino acid residues respectively at the amino terminus of the PI and PIZ 
proteins (fig. 4.2). As these residues are much less hydrophobic than the PI protein, 
in addition to adding ~2 kDa to the molecular weight, they may have a significant 
effect on the mobility of the recombinant protein.
154
4.2.a pPI/Q
ATGAGAGGATCT /  /  GGGATCCGCATGCGAGCTCGGTACCCCGGGTCGACCAGAATG 
M R G S ( 6 X H) G I R M R A R Y P G S T R M
4.2.b pPIZ/Q
ATGAGAGGATCT / /  GGGATCCGCATGCGAGCTCGGTACCCCCTAGACAGAATG 
M R G S (6  x  H) G I R M R A R Y P L N R M
Figure 4.2 The nucleotide and amino acid sequences of the amino-terminal region of 
the PI constructs in pQE32
These are the amino-terminal sequences of plasmids pPI/Q and pPIZ/Q. The sequence shown 
spans the initiation codon of the prokaryotic expression vector to the first codon of the PI 
constructs. The region of the multiple cloning site involved in the subcloning procedure is 
underlined in each case. As described in the text, the subcloning of pPI/Q required only the 
ligation of a Sail end into a Sail site (GTCGAC). The subcloning of pPIZ/Q required the 
ligation of a blunt-ended Xbal end (CTAGA) into a digested Smal site (CCC). The vector- 
derived sequence is in plain font, the insert-derived sequence in bold font.
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4.2.2 Time-course and growth analysis of E. coli transformants
Both constructs pPI/Q and pPIZ/Q were transformed into the Qiagen recommended E. 
coli host strain Ml 5. Small proteins can be more susceptible to cellular proteases, 
because of problems with folding. Suggestions for minimising degradation in strains 
which are not deficient in a cellular protease include reducing the growth temperature 
and shortening the induction time prior to harvesting. A time-course of growth was 
taken, to determine whether shortening the induction period was advisable (fig. 4.3). 
A 1/10 dilution of overnight cultures of pQE32, pPI/Q and pPIZ/Q were grown for 1 
hour. At this point the cultures were split in half, and expression was induced in one 
aliquot of each isolate by the addition of IPTG to a final concentration of 2 mM. The 
cultures were then incubated for a further 3 hours. The uninduced cultures displayed 
no difference in growth rate over the span of 4 hours, having reached stationary phase 
by this time. However, the cultures to which IPTG had been added displayed 
significant differences in growth. The vector control culture showed a small 
reduction in OD600 at the final time point, when compared to the uninduced control. 
Both pPI/Q and pPIZ/Q cultures effectively ceased growing upon the addition of 
IPTG to induce expression of the recombinant proteins, and showed no growth 1 hour 
post-induction. The third graph in figure 4.4 shows another time-course of growth of 
the 3 different transformants. In this case a 1/4 dilution of overnight culture was 
induced with IPTG after 1 hour of growth. OD600 readings were taken at hourly 
intervals. Although vector-transformed E. coli continued to grow (as in graph 2), the 
pPI/Q- and pPIZ/Q-transformed cultures grew minimally over the first hour post­
induction, then ceased growing. Other researchers in the department using the Qiaex 
vectors did not observe a cessation of growth upon induction of the recombinant 
proteins with which they were working. However, the proteins in question were not 
expected to associate with membranes (personal communication, G. Glasssmith).
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Figure 4.4 Time-course assays for growth
9
Overnight cultures of E. coli were used to inoculate fresh medium which was supplemented 
with appropriate antibiotic, and grown with agitation at 37°C. Readings were taken on a 
spectrophotometer at O D ^  of samples from these cultures at the time points specified to assay 
bacterial growth. The 3 graphs presented in this figure plot the timepoint of the sample against 
the ODgoo reading.
Graph 1 and 2 display the data for overnight cultures of E. coli which were diluted 1/10. After 
incubating for 1 hour the cultures were split into two aliquots, and IPTG was added to one 
aliquot of each. Graph 1 presents the data for the uninduced samples, graph 2 for the induced 
samples. Graph 3 presents the data for overnight cultures of E. coli which were diluted 1/4, 
grown for 1 hour, then induced with IPTG.
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Each of the isolates had also been streaked on agar plates +/- glucose. After overnight 
incubation pPI/Q and pPIZ/Q colonies on the glucose plates (the supplement of 2% 
glucose is to maximise repression of expression by the lacl protein) appeared healthy, 
while colonies on the agar plates not supplemented with glucose had grown poorly. 
Glucose supplementation made no apparent difference to the growth of vector- 
transformed E. coli. When pPI/Q and pPIZ/Q post-induction cultures were plated out, 
colonies were observed rather than confluent growth, which was observed with post­
induction pQE32 culture. This suggests that expression of the PI and PIZ proteins 
was toxic to E. coli rather than merely inhibiting growth for a temporary period.
These results are consistent with expression of the recombinant protein upon IPTG 
induction, and that expression of the protein was highly toxic to the cells. Indeed, 
even basal levels of transcription of the recombinant genes appears to be inhibitory to 
growth of the cells. Plasmid DNA was prepared from the isolates, and restriction 
digests were performed. No gross rearrangement of the recombinant plasmids could 
be detected (constructs containing genes encoding toxic proteins may give rise to 
deletions). However, for the western analysis which follows, Carbenicillin (a more 
stable analogue of ampicillin) was used in the culture medium and in agar plates to 
ensure maintenance of the recombinant plasmids in the host strain. The isolates were 
maintained on agar plates and grown in overnight cultures containing 2% glucose to 
maximise repression of expression. Finally, the induction period was reduced to only 
1 hour prior to harvesting.
4.2.3 Western blot analysis of E. coli expressing PI transgenes
The purpose of the western analysis using the prokaryotic expression constructs, as 
explained previously, was to assess the mobility of the encoded polypeptides on SDS- 
PAGE gels, and to evaluate the usefulness of the various antisera available. This
section is therefore subdivided into two sub-sections. The first discusses the western
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blots which used as primary antibody the rabbit 3 antiserum raised against the patient 
1 peptide (described in section 4.1.2). The second sub-section presents western blots 
for which the primary antibody was the monoclonal antibody Z1F11, which should 
recognise the epitope tag at the carboxy terminus of the recombinant protein encoded 
by the pPIZ/Q construct.
4.2.3.1 Antiserum rabbit 3
Western blots of both 12% and 15% polyacrylamide gels on which were loaded 
samples of E. coli induced with IPTG were prepared. Figure 4.4 is an example. A 
blot of total bacterial extracts of pPI/Q, pPIZ/Q, and pQE32 was probed with R3P and 
R3I revealing a reactive band of ~40 kDa in cells transformed with the vector pQE32 
(fig. 4.4). The ladder of bands at ~55-66 kDa is apparently specific to pPI/Q and 
pPIZ/Q transformants (lanes 2 and 3). These bands could represent multimers of the 
recombinant protein, aggregates of the recombinant protein with native E. coli 
protein(s), or induction of stress-response proteins that for some reason react with the 
antiserum. The pPI- and pPIZ-encoded proteins each contain 2 cysteine residues (1 in 
the transit peptide, 1 in the patient I 3' region), sufficient for the formation of 
disulphide bonds, potentially enabling the formation of multimers. However, the 
presence of (3-mercaptoethanol in the loading buffer should prevent multimer 
formation. Preincubation of R3I antiserum with the patient 1 peptide did not 
selectively inhibit any of the bands observed by western blotting, suggesting that none 
of the proteins detected are PI or PIZ. Because of the large number of cross-reacting 
bands I obtained with the rabbit 3 antiserum, I also tested whether the secondary 
antibody or the HRP detection system was responsible for any of the bands, but this 
was negative (data not shown).
In conclusion for this sub-section, no polypeptides were identified as specific to the
pPI/Q or pPIZ/Q transformed E. coli, as recognised by the rabbit 3 antiserum on
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Figure 4.4 Western blots of 12% SDS-PAGE gels loaded with E. coli isolates as 
specified below
Lanes 1, 4 and 7 - pQE32, Lanes 2, 5 and 8 - pPI/Q, Lanes 3, 6 and 9 - pPIZ/Q.
The western blot of lanes 1-3 was probed with rabbit 3 immune antiserum (R3I), which had 
been preincubated with the patient 1-specific peptide (1 #g/ml for 2 hours in blocking 
solution at room temperature), the blot of lanes 4-6 was probed with R3I, and the blot of 
lanes 7-9 was probed with R3P. Primary antibody concentration was 1/1000; secondary 
antibody concentration was 1/2000. The size markers on the left of the figure refer to lanes 
1-3, the size markers on the right of the figure refer to lanes 4-9.
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12/15% polyacrylamide gels. Although it is possible that the fusion proteins would 
have run off a 12% SDS-polyacrylamide gel, it is unlikely that the histidine-tagged PI 
or PIZ would not be present on a 15% SDS-polyacrylamide gel. One possible 
interpretation of the data is that the antiserum does not, in fact, recognise the epitope 
against which it was supposedly raised. Another is that the fusion protein encoded by 
these constructs is either too unstable, too insoluble, or too toxic to be detected.
4.2.3.2 Western blot analysis with the monoclonal antibody Z1F11
Fig 4.5 shows a western blot of a 12% polyacrylamide gel, on which was loaded 
unfractionated E. coli, probed with Z1 FI 1, the monoclonal antibody which should 
recognise the epitope tag region of the pPIZ/Q recombinant protein. Z1F11 failed to 
react with any bands of ~55-66 kDa apparent size, further evidence that these are not 
multimers of the recombinant protein. The monoclonal antibody also failed to react 
with any band specific to the pPIZ lane (lane 2) on this 12% polyacrylamide gel. 
However, strong (non-specific) signal in the 14 kDa range may obscure a meaningful 
band. Neither 15% nor 17.5% polyacrylamide gels detected any bands of low 
molecular weight specific to pPIZ (data not shown).
SDS PAGE analysis was carried out on protein fractions prepared as before (Ni-NTA 
resin purified, supernatant thereof, and pellet) from pPIZ/Q isolates grown at 30 °C 
and 37 °C. Both uninduced and induced fractions were analysed by probing western 
blots with Z1F11. No band specific to pPIZ/Q (in comparison to the vector 
transformed E. coli) was detected on 15% polyacrylamide gels (data not shown). As 
a control, I obtained an aliquot of 65Kdbp (the protein against which Z1F11 was 
raised, sect.4.1.2). I confirmed that the aliquot of antibody in my possession 
recognised the denatured protein on a western blot and that my technique was not at 
fault.
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Figure 4.5 Western blot of a 12% SDS-PAGE gel loaded with E. coli isolates as 
specified below
Lane 1 - pQE32, Lane 2 - pPI/Q, Lane 3 - pPIZ/Q. The primary antibody was Z1F11, the 
secondary antibody was HRP-conjugated anti-mouse; both were used at a concentration of
1/ 2 0 0 0 . ‘
• - >-*
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In conclusion for this sub-section, Z1F11 did not react with the polypeptides indicated 
as potential multimers of the recombinant protein by the rabbit 3 antiserum. Nor did 
the monoclonal antibody clearly indicate any recombinant protein on western blots. 
However, if a recombinant protein of apparent molecular weight <14 kDa was 
produced, which remained in the pelleted fraction, it would not have been detected 
above background using this procedure.
4.2.4 In vitro transcription/translation of the PI constructs
As no positive results were obtained from the western analysis of bacterially- 
expressed PI/PIZ proteins using the available antisera, I decided to translate the 
recombinant proteins in vitro so that their apparent sizes on SDS-PAGE could be 
defined. The templates used were pPI/SK+ and pPIZ/SK+, as the pBluescript vectors 
contain phage T3 and T7 promoters, one to either side of the multiple cloning site. I 
used the Promega TNT™ coupled reticulocyte lysate system for in vitro 
transcription/translation with T3 RNA polymerase, according to the manufacturer's 
instructions. 14C-leucine was chosen for labelling the proteins as the patient I- 
analagous polypeptide has twice as many leucine residues as methionine.
Products of the in vitro reactions were separated in a 17.5% polyacrylamide gel (fig. 
4.6). Lane 1 shows the positive control (DNA template encoding Luciferase which 
was provided with the kit) which produced a visible band by autoradiography after 
overnight exposure, whereas the pPIZ/SK+ in vitro reaction, lane 4, produced a barely 
visible band of <14 kDa after 5 days. After 12 days exposure a faint band appeared, 
in all 3 lanes other than the "no template" negative control (lane 2), of about the same 
size as the putative PIZ band. I repeated the in vitro reactions, but still observed a 
faint band in all 3 reactions using template DNA. This band made it uncertain as to 
whether the pPI/SK+ and pPIZ/SK+ constructs were being translated, although the 
PIZ lane does appear to show a doublet.
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Figure 4.6 In vitro translation
In vitro translation was performed using the Promega TNT™ coupled reticulocyte lysate 
system for in vitro transcription/translation with T3 RNA polymerase, according to the 
manufacturer's instructions. The templates used were as follows: Lane 1 - Luciferase 
control template, Lane 2 - no template DNA, Lane 3 - pPI/SK+, Lane 4 - pPIZ/SK+.
1 6 5
In conclusion, the in vitro translation reaction using pPIZ/SK+ as a template gives a 
product of apparent molecular weight of <14 kDa on SDS-PAGE. The fusion PIZ 
may be displaced by the haemoglobin, giving the in vitro synthesised protein a 
smaller apparent size than it would have in extracts from prokaryotic or eukaryotic 
expression systems. Because of the faint non-specific band produced by all 3 in vitro 
reactions containing template, it is unclear whether the pPI/SK+ reaction was 
successful. One must assume that if it were, the PI protein has a similar apparent size, 
running just below the PIZ protein. The poor yield of product for both reactions may 
be due to the hydrophobic nature of the polypeptides. Finally, all of the available 
antisera cross-reacted to other low molecular weight proteins, so that no reaction to 
the PI or PIZ proteins could be confirmed on western blots.
4.3 Discussion
The experiments described in this chapter set out to characterise the proteins encoded 
by the synthetic genes PI and PIZ, and to determine the utility of various available 
antisera to monitor their expression. Three simple conclusions can be drawn: the PI 
and PIZ proteins are poorly translated in vitro, poorly expressed in E. coli where they 
appear to be toxic, and the proteins were not detected above background in these 
conditions by any of several different antisera supposedly reactive against epitopes 
they contain. These findings each have a series of ramifications and possible 
explanations that are now considered in turn.
The in vitro translation of pPIZ/SK+ demonstrated that the chimeric gene can be 
transcribed and that the message can be translated by eukaryotic cytosolic ribosomes, 
albeit at a low level in the rabbit reticulocyte lysate. Further, it showed that the 
apparent size of the PIZ protein is <14 kDa, detectable on a 15% SDS-polyacrylamide 
gel. It is not clear whether the pPI/SK+ construct was transcribed/translated, although 
there is no obvious reason to account for any difference in the expression levels of the
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2 constructs in vitro. The pPI/SK+ mRNA has a slightly different nucleotide 
sequence in the polylinker region (fig. 4.2), but the three codons which differ from 
pPIZ/SK+ are all found elsewhere in the coding sequence of both constructs and 
therefore should not be a hindrance to translation. However, the PI peptide lacks the 
epitope-tag, which is a highly polar region in a hydrophobic peptide and hence may 
aid solubilisation of PIZ or affect mobility on SDS polyacrylamide gels. As the PIZ 
coding region was amplified by PCR from the same plasmid DNA prep of pPI/SK+ as 
was used for the in vitro translation reaction, and the insert in pPIZ/SK+ was 
sequenced, the insert in this DNA prep of pPI/SK+ cannot contain a point mutation 
creating a premature stop codon. If the PI polypeptide were synthesised in the 
coupled transcription/ translation reaction, its predicted molecular weight would be 
-770 Da less than PIZ. This predicted mobility difference may be increased 
somewhat by the highly charged epitope tag. Because an apparently non-specific 
protein of this size was produced in all 3 in vitro reactions with DNA template, it can 
only be concluded that if the PI protein was synthesised and present on 15% gels, it 
comigrates with the non-specific product.
Nevertheless, a product was observed, specific to the pPIZ/SK+ lane (fig. 4.6), of an 
apparent mobility on SDS-PAGE consistent with the predicted size of PIZ. The in 
vitro translation reactions did not yield a large amount of product, suggesting that in 
this system the PI/PIZ proteins are poorly translated, unstable or insoluble. If the in 
vitro translation were to be repeated, I would try using a system which incorporates 
phospholipid vesicles or some other artificial membranes in order to 
stimulate/stabilise the expression of the hydrophobic polypeptides. In order to 
remove non-specific products one could linearise the constructs and remove 
unnecessary vector sequence, or amplify the transgene portion with the vector- 
encoded transcriptional promoter by PCR.
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No protein specific to the pPI/Q isolates was detected above background using the 
prokaryotic expression system, although the rabbit 3 antiserum appeared to recognise 
the KLH-conjugated peptide on a western blot (carried out by K. Morten). It is 
possible that the two amino acids included in the patient 1-analagous peptide which 
are not specified by the mtDNA nucleotide sequence (fig. 4.1) are somehow critical to 
epitope detection by this antiserum on western blots. No protein specific to the 
pPIZ/Q isolates was detected above background using the monoclonal antibody 
Z1F11. As discussed in section 4.1.2, Z1F11 had been shown to be effective on 
western blots at detecting the protein against which it was raised. However, although 
the epitope had been mapped to two sequential overlapping hexapeptides by ELISA, 
the blocking experiment which was performed to confirm the mapping was performed 
using a heptadecapeptide. Therefore, it cannot be ruled out that other residues in the 
environment of the 7 amino acid epitope are influential in western analysis. It is also 
possible that a post-translational modification occurs in the eukaryotic system that is 
required for epitope detection by western blotting.
The time-course growth analysis of the isolates discussed in section 4.2.3 suggests 
that both pPI/Q and pPIZ/Q constructs are being expressed in the bacterial system. 
Possibly the recombinant protein was degraded very rapidly in E. coli, and was not 
present in sufficient quantity to be detected on a western by either antibody. It is 
possible that the protein was insoluble in the conditions used. Due to its extreme 
hydrophobicity, the full-length COXI forms aggregates, even in the presence of SDS 
(Nijtmans et al., 1998). Another possibility is that the protein was being secreted and 
was therefore not in the preparations loaded onto the acrylamide gels. It is possible 
that the mitochondrial targetting peptide could have functioned as a signal sequence 
for protein export.
Mitochondrial targetting signals share some properties with prokaryotic plasma
membrane targetting signals (Roise & Schatz, 1988). In a membrane environment
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they have an alpha-helical structure, although bacterial sequences tend to be less 
positively charged (the mouse COXIV transit peptide has 4 basic residues out of 22). 
Because of N-terminal processing of secreted proteins, Qiagen recommend the use of 
vectors with a carboxy-terminal histidine-tag for purifying extracellular proteins. 
Although the PI constructs had an amino-terminal histidine-tag, it may have been 
worth trying to purify recombinant protein from the medium. However, as 
extracellular targetting is one approach for enabling the expression of toxic proteins in 
E. coli, and expression of both PI constructs is highly toxic to E. coli, it would seem 
unlikely that secretion of the recombinant protein was the primary problem with the 
western analysis.
As the growth analysis indicated, expression of the constructs appears to be highly 
toxic. This may be due to the presence of the transit peptide sequence at the amino 
terminus of the recombinant protein, the hydrophobic nature of the polypeptides, or 
the combination of both features. Association of the 25 amino acid yeast COXIV 
transit peptide with the outer membrane of mitochondria occurs by partitioning of the 
presequence directly into the lipid bilayer (Roise, 1992). The association of a 
synthetic peptide (in this study the 45 amino-terminal residues of the bovine 
cytochrome P-450 precursor) with the mitochondrial outer membrane is independent 
of cytosolic factors and mitochondrial surface protein components sensitive to trypsin 
(Furuya et al., 1991). In a study using 3 peptides based on the amino-terminus of the 
yeast COXIV precursor which were 15, 25, and 33 residues in length, both the 25- 
and 3 3-residue peptides uncoupled respiration in isolated yeast mitochondria (Roise et 
al., 1986). Another study tested amphipathic peptides for effects on the structural and 
functional properties of isolated rat liver mitochondria, also using the yeast COXIV 
transit peptide as the model peptide in the study. Leakage of the matrix enzyme 
adenylate kinase was measured as a function of outer membrane lysis, and this 
showed that the integrity of the membrane was increasingly compromised as the
amount of peptide increased. The peptide also caused uncoupling of respiration, and
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dissipation of the membrane potential across the inner membrane (Nicolay et al., 
1994).
Therefore, it is not unreasonable to assume that overexpression of a protein such as PI 
or PIZ which included an amino terminal transit peptide could have caused similar 
effects on bacterial membrane structure and properties. In prokaryotes, the 
respiratory chain enzymes are situated in the cytoplasmic membrane, the inner of a 
double membrane structure, while the outer membrane is semi-permeable like the 
outer mitochondrial membrane (Stryer, 1988). It is possible that the recombinant 
protein was associating with the cytoplasmic membrane, and effectively perforating 
it. The fragment of COXI included in the chimeric peptides PI and PIZ include the 
entire first transmembrane domain and half of the second transmembrane domain of 
COXI (Tsukihara et al., 1996). As noted, even background levels of expression of the 
full-length, universal-code version of the mouse COXI gene were apparently 
detrimental to E. coli (section 3.2.6). It is possible that PI and PIZ may be toxic due 
to interference with the assembly or activity of a bacterial cytochrome oxidase, but 
not likely. A heme aa3-type cytochrome c oxidase which is equivalent to the 
mitochondrial enzyme is not found in E. coli. The 2 predominant forms of terminal 
oxidase which are found in E. coli are cytochrome o and cytochrome d, both of which 
have ubiquinol-8 as electron donor (Ludwig, 1987). Neither of these oxidases have a 
subunit with significant homology to the first 70 amino acids of the mouse COXI 
subunit. Therefore it is unlikely that the PI and PIZ proteins were toxic due to 
interaction with other subunits of the E. coli terminal oxidases. As the first 70 amino 
acids of COXI are not involved in metal binding sites (Tsukihara et al., 1996), it is 
also unlikely that the proteins were toxic due to sequestration of cofactors. Nor could 
this small fragment of one COX subunit have acted independently as a proton pump.
To clarify exactly what was toxic to E. coli, possible experiments would include the
expression of the COXIV transit peptide alone, and the COXI fragment alone. This
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would allow one to identify whether either of these peptides individually was 
responsible for the drastic penotype observed in E. coli cultures. The universal 
equivalent of rat COXII has been expressed in E. coli (Cao et al, 1991). Although 
only low levels of expression were achieved, the authors do not report that expression 
of the protein was toxic to E. coli. As a different core subunit of a mammalian 
cytochrome c oxidase was not found to be toxic to E. coli, it may be that the inclusion 
of the transit peptide in the prokaryotic constructs was responsible for the phenotype 
observed.
In retrospect, removal of the targetting sequence coding region from the constructs to 
enable testing in bacterial expression systems would have been a good idea. It is 
possible this would have made the recombinant protein less toxic to the cells. 
Additionally, if I were to repeat this analysis, I would try using the prokaryotic 
expression vector which encodes a carrier protein such as DHFR. It is possible that 
this could improve the stability of the recombinant protein as well as reducing its 
toxicity. As DHFR is reportedly poorly immunogenic in mice and rats, the fusion 
protein could also be used to generate new antisera, for further analysis. Another 
possibility would be to express PI in an alternative expression system, such as 
Baculovirus infection of insect cells, or in yeast.
The expression and characterisation of an unknown peptide in the prokaryotic system 
was hindered by the use of antisera which were not well documented. If the project is 
to be pursued, it will be necessary to obtain an effective antiserum with which to 
assess Patient I transgene expression. There are four options available: obtain an anti- 
COXI antibody which recognises an epitope within the truncated COXI region that PI 
contains, again try to raise an anti-peptide antisera, perhaps including residues either 
side of the formerly chosen sequence, pursue expression and purification of PI in 
order to generate an anti-PI antisera, or to obtain a more reliable epitope-tagging 
system.
Chapter 5
Expression studies of Patient I constructs in mouse
cells
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5.1 Introduction
5.1.1 Aims
The aim of this project was to test the hypothesis that abnormal proteins, encoded in 
affected individuals by chimeric mitochondrial genes, contribute to mitochondrial 
dysfunction and pathogenesis. The evidence for the presence of a fusion protein in 
cases of rearranged mtDNA in humans is summarised in section 1.5.7. Model 
systems, including plants and yeast, in which an abnormal protein in mitochondria 
have been shown to cause dysfunction have been discussed. In this chapter I describe 
the generation and analysis of mouse cell-lines transfected with two patient-analagous 
constructs. Mouse mtDNA and mouse cell-lines were used in this work because the 
long-term aim of the overall project was to create a transgenic mouse model for 
diseases such as Kearns-Sayre syndrome, which are associated with gross 
rearrangements of mtDNA.
The specific aim of this PhD project was to generate mouse cell-lines expressing 
chimeric mitochondrial peptides and to assess the phenotype of the cell-lines 
produced. In chapter 3 I have described the work which was necessary to produce the 
synthetic genes PI and PIZ (’’Patient I", encoding a patient-analagous chimeric 
mitochondrial peptide, and the Z1F11 epitope-tagged version, respectively). These 
genes are capable of cytosolic translation (as they have been mutated to read in the 
universal code) and the expressed proteins are capable of mitochondrial import (as 
they contain a mitochondrial transit peptide). In chapter 4 I have described the 
expression of these constructs in a prokaryotic system, and the in vitro translation of 
the genes. Both PI and PIZ would appear to be highly toxic in E. coli, and poorly 
expressed in the in vitro system used. Additionally, I was unable to detect expression 
of the recombinant proteins above background using the antisera available.
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The work described in this chapter begins with the generation of mouse cell-lines 
carrying the Patient I constructs under the control of an inducible promoter. Northern 
blotting is then described, aimed at establishing whether these cell-lines were 
expressing the transgene. Furthermore, using the antisera described in section 4.1.2, 
western blotting was performed to assay whether the transcripts were being correctly 
translated. Finally, a preliminary analysis of the cellular phenotype generated by 
expression of the abnormal protein PIZ was performed.
5.1.2 The expression vector pMamm#
The expression vector chosen for the analysis was pMam^eo (supplied by Clontech). 
This is a mammalian expression vector which can be used for controlled expression in 
hormonally responsive cell-lines. A gene inserted at the polycloning site is placed 
under the transcriptional regulation of the dexamethasone-inducible MMTV-LTR 
promoter, linked to the RSV-LTR enhancer element. The manufacturer reports that 
this construction enables a 10-fold increase in expression via induction with 
dexamethasone. RNA processing of the transcript is facilitated by the SV40 early 
splicing region and polyadenylation site. The neomycin-resistance marker allows 
selection of transformants growing in media supplemented with the antibiotic G418. 
The plasmid also contains the ampicillin resistance marker and replication origin for 
propagation in E. coli (fig. 5.1).
5.1.3 Cell-lines
The cell-line used initially in this work was the mouse LTK- cell line, derived from 
connective tissue with fibroblast-like morphology. By treatment with ethidium 
bromide (50 ng/ml) I generated a derivative of the line which, on the basis of 
Southern blotting, PCR and a requirement for uridine supplementation in the medium, 
appeared to be p°. My intention was to compare the phenotype of LTK- Patient I
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Figure 5.1 The eukaryotic expression vector pMam/no
This figure depicts the vector used for the expression of both the PI and PIZ constructs in the 
mouse fibroblast cell-line 3T3. All restriction enzyme sites used for cloning and generating 
restriction fragments for templates of random-primed probes are displayed. Vector-encoded 
sequences pertinent to the work described are labelled. The E. coli origin and ampicillin- 
resistance marker are required for propagation of the vector in E. coli. The Multiple Cloning 
Site (MCS) is a region containing several restriction enzyme sites which are unique in the 
vector, enabling subcloning of the gene to be expressed. The MCS is located downstream of 
the Rous Sarcoma Virus enhancer element, and the Mouse Mammary Tumour Virus LTR 
which contain regions requisite for transcription under the control of the inducing agent 
dexamethasone. The SV40 early splicing region and polyadenylation sequence is necessary for 
appropriate processing of the transcript. Note that the neomycin-resistance marker also 
contains these elements.
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clones with LTK-p° Patient I clones in order to assess whether the chimeric protein 
caused mitochondrial dysfunction in a context other than interference with aerobic 
respiration. However, this line of inquiry was not pursued for two reasons. Although 
the LTK-p° cell line demonstrated the same degree of sensitivity to G418 as the 
parental line (800 pg/ml to ensure no resistant colonies), several attempts to transfect 
the cell line with the pMam/PI construct failed. Control transfections indicated that 
the reagent used in the lab at that time was defective. I was also unable to ascertain 
whether the LTK- cell line had appropriate receptors for dexamethasone. However, 
the manufacturers of pMamweo (Clontech) reported that the vector had been 
successfully used with another mouse fibroblast cell line, 3T3, which is commonly 
used in research. By using this line any failure to detect a transcribed product would 
not be attributable to lack of responsiveness to the inducing agent. Therefore, the 
experiments discussed subsequently in this chapter are all with the 3T3-derived 
clones. There was insufficient time to generate a p° derivative of the 3T3 cell line.
5.1.4 The ratio of nuclear to mitochondrial DNA
As discussed in section 1.5.4, many studies have now been carried out to assess the 
relative levels of wild-type and mutant mtDNA molecules in affected patient tissues. 
Techniques used include quantitative amplification of mtDNA from single muscle 
fibres and in situ hybridisation of muscle sections. All studies have shown a large 
increase in the copy number of deleted mtDNA molecules in RRFs, associated with 
mitochondrial proliferation. The studies are contradictory as to whether there is a 
depletion of normal mtDNA in COX- fibers, and in RRF. Thus, another question 
which I addressed was whether the presence of the abnormal polypeptide PIZ would 
have a discernible effect on mtDNA copy number.
As no deleted mtDNA was present in this study, the proportion of mtDNA was
quantitated simply with respect to nuclear DNA. I chose to analyse the effect that
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growth in the two extremes of respiratory stress would have on the relative proportion 
of mtDNA to nuclear DNA; minimal stress, where the media contains glucose and the 
transgene is not expressed, compared to induction of transgene expression in a 
medium which requires cellular respiration for survival. DNA was prepared from 
cell-lines after 4 days growth in the respective media, the same time point at which 
cells were assessed for respiratory competence.
5.1.5 Assay of respiratory chain function
Cells can generate energy in the form of ATP by at least two basic mechanisms, either 
by using the glycolytic pathway or using the respiratory chain. In glycolysis, glucose 
is converted into pyruvate and in the process generates net ATP. The entry of 
galactose into the glycolytic pathway requires 4 additional enzymatic steps to convert 
it to glucose 1-phosphate. Under aerobic conditions pyruvate normally enters the 
citric acid cycle; however, when the amount of oxygen is limiting (such as in actively 
contracting muscle) pyruvate is converted into lactate (Stryer, 1988). In cultured 
fibroblasts, >97% of the glucose utilised has been shown to be converted to lactic 
acid, thus the pyruvate generated does not enter the citric acid cycle (Donnelly & 
Scheffler, 1976). For cells in culture, the main source of aerobic energy is glutamine, 
which feeds into the citric acid cycle later in the cycle (Reitzer et al, 1979). The latter 
study demonstrated that cultured HeLa cells growing in media containing >1 mM 
glucose derive 35% of their energy from the glycolytic pathway, and 65% from 
oxidative phosphorylation. However, if the media provided other hexose sugars (such 
as galactose) for glycolysis, >98% of cellular energy was obtained from the aerobic 
respiratory pathway utilising glutamine as the metabolic source. The hexose sugars 
were primarily found to be metabolised for biosynthetic precursors rather than for the 
generation of ATP. Chu et al (1972,1974) successfully used galactose medium to 
select for respiration-deficient mutants from a Chinese hamster somatic cell-line.
Galactose medium has since been used to assay for a respiratory deficient phenotype
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in cells heterozygous for deleted mtDNA (Hayashi et al, 1991). This study found that 
a clear threshold existed whereby cells grown in glucose medium reached an 
equilibrium state of 75-85% deleted mtDNA, above which they grew poorly. 
However, when clones were grown in galactose medium, the threshold for growth 
decreased to 50% deleted mtDNA, and galactose medium was lethal to cells with 
>72% deleted mtDNA (as well as to p° cells).
On the basis of the above, I have investigated respiratory function in cells transfected 
with the PIZ construct, by growing them in galactose-containing ("gal") medium.
The PIZ clones were also grown in a medium referred to as "superglu", which 
contains all supplements necessary for supporting the growth of p° cells. "Superglu" 
was chosen as the control condition for the experiment because the underlying 
hypothesis was that the presence of the chimeric protein might be detrimental to 
respiration even at very low levels (given the difficulty of detecting a chimeric protein 
in vivo), and it is possible that some transcription of the transgene would occur even 
in the absence of the inducing agent dexamethasone. The cells were thus incubated in 
four media; "superglu" +/- dexamethasone, and "gal" +/- dexamethasone. The 
presence or absence of dexamethasone was to test the effect of enhanced transgene 
expression in the respective media.
5.1.6 Assays of mitochondrial proliferation
Although the distribution of the wild-type and mutant mtDNA in diseased muscle 
fibres is controversial, with reference to the total copy number of molecules per 
muscle fibre, the data suggests that muscle fibres of affected individuals which are 
displaying some respiratory deficiency do not yet have an increase in mitochondrial 
genome copy number, and possess only a small proportion of mutant mtDNA 
molecules. The identification of such fibres supports the hypothesis that
mitochondrial proliferation in RRFs is an ineffective response to biochemical
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deficiencies as opposed to a causal event. Based on this idea, I assayed for 
mitochondrial proliferation in cells expressing PIZ by confocal microscopy. The cells 
were again grown in two conditions (superglu vs. gal + dexamethasone), stained with 
a mitochondrial-specific dye, fixed, then double-labeled with the monoclonal 
antibody Z1F11 (previously described in section 4.1.2). Two forms of the 
mitochondrial-specific dye were used, one which detects all mitochondria present in 
the cell, and the reduced form of the dye, which must be oxidised by functional 
mitochondria in order to fluoresce. Comparison of the two staining patterns enabled a 
preliminary assessment of mitochondrial activity in the cells.
5.2 Results
5.2.1 Subcloning of Patient I constructs into pMam/ieo
The PI and PIZ constructs were subcloned into the pMamweo vector (fig. 5.2). The 
subcloning was performed in E. coli strain XL 1-Blue. Plasmid pPI/SK+ (the Patient I 
construct in pBluescript SK+, described in section 3.2.4, depicted in fig. 3.13) was 
digested with Sail, and the 370 bp Patient I insert sequence was gel-purified. The 
fragment was subcloned into pMamneo, which had been digested with Sail and 
dephosphorylated with calf intestinal alkaline phosphatase. Transformants were 
screened by restriction digest with Sail, and one clone (designated pM/PI) was chosen 
for sequencing. This showed that pM/PI contained the correct insert sequence in the 
appropriate orientation for protein expression.
Plasmid pPIZ/SK+ (the epitope-tagged Patient I construct in pBluescript SK+,
described in section 3.2.5, depicted in fig. 3.15) was digested withXbal andX h o l,
and the insert fragment gel-purified. The isolated 390 bp fragment had an intact Xhol
site overhang at the 3' end of the fragment, and an intact Xbal site (compatible with
Nhel) at the 5' end of the gene fragment. pMamneo was digested with Nhel and Xhol,
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Figure 5.2 Subcloning of the Patient I gene and the epitope-tagged version into pMam/ieo
This figure depicts the orientation of the two genes when subcloned into the pMairweo MCS.
a) depicts the Patient I insert (subcloned from plasmid pPI/SK+).
b) depicts the Z1F11 epitope tagged Patient I insert (subcloned from plasmid pPIZ/SK+).
The key explains the derivation of the various segments of the final constructs.
E 3
PI 3' (cyt b  sequence) czz=zzszzz3 COXIV derived transit peptide
Z 1F 11 epitope tag , Patient I COXI fragment
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and the fragment was ligated into the vector multiple cloning site. Transformants 
were screened by restriction digest with Lspl (one site is present in the insert 
sequence, one in the vector). Two clones displayed the appropriate restriction pattern, 
and were selected for sequencing to confirm that they contained the correct insert 
sequence (designated pM/PIZ8 and pM/PIZIO).
5.2.2 Generation and selection of cell clones
Mouse 3T3 cells were transfected with plasmid DNA by liposome mediation, using 
DOTAP (Boehringer Mannheim) according to the manufacturer's protocol (described 
in sect. 2.6.4). Six vector-transformed clones, and twelve each of the pM/PI- and 
pM/PIZ-transfected clones were plated in 24-well tissue culture dishes. Six colonies 
each from pM/PI, pM/PIZ8 and pM/PIZIO transfections were chosen for screening by 
PCR, to ascertain that the transgene had integrated in a non-disrupted manner (fig. 
5.3). Genomic DNA was prepared from these 18 cell lines, plus 2 colonies 
transfected with vector only. For pM/PI transfected lines the 5' PCR primer used was 
TP1, the oligonucleotide encoding the amino terminus of the COXIV transit peptide, 
sense strand. In this case the 3' PCR primer used was PI4, the oligonucleotide 
encoding the carboxy terminus of the Patient I chimeric gene (cytochrome ^-derived), 
antisense strand. This pair of primers should amplify a product of 375 bp. For 
pM/PIZ transfected cell lines, the 5' PCR primer used was 5'TP/Xba, the 
oligonucleotide which encodes the amino terminus of the COXIV transit peptide on 
the sense strand, but contains an Xbal site for cloning, rather than the Sail site. In the 
latter case, the 3' PCR primer used was PIZ1, the oligonucleotide encoding the 
junction between the cytochrome b (cyt b) region and the Z1F11 epitope tag, on the 
antisense strand. This pair of primers should amplify a product of 377 bp.
Figure 5.4 shows the ethidium bromide-stained gel containing the PCR products from
the PI cell lines. As expected, these PCR reactions produced no product for the
181
a) Patient I insert
TPl Lspl
San
San
PI4
Patient I insert
b) Epitope-tagged Patient I insert
pMAM/
5*MCS 5'TP/Xba
Xbal
Lspl
1=
Xhol
PI3VZ1F-1
Patient I/Z1F11 insert
pMAM/ 
3'splice
100 bp
Figure 5.3 The generation of PCR products to ascertain integration of the transgenes
This figure depicts where the primers used in the PCR reactions described in the text (and 
shown in fig. 5.4 and 5.5) anneal to the target templates. The sequences for the 
oligonucleotides are given in section 2.4. The oligonucleotides used as primers are designated 
as follows:
TP 1 5' section of the sense strand of the COXIV transit peptide
PI4 3' section of the antisense strand of the cyt ^-derived region
5'TP/Xba as TPl, but 27 nt long, with an Xbal site substituted for the Sail site 
PIZ1 junction between the cyt b region and the Z1 FI 1 tag, antisense strand
pMam/5'MCS anneals -40 nt upstream of the vector MCS, sense strand 
pMam/3'splice anneals -170 nt downstream of the vector MCS, antisense strand
fT T T T T
PI 3' (Cyt b sequence) 
Z IF 11 epitope tag 
yMXMneo DNA
3 COIV derived Transit peptide 
i Patient I CO I  fragment
5' oligonucleotide used for PCR 
*—  3' oligonucleotide used for PCR
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Figure 5.4 PCR of 3T3 clones to demonstrate incorporation of the PI construct
PCR was performed on genomic DNA prepared from G418-resistant clones, as well as positive 
and negative controls. The 5' PCR primer used was oligonucleotide TP1; the 3' PCR pnmer 
used was oligonucleotide PI4 (see text and fig. 5.3 for description, or sections 2.4.5 and 2.4.6 
for sequences). The products were run on a 1.65% TAE agarose gel. Lane 1 - no DNA 
template, Lane 2 - Sal I-digested plasmid pM/PI, Lane 3 - marker, Lane 4 - PI.l, Lane 5 - 3T3 
PI.2, Lane 6 - 3T3 PI.3, Lane 7 - 3T3 PI.4, Lane 8 - 3T3 PI.6.
18 3
pMamtteo-transfected control cell-lines. Four of the six pM/PI-transfected cell lines 
contained, based on this assay, an insert of the correct size to be the full-length coding 
sequence of the PI transgene. These four clones were designated PI.l, PI.2, PI.3, and 
PI.6 respectively. Figure 5.5 shows the ethidium bromide-stained gel containing the 
PCR products from the PIZ cell-lines obtained in two separate transfections with 
clones pM/PIZ8 and pM/PIZlO. Of the pM/PIZ8-transfected cell lines, five of six 
contained an insert the correct size to be the full length coding sequence of the 
respective transgene. These clones were designated PIZ8.1, PIZ8.2, PIZ8.3, PIZ8.5, 
and PIZ8.6. Of the pM/PIZlO-transfected cell lines, all five contained an insert the 
correct size to be the full-length coding sequence of the respective transgene. These 
clones were designated PIZ10.1, PIZ10.2, PIZ10.3, PIZ10.4, and PIZ10.5. 
Subsequently, genomic DNA from the set of 3T3-derived clones shown to have been 
successfully transfected with PIZ8 were used as templates in PCR reactions primed 
by vector-specific oligonucleotides situated 5' of the multiple cloning site, and 3' of 
the SV40 splice acceptor site (see fig. 5.3). The predicted size of the correctly 
amplified insert is ~600 bp. Again, for those cell-lines shown in fig. 5.5.a to contain 
the transgene, these reactions produced DNA fragments of an appropriate size to 
contain the intact transgene situated within the vector-encoded sequences necessary 
for gene expression. The vector-transformed cell-line (designated 3T3pM) also 
produced a band of appropriate size (no insert, 227 bp), and no band was observed for 
PIZ8.4 (previously negative) (fig. 5.5.b).
In repeated PCR reactions using both sets of primers clone PIZ8.5 yielded very little 
product compared to the other cell lines. The observed product is unlikely to have 
been the result of PCR contamination, because no band was observed in the negative 
control (no template) lanes by gel analysis, nor was a band of the predicted size for 
the transgene observed in the 3T3pM samples. Nor is the faint product likely to have 
been the result of contaminated template, as genomic DNA was prepared from PIZ8.5
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Figure 5.5 PCR of 3T3 clones to demonstrate incorporation of the PIZ construct
Figure 5.5.a PCR was performed on genomic DNA prepared from G418-resistant clones, 
as well as positive and negative controls. The 5' PCR primer used was oligonucleotide 
5'TP/Xba; the 3' PCR primer used was oligonucleotide PI3VZIF-1 (see text and fig. 5.3 for 
description, or section 2.4.7 for sequences). The products were run on a 1.5% TAE agarose 
gel. Lane 1 - plasmid pM/PIZ8, Lane 2 - LTK- cells, Lane 3 - 3T3pM, Lane 4 - PIZ8.3, Lane 
5 - PIZ10.2, Lane 6 - P1Z8.4, Lane 7 - PIZ8.6, Lane 8 - PIZ10.1, Lane 9 - PIZ10.4, Lane 10 - 
PIZ10.5, Lane 11 -PIZ8.1,Lane 12-PIZ8.2, Lane 13-PIZ8.5, Lane 14-PIZ10.3.
Figure 5.5.b PCR of 3T3 clones to demonstrate incorporation of the PIZ construct 
with pMamfieo-encoded expression signals intact
PCR was performed on genomic DNA prepared from 3T3-derived G418-resistant clones, as 
well as positive and negative conrols. The 5' PCR primer used was oligonucleotide 
pMam/5'MCS; the 3' PCR primer used was oligonucleotide pMam/3'splice (see figure 5.3 for 
description or section 2.4.8 for sequences). The products were run on a 1.4% TAE agarose 
gel. Lane 1 - 3T3pM, Lane 2 - PIZ8.1, Lane 3 - PIZ8.3, Lane 4 - PIZ8.4, Lane 5 - P1Z8.5, 
Lane 6 - PIZ8.6, Lane 7 - plasmid pM/PIZ8.
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on multiple occasions. It is possible that the transgene was less stable in this clone, or 
that the "clone" is a mixed population.
5.2.3 Slot blot analysis of mtDNA copy number
As discussed in section 5.1.4, one question which interested me was whether 
expression of PIZ would have any discernible effect on mtDNA copy number. To 
address this question I prepared a slot blot of total DNA from three transfected cell 
lines, incubated in two different media, and probed it with three different random- 
primed probes. Figure 5.6 depicts this slot blot. The cell lines from which DNA was 
prepared were 3T3pM, PIZ8.3 and PIZ8.5. The cells from which DNA was to be 
prepared were plated out and incubated in the two media considered to be the two 
extremes of low and high respiratory stress conditions, either "superglu" or galactose 
+ dexamethasone, for four days. 5 pg of DNA from each aliquot were loaded in 
triplicate onto the membrane to enable hybridisation with the three different probes. 
The three probes were chosen to detect either mtDNA, a single copy mouse nuclear 
gene, or the transgene. The random-primed probes were prepared using cytochrome c 
oxidase II as the template DNA for the mitochondrial probe, the template DNA for 
the nuclear gene was Etl-1 (kindly donated by Dr. P.Shields) and the transgene 
template DNA was the Sstl/Xhol 800bp fragment from pM/PIZ. The transgene probe 
included the PlZ-coding region and ~400 bp of the MMTV LTR region of the 
plasmid, which encompasses the transcriptional start site of the transgene. Thus, the 
transgene probe should hybridise to the 3T3pM DNA preparation as well, as it 
contains approximately 400 bp of vector sequence.
Although the experiment gave no clear indication with regard to changes in 
mitochondrial DNA copy number in the two different media conditions, it did 
produce relevant data with regard to the transgene. The probe derived from the single
copy nuclear gene should act as an internal loading control. In lane B it would appear
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Figure 5.6 Slot blot analysis of total DNA extracted from selected 3T3 clones
DNA was prepared from 3 cell-lines (3T3pM, PIZ8.3 and PIZ8.5) each grown in two 
different media conditions ("superglu" or "gal" + dexamethasone). 5 #g of these 6 DNA 
preparations were then blotted onto the membrane in triplicate. The membrane was 
hybridised with random-primed probes prepared from 3 different templates - Etl-1, a single­
copy mouse nuclear gene, COXII, a mitochondrial gene, or the SstVXhol fragment from 
pM/PIZ. Hybridisation was performed overnight at 65 °C. Wash conditions were at high 
stringency as specified in section 2.11.2.
Probes: Lane A- COXII
Lane B - Etl-1
Lane C - pM/PIZ
Samples: Rows 1 3T3pM grown in "superglu"
Rows 2 3T3pM grown in galactose + dexamethasone
Rows 3 PIZ8.3 grown in "superglu"
Rows 4 PIZ8.3 grown in galactose + dexamethasone
Rows 5 PIZ8.5 grown in "superglu"
Rows 6 PIZ8.5 grown in galactose + dexamethasone
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that the 5 Jig sample for 3T3pM grown in "superglu" is overloaded with respect to the 
other five samples. One would expect that the relatively strong hybridisation of the 
transgene probe to this DNA preparation (lane C, row 1) is due to overloading as well. 
In rows 1, 2, 5, and 6, the intensity of the bands in lanes B and C are roughly 
equivalent. However, in rows 3 and 4, the bands in lane C are much more intense 
than in lane B. This suggests that clone PIZ8.3 has incorporated multiple copies of 
the transgene. Although the intensity of the signal in lane B is roughly equivalent 
between rows 3 and 4 (the PIZ8.3 grown in "superglu" versus "gal" + 
dexamethasone), the intensity of the signal is much less in row 4, lane C than in row 
3, lane C. This suggests that under conditions of respiratory stress (growth in 
galactose + dexamethasone), this particular cell-line may be losing copies of the 
transgene. This is consistent with the hypothesis that expression of PIZ is detrimental 
to cellular respiration.
5.2.4 Western analysis
The western analysis of the 3 T3-derived clones was performed in parallel with the 
work described in chapter 4. As discussed in chapter 4, the western analysis on E. 
coli transformants proved inconclusive. If the antisera tested recognised the PI or PIZ 
proteins, the reaction was obscured by the cross reactions with other proteins. For the 
western analysis of the mouse cell-lines the same antisera as described in Chapter 4 
were used. These were the anti-Patient I-specific-peptide rabbit polyclonal antisera, 
and the mouse monoclonal antibody Z1F11 which should recognise the carboxy- 
terminal epitope tag of PIZ.
Initially, western analysis was performed on the PI transgenic clones. The rabbit 3 
immune antiserum (R3I) was used to probe blots of total protein from 3T3 clones 
shown to have integrated an intact PI gene by PCR (data not shown). The encoded PI
protein is calculated to be 13.0 kDa in molecular weight, but no bands were detected
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less than 21 kDa in size, and no bands specific to the PI clones as compared to 
3T3pM were apparent. The rabbit 1 and 2 preimmune and immune antisera were also 
tested, but no band specific to the 3T3 PI clones could be detected (data not shown).
Although the polyclonal antiserum was unsuccessful in detecting the PI protein, 
analysis of the PIZ clones with the monoclonal antisera revealed evidence that 
supports transgene expression at the protein level. The calculated size of PIZ, 
including the amino terminal transit-peptide, is 13.75 kDa; if the mitochondrial 
transit-peptide is cleaved correctly the calculated size of the imported polypeptide is
11.4 kDa. Fig. 5.7 shows a western blot of a 17.5% polyacrylamide gel, loaded with 
crude cell extracts from 3T3pM (lane 1) and PIZ clonal cell lines (lanes 2-5 and 7- 
10), which was probed with Z1F11. Migrating at an apparent molecular weight of 
-14 kDa in lanes 2, 4, and 8 (clones 3T3/PIZ8.1, PIZ8.3, and PIZ10.3) there is a 
doublet. Lane 10 (clone 3T3/PIZ10.5) also appears to show a band migrating at this 
apparent molecular weight This doublet/band is not apparent in lane 1, even on long 
exposure. Comparisons of the intensity of cross-reacting higher molecular weight 
proteins suggest that lane 1 is underloaded compared to the other lanes. However, 
lane 5 would appear to have been loaded with at least an equivalent amount of protein 
as lane 2 (note the 31 kDa cross-reacting band), yet no band in the size range of -14 
kDa is evident in lane 5. This is consistent with clone PIZ8.1 expressing the PIZ 
protein, whilst clone PIZ8.6 is either not expressing the protein, or is expressing it at a 
very low level. This correlates with the northern data (fig. 5.8.d) which indicates that 
clone PIZ8.6 is not expressing the transcript for the transgene. It is possible that the 
doublet observed represents the proteolytically processed and unprocessed forms of 
PIZ. This would suggest that the protein is not only being expressed, but that it is 
being imported into mitochondria and that the transit-peptide is being cleaved 
appropriately.
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Figure 5.7 Western blot of selected PIZ clones probed with the Z1F11 monoclonal 
antibody
A 17.5% SDS polyacrylamide gel was loaded with denatured samples of selected 3T3 
clones, run at 150 V, and blotted overnight. The blot was incubated with the Z1 FI 1 
monoclonal antibody, followed by the HRP-conjugated anti-mouse secondary antibody, both 
at a concentration of 1/2000. The Amersham ECL detection system was used. Lane 1 - 
3T3pM, Lane 2 - PIZ8.1, Lane 3 - PLZ8.2, Lane 4 - PIZ8.3, Lane 5 - P1Z8.6, Lane 6 - marker, 
Lane 7 - PIZ 10.1, Lane 8 - PIZ 10.3, Lane 9 - PIZ 10.4, Lane 10 - PIZ 10.5. The arrow 
indicates the putative PIZ protein doublet.
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In order to eliminate some of the background from non-specific cross-reacting bands,
I attempted immunoprecipitation of PIZ (see section 2.14 for details), although Z1F11 
was reportedly inefficient for this purpose (Dr.A. Cross, personal communication). 
Both the monoclonal Z1F11 and the rabbit polyclonal R3I were used to 
immunoprecipitate protein from clones 3T3pM, PIZ8.3 or PIZ8.5 (the first as a 
negative control, and PIZ8.3 because it appeared from the previous western blot to be 
expressing detectable levels of PIZ). Blots of gels containing these samples were 
probed with both antibodies (data not shown). R3I detected no bands smaller than 31 
kDa, and none specific to the PIZ clones. No definitive bands were detected in the 
western probed with Z 1F11.
5.2.5 Effects of transgene expression on mitochondrial density and respiration
As discussed in section 5.1.6,1 wished to assess the effect transgene expression might 
have on mitochondrial proliferation using immunofluorescence labeling with the 
Z1F11 antibody. I had also hoped to show mitochondrial import of the processed 
form of PIZ. However, as is apparent from the data presented in section 5.2.4, the 
monoclonal antibody cross-reacts with many other proteins synthesised in the 3T3 
cell-lines. The background levels of fluorescence from these non-specific reactions in 
the control cell line was of such a degree that, although the cell-line PIZ8.3 appeared 
to fluoresce more brightly, no conclusions could be drawn from these images.
However, the use of mitochondrial-specific dyes did enable a preliminary assessment 
of mitochondrial respiratory activity. Figure 5.8 shows images of cells scanned using 
a confocal microscope. The cell-lines shown are 3T3pM and PIZ8.3, cultured in 
galactose medium, with dexamethasone. Two forms of the mitochondrial-specific 
dye (MitoTracker, obtained from Molecular Probes, Inc.) were utilised; the CMX- 
rosamine form, which detects all mitochondria present in the cell, and CXXRos-H2,
the reduced form of the dye, which must be oxidised by functional mitochondria in
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Figure 5.8 Labeling of 3T3 and PIZ8.3 cells w ith m itochondrial-specific dyes
Cells were cultured in galactose medium with dexamethasone. Panels a and b show 3T3 
cells, panels c and d show PIZ8.3 cells. Panels a and c were labeled with CMX-rosamine, 
the oxidised form of the mitochondrial-specific dye, which detects all mitochondria present 
in the cell. Panels b and d were labeled with CXXRos-H2, the reduced form of the 
mitochondrial-specific dye, which detects only functionally respiring mitochondria.
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order to fluoresce. A comparison of fig. 5.8.a (3T3pM cells stained with the oxidised 
form of the dye) and fig. 5.8.b (3T3pM cells stained with the reduced form of the dye) 
suggests that there is little difference in the degree of fluorescence emitted from the 
cells. This indicates that in the control cell-line the mitochondria are fully functional. 
The degree of fluorescence in fig. 5.8.C (PIZ8.3 cells stained with CMX-rosamine) 
indicates that mitochondria are present at a level at least equivalent to that of the 
control cell line. However, a comparison of fig. 5.8.C and fig. 5.8.d (PIZ8.3 cells 
stained with CXXRos-H2) indicates that there is a substantial difference in the degree 
of fluorescence emitted from the cells using the two forms of the dye. This indicates 
that respiration in the PIZ8.3 cell-line is not functioning at the same capacity as in the 
control cell-line. Due to the different intensities of signal emanating from different 
cells in panel 5.8.d, it would appear that not all cells are equally affected by PIZ 
expression. Data presented in section 5.2.3 suggested that PIZ8.3 cells cultured in 
galactose + dexamethasone (a condition designed to induce respiratory stress) may be 
losing copies of the transgene. It is possible that this occurs in some cells, but not all; 
the lower level of transgenic protein produced in the cells which decrease the copy 
number of the transgene may enable these cells to maintain a higher level of 
respiratory activity, thus explaining the differing degrees of fluorescence observed.
5.2.6 Galactose assay for respiratory competence
As described in section 5.1.4, galactose can be used as the sugar source in tissue- 
culture media to assay for the respiratory competence of mammalian cells. The four 
media conditions used in these assays were "superglu" without dexamethasone, 
"superglu" with dexamethasone, galactose without dexamethasone, and galactose 
with dexamethasone. These four conditions were intended to test the effect of 
transgene expression in low and high respiratory stress conditions. 1 x 105 cells were 
plated in 25 cm2 flasks, for each of the four media conditions to be tested. The cells 
were harvested and counted after 4 days of growth. The data presented in Table 5.1
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displays the number of assays performed for each cell line, and the average number of 
cells harvested in each condition. Appendix 1 lists the raw data for each cell line.
3T3 3T3/pM PIZ8.1 PIZ8.2 PIZ8.3 PIZ8.5 PIZ8.6
n 2 5 3 2 3 3 1
s/g 4.15+/-0.16 3.23+/-0.45 5.00+/-0.31 5.41+/-0.05 2.75+/-0.17 2.48+/-0.10 3.94
s/g+dex 4.35+/-0.16 3.16+/-0.54 4.64+/-0.38 4.91+/-0.51 2.32+/-0.29 2.28+/-0.10 3.76
gal 1.86+/-0.07 1.61+/-0.59 1.98+/-0.18 2.38+/-0.01 1.27+/-0.31 1.26+/-0.10 1.99
gal+dex 2.06+/-0.07 1.62+/-0.36 1.45+/-0.30 1.97+/-0.16 0.88+/-0.22 1.03+/-0.12 1.60
Table 5.1 Growth assays performed on 3T3-derived cell lines
n denotes the number of assays performed on the respective cell line. The following 
four rows denote the mean number of cells x 106 harvested when grown in the media 
condition specified for four days, +/- standard deviation of the sample. As clone 
PIZ8.6 was only tested on one occasion, there is no s.d. for these samples.
Glucocorticoids are reported to inhibit the proliferation of fibroblasts (Ramalingam et 
al., 1997, Stewart et al., 1995); however, this was not observed in the samples taken 
from either the 3T3 or 3T3pM control cell lines. Although the rate of growth of the 
vector-transfected control cell line 3T3pM is not altered by the presence of 
dexamethasone, it is noted that the growth rate in three of the medium conditions 
tested is slower than that of three PIZ clones tested (PIZ8.1, PIZ8.2 and PIZ8.6). It is 
possible that the observed difference in growth rate in the minimal stress medium 
("superglu" without dexamethasone) is due to some positional effect of the transgenic 
insertion in this clone. For this reason, comparison of cell numbers harvested 
between clones is less informative than comparing the relative rates of growth in 
differing media conditions for individual clones. Thus, a f-test statistical analysis of 
the data presented in table 5.1 was performed, in which the effect of dexamethasone 
(which induces transgene expression in PlZ-transfected clones) on the rate of cell 
growth was assessed.
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A /-test is the standard statistical method for analysing data from two independent 
samples with respect to one variable. The assumptions made in choosing a /-test are 
that the samples have been drawn from normal populations with equal variance and 
with measurements on an interval scale. The /-test is applicable when the sample size 
is small, because / takes the number of observations in the sample into account. The 
test is executed with respect to the null hypothesis, i.e., the variable tested has no 
effect on the populations tested. In this case, the null hypothesis is that induction of 
transgene expression will have no effect on the rate of growth of the cells in culture. 
The value for / obtained by the test is a deviation from the mean expressed in units of 
standard deviation. By taking the degrees of freedom into account (which is 
determined by the two sample sizes) one can determine the statistical probability of 
whether the two samples could have been obtained from the same population. In 
general, if the probability (p) obtained is less than or equal to 5%, then the null 
hypothesis can be rejected in favour of the experimental hypothesis that the variable 
tested does indeed have a statistically significant effect. A further consideration is 
whether to apply a one-tailed or two-tailed criterion to the value of / obtained for the 
samples compared. A one-tailed test can be used where the experimental hypothesis 
is directional. In this case the prediction is directional, because the expectation is that 
expression of the PIZ protein will have a detrimental effect on respiratory function, 
thereby decreasing the rate of cell growth.
As can be seen from table 5.2, untransfected 3T3 cells and the vector-transformed cell 
line, 3T3pM, displayed no significant alteration in growth rate, as measured by the t- 
test, upon the addition of dexamethasone to the culture medium, whether the medium 
contained glucose or galactose as the carbon source. For clones PIZ8.1 and PIZ8.2 
(two of the PIZ transfected clones which grew rapidly in "superglu" medium as 
compared to the control cell lines) there is no significant reduction in growth rate
when transgene expression is induced in this low respiratory stress condition (glucose
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Media n X s t df P
3T3 s/g 2 4.15 0.16
s/g+dex 2 4.35 0.16 0.50 2 N/S
gal 2 1.86 0.07
gal+dex 2 2.06 0.07 2.00 2 N/S
3T3/pM s/g 5 3.23 0.45
s/g+dex 5 3.16 0.54 0.18 8 N/S
gal 5 1.61 0.59
gal+dex 5 1.62 0.36 0.03 8 N/S
PIZ8.1 s/g 3 5.00 0.31
s/g+dex 3 4.64 0.38 1.04 4 N/S
gal 3 1.98 0.18
gal+dex 3 1.45 0.30 2.16 4 p<0.02
PIZ 8.2 s/g 2 5.41 0.05
s/g+dex 2 4.91 0.51 0.97 2 N/S
gal 2 2.38 0.01
gal+dex 2 1.97 0.16 2.67 2 p<0.05
PIZ8.3 s/g 3 2.75 0.17
s/g+dex 3 2.32 0.29 1.80 4 p<0.05
gal 3 1.27 0.31
gal+dex 3 0.88 0.22 1.44 4 p<0.05
PIZ8.5 s/g 3 2.48 0.10
s/g+dex 3 2.28 0.10 1.97 4 p<0.02
gal 3 1.26 0.10
gal+dex 3 1.03 0.12 2.03 4 p<0.02
Table 5.2 t-test analysis of the effect of transgene expression on cell growth
This t-test tests the null hypothesis that transgene expression has no effect on cell 
growth. Cell lines are as described previously. Media conditions are: s/g 
("superglu”), s/g+dex ("superglu" with dexamethasone), gal (galactose), gal+dex 
(galactose with dexamethasone). n denotes the number of assays performed on the 
respective cell line, x denotes the mean number of cells x 106 harvested when grown 
in those media conditions for four days, s indicates standard deviation. The value for 
t has been calculated to compare the growth of a cell line in the respective media 
with or without dexamethasone. "df ’ indicates the degrees of freedom for the 
respective calculation. The probability (p) is given for the premise that the 2 
respective samples have arisen from the same population, using values for a 1-tailed 
test. N/S indicates not significant.
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medium). The value for / obtained for these two cell lines in galactose medium 
indicates that transgene expression does significantly decrease the rate of growth in 
high respiratory stress conditions. This would suggest that the PIZ protein is 
detrimental to respiration. However, the standard deviations for the samples which 
were compared for clone PIZ8.2 appear to be disparate, so a variance ratio test is 
performed below to assess the validity of applying a /-test to this data. For clones 
PIZ8.3 and PIZ8.5 there is a statistically significant difference in the samples obtained 
for the two conditions tested (with or without dexamethasone) in both media. Thus 
the expression of PIZ appears to be detrimental to cell growth in these two cell lines 
whether the cells are in a low or high respiratory stress environment. A possible 
explanation of why two clones are affected by transgene expression in a low 
respiratory stress environment, whilst the other two are not, is the level of expression 
of the transgene. Whether because of a positional effect of the transgene insertion 
site, or due to copy number if multiple integrations of the transgene have occurred, it 
is likely that the clones PIZ8.3 and PIZ8.5 are expressing the gene product at a higher 
level than clones PIZ8.1 and PIZ8.2.
The variance ratio test is used in conjunction with the /-test. It is used to compare the 
standard deviations of samples which contain fewer than 30 observations, in order to 
assess whether the samples are so different in variance that the t-test cannot be used 
reliably with the sampled data. As with the t-test a probability (p) of less than or 
equal to 5% is considered significant. There was no need to test the samples for the 
3T3 cell line because the standard deviations for the respective samples were equal. 
The variance ratio test results indicate that all samples compared, apart from clone 
PIZ8.2 in galactose medium, are similar enough in dispersion for the /-test results to 
be accepted within the standard limits of probability, i.e., the two samples compared 
have a 95% probability of having been sampled from populations of equal or very 
similar variance. The F-test of clone PIZ8.2 in galactose medium indicates there is a
5% probability that the two samples are from populations heterogeneous in
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Media Variance F-value df p=0.05
3T3/pM s/g 0.2007
s/g+dex 0.2927 1.5 4x4 N/S
gal 0.3422
gal+dex 0.1318 2.6 4x4 N/S
PIZ8.1 s/g 0.0973
s/g+dex 0.1467 1.5 2x2 N/S
gal 0.0313
gal+dex 0.0876 2.8 2x2 N/S
PIZ8.2 s/g 0.0020
s/g+dex 0,2601 130.1 lx l N/S
gal 0.0001
gal+dex 0.0241 240.5 lx l significant
PIZ8.3 s/g 0.0285
s/g+dex 0.0853 3.0 2x2 N/S
gal 0.0955
gal+dex 0.0488 2.0 2x2 N/S
PIZ8.5 s/g 0.0098
s/g+dex 0.0097 1.0 2x2 N/S
gal 0.0104
gal+dex 0.0153 1.5 2x2 N/S
Table 5.3 Variance ratio test for the data presented in table 5.2
The variance ratio test (or F-test) tests the assumption of homogeneity of variance of 
the 2 sets of data compared in the t-test. The comparison is made between samples 
for a cell line in the respective media, with or without dexamethasone, the hormone 
which induces transgene expression in transfected cell lines. Cell lines are as 
described previously. Media conditions are: s/g ("superglu"), s/g+dex ("superglu" 
with dexamethasone), gal (galactose), gal+dex (galactose with dexamethasone). The 
F-value has been calculated to compare the variances (s2) obtained for the respective 
samples, "df' indicates the degrees of freedom for the respective calculation. The 
variance ratio is considered with respect to a probability (p) that there is a less than or 
equal to 5% chance that the 2 respective samples were drawn from populations 
heterogeneous in variance. (N/S indicates not significant, i.e., the populations 
considered are 95% probable to be homogeneous for variance).
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dispersion. However, the value calculated for / when comparing these two samples is 
more than one unit of standard deviation above the tabulated value for / which gives 
p=0.05. Thus, the results of the /-test for PIZ8.2 should be considered with caution, 
rather than rejected outright; additional data should be collected for this clone.
All cell lines containing an intact transgene have displayed a reduction in growth rate 
in galactose medium in the presence of dexamethasone, whether an encoded 
transcript/protein has been detected or not. This suggests that the presence of the 
chimeric gene product (whether RNA or protein), even at levels below the detection 
threshold of the techniques used, may be detrimental to cell growth when growth is 
dependent upon mitochondrial respiratory pathways.
As discussed in section 5.1.4, it is estimated that HeLa cells obtain about 65% of their 
energy in normal media conditions from oxidative phosphorylation, and only 35% 
from glycolysis. Therefore, even in highly supplemented media it is likely that cells 
derive a proportion of their energy from aerobic respiration. Likewise, it is probable 
that 3T3 cells will also derive a proportion of their energy from aerobic respiration 
even in "superglu" medium, and it is therefore possible that were expression of PIZ 
significantly impairing respiration an effect on cell growth rate would be observed in 
the supplemented medium. Thus, it seems probable from the /-test that the expression 
of the transgene in clones PIZ8.3 and PIZ8.5 is having a detrimental effect on 
respiration even in the glucose medium. The rates of growth in galactose compared to 
"superglu" medium may reflect the relative contribution of aerobic respiration to cell 
viability
In order to perform a /-test analysis comparing growth of the cell-lines in galactose
medium with growth in "superglu" medium, it was not possible to do a direct
comparison, as the growth rate of the cells is so disparate in the two different media
that even the control cell lines display a statistically significant slowing of the growth
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rate when galactose is substituted for glucose in the medium. Given that each time a 
cell growth assay was performed on a clone the initial step was to set up four identical 
flasks (prior to changing the medium to one of the four test media), it is appropriate to 
consider flasks in pairs. This enables the calculation of a value for growth rate which 
represents the proportion of cells growing under conditions subject to one test 
variable, the carbon source (galactose versus "superglu"). Thus, for each assay 
performed with each clone, the number of cells which had grown in galactose 
medium (without dexamethasone) was divided by the number of cells which had 
grown in "superglu" medium (without dexamethasone) to attain a ratio of cell growth 
for the two test conditions. These calculations were also performed to find the ratio 
for growth in the presence of dexamethasone. The ratio values could then be utilised 
to perform a /-test comparing a clone's relative rate of growth (either in the presence 
or absence of dexamethasone) to that of the control cell line. If the relative rate of 
growth of the PIZ clones differs significantly from that of the 3T3pM control cell line 
in the presence of dexamethasone, but not in the absence of dexamethasone, this 
would imply that PIZ expression inhibits growth to a greater degree in the high 
respiratory stress medium than in the low respiratory stress medium. This would 
suggest that PIZ expression is directly affecting respiration in the patient analagous 
cell lines.
Table 5.4 displays the results of the /-test analysis performed on the data as described 
above. For all four PIZ clones there is no statistically significant difference in the 
relative rate of growth of the clones when grown in the absence of dexamethasone 
when compared to 3T3pM. For three of the clones (PIZ8.1, PIZ8.2, and PIZ8.3) there 
is a significant difference in the ratio of growth in the presence of dexamethasone. 
This supports the hypothesis that PIZ expression inhibits growth to a greater degree in 
the high respiratory stress medium than in the low respiratory stress medium. The 
statistic for clone PIZ8.2 also indicates that expression of the chimeric peptide at a
level below the detection threshold of the western analysis (fig. 5.11 .a) is detrimental
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Dex n X s t df P
3T3/pM without 5 0.492 0.134
PIZ8.1 without 3 0.400 0.059 0.977 6 N/S
3T3/pM with 5 0.520 0.105
PIZ8.1 with 3 0.310 0.046 2.852 6 p<0.002
3T3/pM without 5 0.492 0.134
PIZ8.2 without 2 0.440 0.010 0.459 5 N/S
3T3/pM with 5 0.520 0.105
PIZ8.2 with 2 0.400 0.010 1.368 5 p<0.05
3T3/pM without 5 0.492 0.134
PIZ8.3 without 3 0.457 0.098 0.342 6 N/S
3T3/pM with 5 0.520 0.105
PIZ8.3 with 3 0.373 0.055 1.951 6 p<0.01
3T3/pM without 5 0.492 0.134
PIZ8.5 without 3 0.510 0.022 0.201 6 N/S
3T3/pM with 5 0.520 0.105
PIZ8.5 with 3 0.453 0.042 0.918 6 N/S
Table 5.4 Mest comparing the proportional growth rates of the PIZ clones in 
two media to the control cell line 3T3pM, either with or without 
dexamethasone
The statistical measure of t is described previously. In this test the analysis considers 
whether incubation in galactose medium inhibits growth of the PIZ clones to a greater extent 
when expression of the transgene is induced than when it is not. A direct comparison of the 
cell counts in galactose medium to "superglu" medium is not possible, as even the control 
cell line grows significantly slower in galactose medium. Therefore, for each sample taken 
in each cell line the cell count in galactose medium was divided by the cell count in 
"superglu" medium to arrive at a proportional rate of growth. This was also done comparing 
the cell count in galactose medium with dexamethasone to the cell count in "superglu" with 
dexamethasone in the medium. The t-test above compares this proportional rate of growth 
of an individual PIZ clone to the control cell line 3T3pM in order to assess whether there is a 
significant difference in how dexamethasone affects the rate of growth. Cell lines are as 
described previously. The growth conditions are either with or without dexamethasone 
(Dex). n denotes the number of assays performed on the respective cell line, x denotes the 
mean of the proportional counts for the various cell lines in the respective media, s indicates 
standard deviation. The value for t has been calculated to compare the proportional rate of 
growth of a PIZ clone to that of the control cell line 3T3pM in media either containing 
dexamethasone (the hormone which induces transgene expression) or without, "df' 
indicates the degrees of freedom for the respective calculation. The probability (p) is given 
for the premise that the 2 respective samples have arisen from the same population, using 
values for a 1-tailed test. A 1-tailed test is valid because the prediction for the effect of 
dexamethasone on cell growth was directional, i.e., that the induction of transgene 
expression would be detrimental to cell growth. A probability of less than or equal to 5% is 
considered significant, indicating that the null hypothesis can be rejected. (N/S indicates not 
significant).
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to mitochondrial respiration. Although the /-test analysis of the data for the fourth 
clone, PIZ8.5, indicates that the results are not statistically significant, PIZ8.5 does 
display an apparent decrease in the ratio [rate of growth in galactose + dexamethasone 
over "superglu" + dexamethasone] when compared to the ratio [rate of growth in 
galactose - dexamethasone over "superglu" - dexamethasone]. Thus, this clone 
follows the trend set by the other three PIZ clones.
The variance ratio test is described previously (see Table 5.3). In order to assure the 
validity of the data presented in Table 5.4, an F-test was performed. The results are 
displayed in Table 5.5. The variance ratio test results indicate that all samples 
compared, apart from the proportional rate of growth for clone PIZ8.5 grown in the 
absence of dexamethasone, are similar enough in dispersion for the /-test results to be 
accepted within the standard limits of probability, i.e., the two samples compared 
have a 95% probability of having been sampled from populations of equal or very 
similar variance. The F-test of clone PIZ8.5 grown without dexamethasone in the 
medium compared to the control cell line 3T3pM indicates there is a 5% probability 
that the two samples are from populations heterogeneous in dispersion. Thus, the /- 
test data for those samples is not reliable. However, the /-test data for clones PIZ8.1, 
PIZ8.2, and PIZ8.3 is reliable within the limits of the statistical analysis.
In the studies performed by Chu et al., (1972,1974) mutants incapable of growth by 
respiration were selected, using the galactose medium. The phenotype observed here 
is much less severe, as the transgenic clones can continue to grow and divide, but is 
nevertheless suggestive of a deficiency in aerobic respiration, associated with the 
expression of the transgene. I would suggest that the data presented in this section 
support the conclusion that there is a detrimental effect caused by PIZ expression, and 
that it is mediated by inhibiting aerobic respiration.
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Dex Variance F-value df p=0.05
3T3/pM without 0.0179
PIZ8.1 without 0.0035 4.29 4x2 N/S
3T3/pM with 0.0110
PIZ8.1 with 0.0021 4.41 4x2 N/S
3T3/pM without 0.0179
PIZ8.2 without 0.0001 111.60 4x1 N/S
3T3/pM with 0.0110
PIZ8.2 with 0.0001 68.50 4x1 N/S
3T3/pM without 0.0179
PIZ8.3 without 0.0095 1.57 4x2 N/S
3T3/pM with 0.0110
PIZ8.3 with 0.0030 3.01 4x2 N/S
3T3/pM without 0.0179
PIZ8.5 without 0.0005 31.88 4x2 significant
3T3/pM with 0.0110
PIZ8.5 with 0.0017 5.30 4x2 N/S
Table 5.5 Variance ratio test for the data presented in table 5.4
The purpose of the variance ratio test is described previously. The comparison is 
made between the specified PIZ cell line and the 3T3pM control line. Cell lines are 
as described previously. Data is for the proportional rates of growth in galactose 
medium/"superglu" medium, either with or without dexamethasone as specified. The 
F-value has been calculated to compare the variances (s2) obtained for the respective 
samples, "df' indicates the degrees of freedom for the respective calculation. The 
variance ratio is considered with respect to a probability (p) that there is a less than or 
equal to 5% chance that the 2 respective samples were drawn from populations 
heterogeneous in variance. (N/S indicates not significant, i.e., the populations 
considered are 95% probable to be homogeneous for variance).
205
5.3 Discussion
The work described in this chapter presents the evidence that the Patient I constructs, 
nuclear versions of a chimeric mitochondrial gene, were successfully expressed in 
mammalian cells. It goes on to analyse the effect that the expression of these 
chimeric mitochondrial proteins had on cell phenotype.
Using PCR it was demonstrated that selected G418-resistant clones had incorporated 
the PI construct DNA. Northern analysis of these clones was inconclusive. The 
putative PI transcript was obscured by the endogenous COXI transcript due to 
upregulation of mitochondrial transcription caused by the transgene induction agent 
dexamethasone, and the choice of a COXI fragment as template for the synthesis of 
the probe. Western analysis of these clones using rabbit polyclonal antisera raised 
against a peptide specific to the Patient I polypeptide yielded no positive data. As the 
rabbit antisera had also been unsuccessful in detecting the PI polypeptide in a 
bacterial expression system, (see chapter 4), the remainder of the project focussed on 
the PIZ clones.
Using PCR it was demonstrated that selected G418-resistant clones had incorporated 
the PIZ constructs with appropriate vector-encoded expression signals intact. 
Northern analysis of the cell lines suggests that the transgene was being expressed in 
clones PIZ8.2, PIZ8.3 and possibly PIZ8.5. It would also appear that the use of the 
glucocorticoid dexamethasone as the induction agent for expression of the transgene 
has increased the rate of mitochondrial transcription in the cells, leading to an 
increased level of endogenous mitochondrial transcripts and partially processed 
transcripts which cross-hybridise to the probes used to detect the transgene transcript. 
To confirm the identity of the putative transgene transcript, and to clarify whether the 
other PlZ-transfected cell-lines are expressing the transgene, the northern analysis
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would need to be repeated using an oligonucleotide probe which was transgene- 
specific.
Analysis of total DNA prepared from cell lines 3T3pM, PIZ8.3 and PIZ8.5 suggest 
that the clone PIZ8.3 harbours multiple copies of the transgene PIZ. A multiple 
integration event is supported by the observation that clone PIZ8.3 exhibited a band 
of greater intensity than the other three PIZ clones for the putative neomycin 
phosphotransferase transcript when the northern blot was hybridised to a probe 
containing the SV40 early splicing region which detected the 3' untranslated RNA of 
this transcript. The analysis by slot blot also indicates that under growth conditions 
which increase the requirement for respiration (galactose as the sugar source), clone 
PIZ8.3 is apparently deleting some copies of the transgene. This would support the 
conclusion that expression of the transgene is detrimental to respiration and cell 
survival or growth. Although no apparent change in the ratio of mitochondrial to 
nuclear DNA was observed when the expression of PIZ was induced, several 
possibilities are still consistent with the expression of a chimeric peptide, encoded by 
mutant mtDNA, being pathogenic. It is possible that additional factors, perhaps 
tissue-specific, are required to signal to the nucleus that mtDNA replication is an 
appropriate response to respirational deficiency, or, that the threshold of respiratory 
insufficiency has not been reached which will stimulate the proliferation response. 
Perhaps the proliferation of mutant mtDNA molecules escalates in proportion to the 
initial depletion of wildtype mtDNA molecules (the hypothetical replicative 
advantage of the smaller genome) and, as only one form of the mitochondrial genome 
is present in this study, no change will occur in copy number. It is also probable that 
insufficient time was allowed to observe a significant change. If this experiment were 
to be repeated, one would include all PIZ clones used in the statistical analysis. One 
would also use all 4 media conditions, rather than the 2 extremes only. Finally, it 
would be best to have access to a phosphoimager, or similar device, for analysis of the 
results.
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Western analysis of the PIZ clones using the monoclonal antibody Z1F11, which 
recognises the carboxy terminal epitope tag of the PIZ protein, detects what appears 
to be a doublet of less than 14 kDa in clones PIZ8.1, PIZ8.3 and PIZ10.3 (fig. 5.11). 
The appearance of two bands in the approximate size range for PIZ suggests that not 
only is the protein being expressed, but that the amino-terminal peptide is being 
cleaved - indicating that PIZ is being imported into the mitochondria. The doublet is 
not apparent in the control cell line 3T3pM, but it is not apparent in some of the other 
PIZ clones either (e.g., PIZ8.2, which does express the putative transgene mRNA). It 
is formally possible that the proteins represented by the two bands are below the 
detection threshhold in all cell-lines tested other than PIZ8.1 and PIZ8.3, including 
3T3pM. In order to test whether 3T3pM was expressing proteins in this size range, 
and to try to isolate PIZ from cross-reacting proteins, immunoprecipitation utilising 
the Z1F11 monoclonal antibody was performed on clones 3T3pM, PIZ8.3 and PIZ8.5 
(fig. 5.12). Although the signal to noise ratio of the blot is far from optimal, it 
appears that there is a diffuse band of less than 14 kDa in size, specific to the lanes 
containing PIZ8.3 and PIZ8.5 cellular proteins. This supports the conclusion that the 
doublet apparent in fig. 5.11 is specific to the PIZ clones.
To confirm the identity of the putative PIZ protein bands, the western analysis would 
need to be repeated, using additional techniques to attempt to reduce background 
signal. Such techniques could include a gel-system which yields better resolution of 
low molecular weight proteins, alternative detergents, or altering the pH at which 
incubation with the antiserum was performed. Alternatively, it would be necessary to 
obtain a better antibody, as discussed in section 4.3. Although the western blots 
presented do not independently confirm the expression of PIZ, the data discussed 
below supports the interpretation that the transgene protein is being expressed in the 
PIZ clones.
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Fluorescence microscopy of transfected 3T3 cells stained with mitochondrial-specific 
dyes (section 5.2.5) supports the conclusion that PIZ was being expressed in cell-line 
PIZ8.3, and that expression of the protein inhibits respiratory activity. The apparent 
variance in respiration between individual PIZ8.3 cells could be due to loss of copies 
of the transgene. Although these results are preliminary, they are intriguing, and 
warrant further investigation. An additional control could be added by using a p° 
derivative of the cell line (if it were available) to ensure that cells known not to be 
functionally respiring exhibited no staining with the reduced form of the dye.
In order to test whether the chimeric peptide conveyed a respiratory phenotype on the 
3T3 cell line, assays of growth in galactose medium were performed. The cell lines 
were grown in four different media conditions, which should create high or low stress 
environments for the cells depending on the carbon source and the presence or 
absence of the inducing agent for expression of the transgene. Two /-tests were 
performed on the data obtained; the first /-test utilised cell numbers from individual 
clones grown in either glucose or galactose medium and compare them for the 
presence/absence of dexamethasone as the independent variable. The presence of 
dexamethasone in the medium had no significant effect on cell numbers for the 
control cell line 3T3pM in either galactose or glucose medium. Clones PIZ8.1 and 
PIZ8.2 showed no significant effect of dexamethasone induction of transgene 
expression in glucose medium, but in galactose medium (which requires a greater 
proprtion of cellular energy to be derived from respiration) the induction of PIZ 
expression did reduce the growth rate significantly. However, a variance ratio test 
indicated that the results for clone PIZ8.2 are questionable. Clones PIZ8.3 and PIZ8.5 
demonstrated a significant reduction in growth rate in both glucose and galactose 
media in the presence of dexamethasone. Thus, expression of the transgene does 
appear to inhibit growth, but it could not be attributed specifically to inhibition of 
respiratory activity.
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The second /-test was intended to analyse for inhibition of respiratory activity 
directly. None of the four clones tested differed significantly in the proportional rate 
of growth (galactose/"superglu") from the control cell line when dexamethasone was 
absent from the growth media. However, when expression of PIZ was induced, the 
proportional rate of growth for clones PIZ8.1, PIZ8.2 and PIZ8.3 was significantly 
reduced in comparison to 3T3pM. Because the numerator in this function (growth in 
galactose medium) relies to a greater degree on respiratory activity than the 
denominator (growth in glucose medium), this suggests that PIZ is specifically 
inhibiting growth via the inhibition of respiration.
However, a possible difficulty with the analysis of the PIZ clones has become 
apparent in the course of the work. In the introduction to this chapter I stated that the 
advantage of the approach chosen for analysis of PIZ was that by expressing the 
protein transgenically in a controlled fashion any observed phenotype could be 
attributed to a single variable. It is now apparent that the agent which enabled the 
controlled expression of the transgene has a direct effect on mitochondrial 
transcription. Experiments have shown that dexamethasone treatment of a rat 
hepatoma cell line led to a 3- to 4-fold increase in mitochondrial RNA levels 
(including COXI mRNA specifically), without changing the levels of mitochondrial 
DNA in the cells. An increase in the levels of incompletely processed precursors was 
also detected. These observations were attributed to increased levels of transcription 
(Van Itallie, 1990 and 1992). Steroid hormones may act directly on mitochondrial 
gene transcription via steroid receptors which bind to hormone response elements. 
The sequences of hormone response elements from human and mouse mitochondrial 
genomes confered dexamethasone-inducibility on hybrid reporter consructs 
(Demonacos et al., 1996). Gel retardation assays have shown that glucocorticoid 
response elements from cytochrome c oxidase I and III genes, and from within the D- 
loop region, all bind purified glucocorticoid receptor, as well as protein from
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mitochondrial extracts which is apparently the glucocorticoid receptor (Demonacos et 
al., 1995).
Thus, it is possible that the increased rate of mitochondrial transcription induced by 
the presence of dexamethasone is placing additional demands on the resources of the 
mitochondria, and on the expression mechanism. If, for instance, the presence of an 
abnormal polypeptide such as PIZ interferes with mitochondrial activity by interfering 
with a component of the translation mechanism (e.g., binding available chaperonins) 
then the effects of the two factors - dexamethasone and PIZ - cannot be disentangled. 
However, as discussed in the previous two paragraphs, because the PIZ clones 
demonstrate a statistically significant reduction in growth in galactose 
+dexamethasone/"superglu" + dexamethasone when compared to the 3T3pM control 
cell line, and the level of staining with CXXRos-H2 differs dramatically between the 
two cell lines, it suggests that the presence of the abnormal polypeptide is inhibiting 
growth via the inhibition of respiration directly, whatever the precise mechanism.
Another possible objection to the interpretation of the data is the presence of the 
carboxy terminal epitope tag. The statistical analysis of the cell growth assays 
indicates that PIZ expression is detrimental to respiration. Although epitope-tagging 
is a commonly used technique, PIZ is an amended version of the Patient I protein. To 
be certain that the Z1F11 epitope tag is not contributing to the phenotype of 
respiratory deficiency, the cell growth assays should preferably be repeated utilising 
Pi-transfected clones which have been shown to express the transgene by northern 
analysis.
A third potential objection involves the transit peptide. The mitochondrial targeting 
peptide from Neurospora crassa COXIV increases permeability of the inner 
membrane from isolated rat liver mitochondria (Sokolove and Kinnally, 1996). The
authors suggest that this is attributable to the creation of a pore in the inner
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membrane. It is possible that overexpression of a targeted protein to mitochondria 
would produce a similar effect. However, as a precaution because of the possible 
detrimental effects of overexpression of amphipathic molecules, in the induction of 
transgene expression, the lowest concentration of the inducing agent recommended by 
the suppliers of the expression vector was used for the galactose assays. Additionally, 
in the cellular environment, cytosolic chaperones would be available to escort the 
transgenic protein to the mitochondral import apparatus, making random insertion 
into the mitochondrial membranes less likely. Because a doublet was detected by 
western analysis, at least some of the transgenic protein appears to have been 
processed, and therefore this proportion of the transit peptide has entered the matrix. 
In order to control for a detrimental effect of (overexpression of) the transit peptide, 
one could simply use the COXIV protein as a passenger, presuming it to be 
"nontoxic". Although the targeting peptide from another nuclear-encoded 
mitochondrial protein could be used to target PIZ (as it is essential to target nuclear- 
encoded proteins), there is no reason to presume that another transit peptide would 
have an effect which differed from the COXIV transit peptide.
In summary, data have been presented that are consistent with expression of a 
mitochondrial fusion gene in several clonal cell lines transfected with construct PIZ. 
Preliminary fluorescence data suggested that mitochondrial membrane potential was 
decreased in the one PIZ clone examined, compared to a control. The statistical 
analysis of the cell growth assays using alternative carbon sources as respiratory 
substrates implied that PIZ expression inhibited respiratory function. This negative 
growth phenotype represents good, albeit indirect, evidence that the inserted 
mitochondrial transgene was transcribed, translated, and targeted to mitochondria.
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Chapter 6 
Concluding remarks
213
6.1 The approach adopted for this work
Based on the arguments presented in section 1.5.6, it was proposed that a novel 
protein encoded by a chimeric mitochondrial gene created by a rearrangement event 
in mitochondrial DNA could contribute to respiratory deficiency in affected patient 
tissues. The aim of this project was to create a model system in cultured mouse 
fibroblast cells which could be used to investigate the effect such a chimeric 
mitochondrial polypeptide might have on respiration. The strategy adopted required 
the relocation of a chimeric mitochondrial gene to the nucleus. In this way any 
observed phenotype could be attributed specifically to the presence of the protein, as 
opposed to the rearranged mtDNA or chimeric transcripts, in the mitochondria.
In my analysis of the phenotype attributable to the novel protein, the constructs were 
placed under the transcriptional control of an inducible promoter. This is an 
advantage over alternative approaches such as the culturing of patient-derived cell 
lines, or the creation of cybrids harbouring patient-derived mitochondria, in which the 
mitochondrial protein will be constitutively expressed. In some cases researchers 
have reported difficulty in generating stable cell lines harbouring mtDNA with partial 
duplications, using the two techniques described (Poulton et al., 1993, Holt et aL,
1997). The ability to inhibit expression whilst a cell-line is being established enables 
one to clearly establish whether expression of the chimeric protein is associated with 
any observed phenotype. Transfection into a standard cultured cell-line reduces the 
possibility of an unknown mitochondrial defect confusing the interpretation of the 
phenotype, nor is there the risk of incompatibility between the nuclear and 
mitochondrial genomes. Lastly, there is no restriction on the recipient cell lines 
which can be used for further analysis, unlike the other two approaches which are 
restricted to patient-derived cell lines which can be cultured from primary tissue, or to 
those p° cell lines that are available as recipients for cybrid formation.
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6.2 A summary of the work presented
I have described in chapter 3 the mutagenesis and subcloning procedures required to 
convert the mouse COXI gene into a nuclear version; 43 point mutations for the full- 
length gene, synthesis and subcloning of a transit-peptide encoding region. Also 
described are the synthesis and subcloning of construct-specific coding regions for PI 
and PIZ which encode a peptide, in untagged and epitope-tagged forms respectively, 
which is analagous to a putative patient fusion peptide encoded by rearranged mtDNA 
in a specific patient.
In chapter 4 I have described the analysis of the PI and PIZ constructs in a prokaryotic 
expression vector using the antisera available. The time-course growth analysis 
suggested that both pPI/Q and pPIZ/Q constructs were being expressed in the 
bacterial system, and that expression of both PI and PIZ was highly toxic to E. coli. 
This may have been due to interference with assembly/activity of the bacterial 
cytochrome c oxidase, and/or detrimental effects of the amphipathic transit peptide on 
membrane integrity. Neither PI nor PIZ, when expressed in E. coli, was detected by 
any of the available antisera above background levels. Possibly the recombinant 
protein was degraded very rapidly in E. coli, and was not present in sufficient quantity 
to be detected on a western by either antibody. It is also possible that the proteins 
were insoluble in the conditions used. In vitro translation suggested that PIZ was 
synthesised at low levels by eukaryotic cytosolic ribosomes, whilst evidence for the 
translation of PI was inconclusive. All of the available antisera cross-reacted to other 
low molecular weight proteins, so that no reaction to the PI or PIZ proteins could be 
confirmed on western blots.
In chapter 5 I have presented data showing that the PIZ construct was successfully 
transfected into 3T3 cells, generating multiple, clonal cell-lines. Northern and
western analysis suggested that the PIZ constructs were expressed in most of these
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clones. Staining of cells with mitochondrial-specific dyes indicated that respiration in 
the PIZ8.3 cell-line was not functioning at the same capacity as in the control cell- 
line. The assays of growth in galactose medium indicated that expression of the PIZ 
protein generates a phenotype indicative of respiration deficiency. The analysis of all 
the available data indicates that PIZ has been successfully expressed in several clones, 
and that expression of this protein produces a moderate respiratory deficiency.
6.3 Retrospective comments
My analysis of the cell-lines generated was frustratingly hindered by the lack of a 
specific antibody. The rabbit polyclonal antisera had been raised against a peptide 
derived from a novel region of the patient 1 chimeric mitochondrial gene. The level 
of cross-reactivity of the antisera was a problem, as was the apparent inability to 
detect the fusion protein. My anticipation of this possibility, by constructing an 
epitope-tagged version, did enable detection of the fusion protein in 3T3 cells. 
However, the high level of cross-reactivity was, once again, frustrating. In order to 
pursue any further research with these cell lines, and to validate the conclusions 
drawn from this work, a suitable antibody would be essential. A Pi-specific antibody 
would be preferred, but the expression of the constructs in a prokaryotic expression 
vector was apparently highly toxic to the cells. As stated in section 4.3, possible 
approaches would be the removal of the transit peptide, and/or using a carrier protein 
such as DHFR. However, another possibility would be to express PI in an alternative 
expression system, such as Baculovirus infection of insect cells. This option might be 
more costly, but it could prove faster to optimise, given that expression in eukaryotic 
cells produced a much more subtle phenotype than in prokaryotic cells. A COXI 
antibody which recognises an epitope in the amino-terminal region would be 
sufficient for the PI- and PlZ-transfected cell-lines. If the PII construct is generated in 
the future, an anti-COXI antibody may not be sufficient for the analysis of these cell
lines as the PII protein may have an apparent molecular weight similar to the native
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COXI by SDS-PAGE. Alternatively, the PI construct could be tagged with a new 
epitope, and new cell lines generated for analysis. However, the level of cross­
reactivity I experienced would not be acceptable. If I were to repeat this work, I 
would choose a commercially available antibody, with several publications to support 
the efficacy of the epitope-tag, preferably in a mitochondrial/hydrophobic membrane 
protein.
If another model chimeric mitochondrial gene was chosen, it may be simpler to 
synthesise it de novo from overlapping oligonucleotides, rather than subclone and 
mutagenise the mitochondrial version, although all eight mutations required to 
express the PI portion of COXI in the nucleus were achieved in one successful round 
of mutagenesis. The original rationale for using site-directed mutagenesis was 3-fold; 
firstly, the full-length COXI would be useful as a control, secondly, it could answer 
the academic point of whether COXI is capable of being synthesised in the cytosol 
and imported into mitochondria, and, thirdly, the PII model gene was also desired. If 
I were to begin the project anew, I would choose direct synthesis of the chimeric 
gene, although this approach also has its potential problems. Unpredicted alignments 
of oligonucleotides were observed in the construction of the transit peptide- and 
cytochrome 6-encoding regions.
If more time had been available, it would have been desirable to repeat the 
microscopy experiments to assay respiratory activity using the Mitotracker dyes with 
other clones. Preliminary data suggested that expression of PIZ was detrimental to 
respiratory function, i.e., in the presence of dexamethasone, clone 3T3 PIZ8.3 
exhibited staining comparable to the control cell line with the general mitochondrial 
dye, but a less intense staining with the mitochondrial dye which required respiratory 
activity to activate fluorescence. If a better antibody were available, it would be 
desirable to test for colocalisation of the chimeric protein with mitochondria by
immunofluorescence labeling of the PIZ (or PI) clones. However, because of the high
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level of cross-reactivity of the Z1F11 monoclonal antibody with other proteins 
expressed by the 3T3 cells in the presence of dexamethasone, it was impossible to 
ascertain the cellular location of PIZ by confocal microscopy.
6.4 What mechanism is responsible for the observed respiratory phenotype?
In order to test whether the respiratory deficiency observed is attributable to PIZ 
expression specifically, to chimeric mitochondrial proteins in general, or the result of 
the presence of an exogenous protein (any non-mitochondrial protein) inside 
mitochondria, further analysis is necessary. As mentioned in section 5.3, the 
galactose assays could be repeated using the Pi-transfected cell lines to ascertain that 
the Z1F11 epitope tag is not contributing to the phenotype. The PII constructs, which 
can now be completed because the full-length nuclear COXI gene has been 
engineered, are potentially available to test whether another chimeric mitochondrial 
gene would produce the same phenotype. Alternatively, another model chimeric gene 
could be chosen which does not involve COXI in order to test that the mechanism of 
pathogenesis is not specifically due to an attribute of cytochrome c oxidase I. For 
example, one could repeat these experiments using an ND subunit fusion peptide. It 
would be interesting to observe whether such a cell line would develop a biochemical 
defect limited to complex I, as can happen in vivo (Morgan-Hughes et al., 1990; 
Hammans et al., 1992a). This would address the question of whether the fusion 
protein acts by a specific mechanism, disrupting the assembly/activity of the 
respiratory complex in which the non-mutated gene product would have inserted (one 
interpretation of the results in the papers previously referenced), or by a more general 
mechanism, such as insertion into the inner membrane or sequestration of 
mitochondrial chaperones. The mechanism responsible for the respiratory deficiency 
observed in the PIZ cell lines could also be addressed by targeting random peptides 
(initially of a hydrophobicity similar to mitochondrially-encoded proteins) into
mitochondria. If random proteins were found to cause mitochondrial dysfunction, it
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would support the hypothesis that fusion proteins are detrimental, but that they act by 
some mechanism which is probably not specific to the respiratory complexes 
themselves. It is also possible that the mechanism of pathogenesis is not universal for 
all chimeric proteins.
Another experiment which should be performed is to transfect cell lines with the PI 
and PII constructs which have had the transit-peptide encoding region deleted. The 
constructs were designed such that there is a restriction enzyme site between the 
transit-peptide coding region and the coding region for COXI, with the intention that 
this could be removed if the COXIV transit peptide did not function correctly. By 
removing the transit peptide, one could test whether the expression of non- 
mitochondrially targeted PIZ produced a wide-ranging deleterious phenotype by 
interacting with membranes in general, as opposed to a respiratory phenotype due to 
mitochondrial dysfunction.
It is possible that the COXIV transit peptide itself is deleterious to mitochondrial
function by creating a pore in the inner membrane (Sokolove and Kinnally, 1996). In
order to test whether the induction of PIZ expression causes an increase in the
permeability of the mitochondrial inner membrane in the PIZ cell lines, one could use
microscopy to inspect the mitochondria for swelling. However, swollen mitochondria
are observed in RRFs in patients of mitochondrial diseases, and conceivably (if
swollen mitochondria were observed) this could equally be the result of transgene
expression, if PIZ is causing mitochondrial dysfunction in an analagous manner to the
disease state. Thus, one would also have to control in such an experiment by creating
a cell line which used the COXIV transit peptide to target a protein that should have
no adverse effect on mitochondrial function, such as a matrix protein, or DHFR,
which has been used as a passenger protein previously (Hurt et al., 1985). Another
experiment to test for pore formation by the COXIV transit peptide would be to
fractionate the mitochondria; if a significant amount of unprocessed PIZ were isolated
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in association with the inner membrane, this would suggest that the transit peptide is 
inserted into the inner membrane, but has not entered the matrix for processing. One 
could then treat isolated mitoplasts from PIZ cell lines with protease to digest exposed 
proteins, to see whether a significant amount of COXIV transit peptide is then found 
inserted into the inner membrane. Cross-linking of import intermediates to the 
mitochondrial import apparatus would also distinguish between PIZ which was being 
imported, and PIZ inserted into the membrane in a non-specific fashion (Cyr et al., 
1995).
In order to see exactly where inside mitochondria the PIZ protein is localising, one 
could perform mitochondrial fractionation on the PIZ clones. A good antibody would 
be necessary for this work. PIZ is likely to be found in either the matrix or inner 
membrane fraction, because processing of the transit peptide was inferred to have 
taken place. One possibility is that PIZ is interfering with the activity of complex IV, 
and therefore one might expect to find it in association with other subunits of the 
cytochrome oxidase complex. Use of two-dimensional blue native-SDS PAGE gels 
could be used to test for incorporation of the chimeric protein into the complex 
(Nijtmans et al., 1995). Alternatively, PIZ may be disrupting assembly of complex 
IV. This could be tested by immunoprecipitation of assembled complex (Spelbrink et 
al., 1994) and comparison to a control cell line. One could also assay the levels of the 
subunits of the complex, to see whether lack of assembly has led to an increased 
turnover rate for the respective proteins, as in the yeast QCR6 mutant (Schmitt and 
Trumpower, 1991). This could be accomplished by western analysis with the 
appropriate antibodies, or by 35S-Met labelling of mitochondrial translation products. 
Another possibility is that PIZ is causing respiratory dysfunction by inserting into the 
inner membrane in a non-specific fashion; it might then be isolated in the inner 
membrane fraction, but not specifically associated with complex IV subunits. If the 
phenotype is due to sequestration of mitochondrial chaperones it would be predicted
that PIZ would be isolated in the matrix fraction.
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6.5 Further studies
The PI constructs have been subcloned into the pMamweo vector, and can now be 
used to analyse expression in any nuclear background which is compatible with 
steroid induction. Because the nuclear constructs were designed in cassette fashion, 
with restriction enzyme sites at either end of the PI and PIZ genes, the constructs can 
be easily subcloned into other vectors which would allow their analysis in cell lines 
which are not compatible with steroid induction. In the study by Holt et al., (1997) in 
which cybrids were created using patient-derived mitochondria harbouring mtDNA 
with a partial duplication, two different recipient cell lines were used (discussed in 
section 1.5.5). The researchers found a subtle respiratory phenotype in one nuclear 
background, and mtDNA depletion in the other. This intriguing result suggests that 
my constructs should be tested in other cell lines. Obvious candidates for further cell 
lines in which to test expression are muscle and neural cell lines, given the clinical 
presentations of the syndromes associated with rearrangements of mtDNA.
Promoters are also available which enable expression at varying levels, as opposed to 
the on/off expression of the vector which I have used. This could address the 
question of what level of protein is necessary to observe a respiratory phenotype. 
However, from a physiological point-of-view, the question of threshold is probably 
better addressed by the use of cybrids/patient-derived cell lines in which the 
proportions of wild-type to mutant mtDNA can be assessed.
An additional advantage of the approach adopted is the possibility of creating 
transgenic mice, as discussed in section 1.6. The chimeric gene could be placed under 
the control of a tissue-specific promoter; this would enable investigation of the effect 
the presence of the chimeric protein would have on a particular tissue in vivo, in 
isolation. Again, muscle tissue would be an obvious choice. Given the frequent
occurrence of diabetes in association with the presence of partially-duplicated
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mtDNA molecules, another possibility would be to use a promoter specific to the 
pancreas, e.g., to see if a diabetic phenotype is elicited.
6.6 Clinical implications
The research reported here has important potential implications for treatment and 
therapy of the individuals which harbour rearranged mtDNA molecules. Lightowlers 
et al., (1997), have reviewed recent research into altering the proportions of mtDNA 
heteroplasmy in vivo. Using a peptidyl-nucleic acid (PNA) construct specific to a 
mutant template differing at a single base from the wild-type sequence, Taylor et al., 
(1997) demonstrated selective binding at physiological conditions. The PNA was 
shown to inhibit replication of the mutant mtDNA, but not wild-type mtDNA, even at 
a 1000-fold molar excess. Furthermore, a mitochondrial transit peptide has already 
been shown to import covalently coupled double-stranded DNA molecules into the 
mitochondrial matrix (Seibel et al., 1995). Lightowlers et al., report that they have 
coupled a transit peptide to the PNA construct and achieved mitochondrial targeting 
within cultured muscle cells. If the chimeric peptide is the primary step in 
pathogenesis, then treatment which will prevent development of the associated 
syndromes is possible. In familial cases, infants at risk could be treated from birth, 
because the rearrangement would be known in advance. Using the targetted PNA, 
both replication of the rearranged mtDNA molecules and translation of any chimeric 
transcripts present could be blocked. By blocking replication at an early stage, it may 
be possible to effectively 'cure' the individual. In cases which are sporadic, an early 
diagnosis would be essential to prevent further deterioration of the child. In such 
cases, lifelong treatment with the blocking peptide may be necessary to prevent 
translation of the chimeric peptide.
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6.7 Conclusions
The expression of the chimeric protein PIZ in isolation from other potential variables 
produced a subtle, but statistically significant respiratory phenotype in the fibroblast 
cell-line tested. Chimeric mitochondrial genes formed by rearrangements of mtDNA 
are transcribed and processed in vivo, and there is no obvious reason why chimeric 
transcripts in particular would not be translated. Failure to detect a fusion peptide in 
vivo may indicate that the protein is usually too unstable. It does not negate a role for 
such a protein (as discussed with reference to CMS in Petunia). In patient muscle, 
biochemical deficiency precedes mitochondrial proliferation and the formation of 
RRFs. Therefore, the expression of a chimeric mitochondrial protein in vivo may be a 
contributory factor to the biochemical deficiency observed. In fact, the observation of 
a respiratory deficiency in cell culture, attributable solely to the presence of the 
chimeric protein, suggests that expression of a chimeric mitochondrial protein may be 
the primary step in pathogenesis.
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Appendix 1
SUPERGLU SG+DEX GALACTOSE GAL+DEX
3T3 4.300 4.500 1.810 2.020
4.000 4.200 1.900 2.100
3T3pM 2.520 2.200 1.210 1.480
3.860 3.740 2.260 2.050
3.470 3.610 2.380 2.040
3.020 3.160 1.060 1.160
3.260 3.100 1.125 1.360
PIZ8.1 5.150 4.110 1.750 1.070
4.570 4.810 2.180 1.790
5.290 5.000 2.010 1.500
PIZ8.2 5.360 5.420 2.390 2.120
5.450 4.400 2.370 1.810
PIZ8.3 2.580 1.910 0.830 0.570
2.980 2.480 1.500 1.000
2.690 2.570 1.470 1.070
PIZ8.5 2.340 2.170 1.360 1.150
2.570 2.410 1.300 1.080
2.520 2.270 1.120 0.860
PIZ8.6 3.940 3.760 1.990 1.600
This table displays the raw data for the statistical analysis of the PIZ cell lines in 
section 5.2.7.
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